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Abstract 
Hospital admissions of patients with diabetes have been increasing steeply in 
parallel with the increasing prevalence of known diabetes in the general population. 
Furthermore patients with diabetes have poor clinical outcomes during their hospital 
stay. There are major implications for secondary care: 1) increasing demand placed 
on hospital staff and diabetes specialist teams may impact on the quality of care 
provided to patients with diabetes; and 2) financial strains will result due to the 
greater cost associated with in-hospital care of patients with diabetes.  
Health informatics solutions including clinical decision support systems have been 
implicated as tools that may improve effectiveness, efficiency and quality of services 
provided to hospitalised patients. In this thesis I have explored the role of health 
informatics, in particular clinical decision support systems, in the care of hospitalised 
patients with diabetes through a systematic review and by analysing data from 
University Hospital Birmingham captured by two electronic patient information 
systems: 1) electronic prescribing, information and communication system; and 2) 
electronic patient administration system.  
Findings from the thesis: 1) highlight the potential role of computerised physician 
order entry system in improving guideline based anti-diabetic medication prescription 
in particular insulin prescription, and their effectiveness in contributing to better 
glycaemic control (chapter 2); 2) quantify the occurrence of missed discharge 
diagnostic codes for diabetes using electronic prescription data and suggests 60% of 
this could be potentially reduced using an algorithm that could be introduced as part 
of the information system (chapter 3); 3) add evidence to the poor clinical outcomes 
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of diabetic patients with hypoglycaemia whom were found to have higher in-hospital 
mortality rates and longer length of stay (chapter 4); 4) quantify the hypoglycaemia 
rates in non-diabetic patients and proposes one method of establishing a 
surveillance system to identify non diabetic hypoglycaemic patients (chapter 4); 5) 
describe metrics that may be useful in monitoring institutional blood glucose control 
(chapter 4); 6) add evidence to the factors including foot disease, that may explain 
the excess inpatient mortality and length of stay in admissions with diabetes (chapter 
5); and 7) introduce a prediction model that may be useful to identify patients with 
diabetes at risk of poor clinical outcomes during their hospital stay (chapter 5).  
Generally the findings support the important contributions health informatics could 
make in improving care for hospitalised patients with diabetes. To maximise the 
impact of the research findings in this thesis it is essential when implementing the 
recommendations they are evaluated to high standards. This will help to 
continuously improve the performance of the tools suggested and at the same time 
will maximise the generalisability of tools to other settings other than University 
Hospital Birmingham.     
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 Introduction
1 
 
1 Introduction 
In this chapter I will first highlight the burden of diabetes mellitus (which will be 
referred to as diabetes throughout the thesis) giving particular attention to inpatient 
care and inpatient outcome. Then I will summarise the current guidelines for 
inpatient management of patients with diabetes. Thereafter I will draw attention to 
health informatics and the role of clinical decision support systems in health care. 
Finally I will lay out the aims and objectives of this thesis. 
1.1 Diabetes Mellitus 
Diabetes has emerged as one of the biggest global health challenges in the last few 
decades. Estimates suggest the global prevalence has risen from 8.3% to 9.8% in 
men and 7.5% to 9.2% in women from 1980 to 2008 [1]. In numbers this is an 
increase from 150 million to 350 million individuals with diabetes during this period 
globally [1]. These estimations underscore the need for the global health community 
to implement effective preventative methods. In addition health care facilities should 
identify means to efficiently use resources in detecting and treating people with 
diabetes to limit disease progression. Control of disease progression is important as 
diabetes has serious long term consequences such as cardiovascular disease, 
blindness, chronic renal disease and amputations. 
Diabetes is a state of persistent high blood sugar as a result of deficiency in insulin 
production from the pancreas or due to poor utilisation of insulin (insulin resistance) 
by peripheral tissues [2]. Type 1 diabetes is a where there is absolute deficiency of 
insulin production and therefore patients are dependent on lifelong exogenous 
insulin treatment [2]. Type 2 diabetes is often a combination of insulin deficiency and 
insulin resistance and patients are treated with lifestyle modification, oral 
hypoglycaemic agents and/or insulin [2].  The aetiology of type 1 diabetes suggests 
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autoimmune mediated destruction of β-cells in the pancreas and strong links with 
specific Human Leucocyte Antigen (HLA) genes, whereas in type 2 diabetes obesity, 
aging, genetic predisposition and physical inactivity are the key risk factors that lead 
to insulin resistance and relative insulin deficiency [2]. 
The World Health Organisation (WHO) defines diabetes as either a fasting plasma 
glucose of ≥7.0 mmol/l or random plasma glucose of ≥11.1mmol/l on two occasions 
or once if symptoms are indicative of diabetes [3]. These symptoms include polyuria, 
polydipsia and unexpected weight loss. Alternatively post prandial blood glucose of 
≥11.1mmol/l after 2 hours of an Oral Glucose Tolerance Test (OGTT) is diagnostic of 
diabetes [3]. WHO in a recent document [4], following the American Diabetes 
Association (ADA) directive to use Haemoglobin A1c (HbA1c) as a diagnostic test 
[5], have accepted a cut point of ≥ 6.5% (≥ 48 mmol/mol) for HbA1c as diagnostic of 
diabetes. These criteria have been accepted and are in use in United Kingdom (UK) 
[6,7]. 
1.1.1 Diabetes in England, UK 
United Kingdom has a population of 63 million based on the latest census carried out 
in 2011 [8]. Fifty three million are from England and the rest from Scotland, Northern 
Ireland and Wales [8]. In England, based on National Diabetes Audit (NDA) the 
prevalence of diabetes was 4.57% in 2010-11 [9]. This means in total approximately 
2.5 million individuals have diabetes in England. Around 9% of them had type 1 
diabetes and the rest had type 2 diabetes [9]. The NDA identified gaps in care 
processes in primary care and noted that only 63% had good glycaemic control 
(HbA1c ≤7.5% / 58mmol/mol) and only 36% had blood pressure within target range 
(<140/80mmHg for those without and <130/80mmHg  for those with end organ 
damage) [9]. 
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In the Health Survey for England (HSE) [10], prevalence of adults (≥16 years) was 
higher in the aged population (example; 2.6% of men aged ≤45 years rising 
gradually  to 25.7% in ≥85 years), in males (7.0% men vs. 4.9% women) and in 
those from low income households (lowest quintile men 11.0% and women 5.9% vs. 
4.7% in men and 3.7% women from highest quintile). The survey also demonstrated 
the relationship between obesity and diabetes, for example in females with a Body 
Mass Index (BMI) ≥30kg/m2 the prevalence was 9.9%; 4.3% in BMI 25-30kgm2; and 
1.5% in BMI <25kg/m2 [10]. A recent study demonstrated high incidence in Indian 
Asian and African Caribbean population and suggested this is likely linked to their 
greater insulin resistance and truncal obesity [11]. Similar observations have been 
noted in the British Pakistani population as well [12].    
The NDA in its second part of the report for 2011compared hospital admissions with 
complications for people with diabetes to those of the general population from 
England [13]. They found a 48% increase in myocardial infarction admissions in 
diabetic patients when compared to the general population. The risk of admission for 
Heart failure was 65% higher; 25% higher for stroke; 144% higher for renal 
replacement therapy; 329% higher for minor amputation (below the ankle); and 
186% higher for major amputation (above the ankle). 
In the last 4 years there have been annual audits of diabetic care in hospitals 
(National Diabetes Inpatient Audit or NaDIA) in England and Wales. Audits for the 
year 2009, 2010 and 2011 are available.  These audits provide a comprehensive 
picture of inpatient care and highlight areas for improvement. Key results from 2010 
and 2011 for England are listed below and the findings will be reiterated in the 
sections below where a detailed discussion of the consequences of diabetes in 
hospitalised patients is given [14,15]. 
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The burden of inpatient diabetes 
 Around 15% of audited beds were occupied by patients with diabetes (2010/11) 
 Patients with diabetes were likely to be older than those without diabetes (median 
age 75 years Vs. 65 years in 2011) 
 Median length of stay is 8 days in patients with diabetes vs. 5 days in non-
diabetics (2010/11) 
 Only 9% are admitted for diabetes specific disease management, almost a half of 
these were related to active foot disease (2010 /11) 
 Nearly 40% are treated with insulin while in hospital (2010 /11) 
Provision of diabetes care 
 37% of patients with diabetes had at least one medication error in 2010 although 
this dropped to 32% in 2011, it is still very high  
 Those with medication error were twice likely to have a severe hypoglycaemic 
episode than those without a medication error (2011) 
 8% of insulin infusions were considered to be in place for longer than necessary 
(2011) 
 In the 2011 audit, on average 58% of patient days had “good glycaemic control” 
(defined as patient days with blood glucose no more than once ≥11mmol/l and no 
single measure below 4mmol/l)    
 69% of hospitals did not provide specialist dietetic services for people with 
diabetes (2011) 
 31% of hospitals had no inpatient podiatry services (2011)  
 Only 27% of patients with diabetes had foot examination documented during their 
stay (2010 /11) 
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1.1.2 Consequences of diabetes in hospitalised patients 
Patients with diabetes admitted to hospital or those with hyperglycaemia during 
inpatient stay have a range of poor clinical outcomes [16-31].  They include excess 
mortality [17-21,24,25,31-33], higher complication rates, in particular infection 
[25,27,30,34], and increased length of stay [14,27,31,35]. These outcomes are often 
linked in these studies to hyperglycaemia. In fact it has been shown that those with 
hyperglycaemia detected for the first time during their hospital stays have similar or 
worse clinical outcomes than those with known diabetes having hyperglycaemia [31]. 
In addition to these poor clinical outcomes, antidiabetic medication prescription 
errors, especially insulin, have resulted in harm to inpatients [36].  Furthermore, 
patients with diabetes complain of poor management of their diabetes while in 
hospital [37,38].  
The underlying mechanism on how hyperglycaemia results in poor clinical outcomes 
is unclear but it is proposed as a response to metabolic stress there is a rise in 
stress hormones and peptides, which in turn alters the glucose metabolism resulting 
in increased metabolites such as Free Fatty Acids (FFA), ketones and lactate 
[39,40]. Along with this there is immune dysfunction giving rise to infection. 
Moreover, reactive oxidative stress leads to changes that raise secondary mediators. 
In combination all these changes induce cellular injury, inflammation, tissue damage 
and altered tissue wound repair. A process that ends with complications, prolonged 
length of stay and death [40] (Figure 1.1). 
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Figure 1.1: Underlying patho-physiological changes that may explain poor 
hospital outcomes in people with diabetes  
 
Source: Clement S et al. Diabetes Care. 2004; 27:553-591[40] (reproduced with permission) 
In a recent report titled “Mortality among inpatients with diabetes” for England [33], 
Diabetes Health Intelligence, a unit at the Yorkshire and Humberland Public Health 
Observatory (YHPHO) found that diabetes patients were 10% more likely to die in 
hospital than those without diabetes. In particular there was wider variation across 
hospitals after adjustment for co-morbidities, with 24 hospitals being identified as 
outliers; one hospital with a higher mortality rate was University Hospital of 
Birmingham.  The methods used to analyse the data have limitations, as no 
methodology can give an accurate picture of the case-mix. Nevertheless it indicates 
the need to identify possible reasons for excess mortality and emphasises the need 
to implement interventions to reduce adverse outcomes including excess mortality.  
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Kerr [41] in her national report titled “Inpatient care for people with diabetes: the 
economic case for change”, highlighted the economic cost of diabetes. She reported 
that 11% of total NHS expenditure on in-hospital care was spent on people with 
diabetes, totalling around 2.5 billion pounds for the year 2009/10. Furthermore, of the 
above cost a sum of around 600 million pounds is excess expenditure compared to a 
similar population without diabetes.   It was also found patients with diabetes had 
higher rates of admission and were likely to stay on average 3 days more than non 
diabetic patients, a finding that corroborates with previous studies [14,35,42].  
Patient surveys and qualitative studies using validated questionnaires [37,38,43,44] 
have highlighted issues around incorrect medications, disempowerment, poor meal 
timing and choice, and inadequate specialist team input in their care. This is further 
exacerbated by numerous errors in prescriptions for people with diabetes [36]. In 
particular Insulin is considered as one of world’s top ten dangerous drugs [45] and 
has been even used with malicious intent by health care workers as a murder 
weapon [46]. A national guideline exists to improve error free prescription of insulin 
and key recommendations include electronic prescriptions [47].  
1.1.3 Current evidence based guidelines in caring for hospitalised patients 
with diabetes 
There are numerous guidelines addressing management of diabetes. In this section I 
will summarise the key messages from national documents produced in England 
addressing inpatient management. These national documents are: 
1) Safe and effective use of insulin in hospitalised patients [47] 
2) Hospital management of hypoglycaemia in adults with diabetes mellitus [48] 
3) Inpatient management of diabetic foot problems: NICE guideline [49] 
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4) The management of diabetic ketoacidosis in adults [50] 
5) Self management of diabetes in hospital [51] 
1.1.3.1 Safe and effective use of insulin in hospitalised patients [47] 
Earlier I discussed the undesirable effect of hospitalised patients with diabetes which 
have been mainly shown to be associated with hyperglycaemia. In the early part of 
the last decade Van Den Berghe et al [52] demonstrated that tight glycaemic control 
(<6.1mmol/l) could reduce adverse clinical outcomes including mortality for patients 
with hyperglycaemia in critical care setting. However recent studies found harm in 
administering such a tight glucose control strategy in Intensive Care Units (ICU), 
showing that resulting hypoglycaemia was associated with increased mortality 
[53,54]. A meta-analysis involving these and other similar studies did not find any 
reduction in mortality in ICU [55]. Nevertheless good glucose control (<10mmol/l) 
remains as an important component of managing critical care patients [56]. In the 
non critical care setting a recent (2012) systematic review involving ten observational 
studies and nine randomised controlled trials showed good glycaemic control (varied 
targets but often close to current recommended target of <7.8mmol/l pre-meal and 
less than 10 mmol/l any  other time), reduced infection rates (relative risk (RR) 0.41; 
with 95% confidence interval(95%CI) 0.21-0.77) but potentially increased the rate of 
hypoglycaemia (RR 1.58;95%CI 0.97-2.57)[57]. No benefit or harm in terms of 
mortality or occurrence of co-morbidities such as myocardial infarction or stroke was 
noted, though the trend was towards reduction of these outcomes. However the 
studies included in the systematic review mostly reflected surgical units and were 
often of poor quality. Therefore the review supported the urgent need for a large well 
conducted randomised controlled trial to determine the value of good glycaemic 
control in non critical care setting. Until this is carried out there is consensus among 
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the endocrinology community to take an approach that will limit hyperglycaemia as 
well as hypoglycaemia. This guideline outlines the recommendation on glucose 
control targets and safe use of insulin to achieve this.   
The document draws attention to the importance of recording diabetes status of 
patients clearly, the benefits of using electronic information system for record 
keeping and the utility of electronic prescriptions to prevent insulin prescription 
errors. Guideline based insulin administration and the necessity to avoid sliding scale 
insulin is also highlighted.  The recommended target for blood glucose control set out 
in the guideline are 5 to 7.8 mmol/l pre-meal and <10mmol/l at any random time 
point or post meal. Additional information includes general training of doctors and 
other health professionals towards safer prescription of insulin and the functions of a 
diabetes team in promoting good glycaemic control across the institution. 
1.1.3.2 Hospital management of hypoglycaemia in adults with diabetes 
mellitus [48] 
Hypoglycaemia, like hyperglycaemia, is associated with poor clinical outcomes in the 
non critical care setting (chapter 4) [58,59]. Therefore it is important to avoid 
extremes of blood glucose control. The document aims to give guidance on how to 
detect hypoglycaemic episodes and treat them appropriately. It emphasises the need 
for early detection, involvement of the diabetes team where it is recurrent or severe, 
immediate availability of treatments in a “Hypo Box” and training of staff in optimum 
management of hypoglycaemia. 
1.1.3.3 Inpatient management of diabetic foot problems [49] 
Diabetic foot problems refers to any inflammation or swelling of the foot, break in 
skin or blisters, ulcers, unexplained pain in the foot, fracture or dislocation of any part 
of the foot without any preceding significant injury or gangrene of the foot [60]. 
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Diabetic foot disease leads to long term sequelae such as poor quality of life, 
amputation and mortality [61-65]. In-hospital outcomes include longer length of stay 
and high economic cost [66]. Evidence on association between foot disease and 
inpatient mortality is demonstrated in chapter 5. This guideline tries to address the 
inpatient management of foot disease to avoid such poor clinical outcomes. 
The guideline highlights the need for a multidisciplinary foot care team which may 
have a positive impact on reducing these poor clinical outcomes. The guideline 
describes the composition of the team, which should include a diabetologist with an 
interest in diabetic foot disease, podiatrist, vascular surgeon, diabetes nurse 
specialist and tissue viability nurse.  It also emphasises the need for foot assessment 
of every patient with diabetes within the first 24 hours of admission. Furthermore it 
states the need for the multidisciplinary team to review patients referred to them at 
least within 24 hours of being informed. Additional aspects address clinical 
assessment and management of diabetic foot disease. 
1.1.3.4 The management of diabetic ketoacidosis in adults [50] 
Diabetic Keto-Acidosis (DKA) indicates a state of hyperglycaemia and metabolic 
acidosis (due to increased ketones in blood). The guideline gives detailed 
management of these patients and is mostly aimed at clinical practitioners to guide 
appropriate treatment. The relevant message for this thesis is that it recommends 
that diabetes specialist teams should be involved in the management of all DKA 
patients. 
1.1.3.5 Self management of diabetes in hospital [51] 
Earlier I identified how patient surveys have underscored the importance of 
empowering patients to be involved in their care of diabetes during hospital stay. The 
guideline recommends, where exclusion criteria do not apply, that patients should be 
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given the option of self managing their medication with the aim to lessen prescription 
errors, reduce length of stay and improve patient satisfaction. The document lays out 
the process of safely implementing the self management initiative. 
1.2 Health Informatics and Computerised Clinical Decision Support Systems 
Terminologies used in health informatics, also often described as medical informatics 
[67] have considerable overlap. Wyatt et al produced a glossary to define most of the 
terms used in medical informatics [67]. I will first define key terms mainly based on 
this glossary and then discuss in detail clinical decision support systems, their 
usefulness and the challenges they pose.  
1.2.1 Health informatics 
 
Previously health informatics and medical informatics were recognised as the same 
discipline and were defined as: 
“Medical informatics is the study and application of methods to improve the 
management of patient data, clinical knowledge, population data, and other 
information relevant to patient care and community health” [67] 
Or 
"Medical Informatics comprises the theoretical and practical aspects of information 
processing and communication, based on knowledge and experience derived from 
processes in medicine and health care." [68] 
Both definitions acknowledge the spectrum of issues medical/health informatics 
cover, from coding of specific conditions and medical terminologies in a meaningful 
way, to that of using computers to support decision making at an individual patient 
and population level. Even though Wyatt et al [67] described bioinformatics 
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(molecular biology), clinical informatics (individual patient care), consumer health 
informatics (information technology supporting the pubic to access health information 
and make decision) and public health informatics ( population health intelligence and 
surveillance) as branches of medical / health informatics, recent definitions see 
bioinformatics and health informatics as two different disciplines of a spectrum 
known as biomedical informatics, interlinked by what is called translational 
bioinformatics [69]. The American Medical Informatics Association (AMIA) defines 
biomedical informatics as the “interdisciplinary field that studies and pursues the 
effective uses of biomedical data, information, and knowledge for scientific inquiry, 
problem solving and decision making, motivated by efforts to improve human health” 
[70]. Translational bioinformatics is described as, “a system theory approach to 
bridge the biological and clinical divide through a combination of innovations and 
resource across the entire spectrum of biomedical informatics” [69] (Figure 1.2). 
Figure 1.2: Translational bioinformatics 
 
Source: Sarkar et al. J Am Med Inform Assoc 2011; 18(4): 354-357. (reproduced with permission) 
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Another much more complex but informative spectrum is shown in figure 1.3. Current 
proposed definitions by AMIA in 2012 recognise the combination of clinical and 
public health informatics as health informatics [70]. They see medical informatics 
(physician orientated), nursing informatics (nursing orientated) and dental informatics 
(dental practitioner orientated) as branches of clinical informatics [70]. For the 
purpose of this thesis the focus is on health informatics (clinical and public health 
informatics) tools, in particular Computerised Clinical Decision Support System 
(CDSS), in improving the care of hospitalised patients with diabetes.   
Figure 1.3: Detailed spectrum of biomedical informatics 
 
Source: Enbi et al. J Am Med Inform Assoc 2009; 16:316-327. (reproduced with permission) 
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1.2.2 Computerised Clinical Decision Support Systems (CDSS) 
CDSS has been defined as: “A computer system that uses two or more patient data 
to generate case specific or encounter specific advice” [67]. However this implies 
CDSS helps to make decisions for individual patients, though similar tools can be 
used to make decisions for populations. For example a physician may use a risk tool 
such as the Framingham cardiovascular risk engine [71] in a computer to decide the 
need for lipid lowering therapy in an individual patient. At the same time the same 
physician can use the computer with an inbuilt decision support system to identify all 
patients whom may fulfil the criteria for the need for lipid lowering therapy using 
Framingham risk tool. Here a decision can be made to invite all these patients to 
assess suitability of lipid lowering therapy, a decision at the population level.  CDSS 
are therefore best loosely described as information systems designed to assist and 
improve clinical decision making [72]. In this thesis assisting decision making could 
be both at an individual level and at times at population level. 
1.2.2.1 Types of clinical decision support systems 
There are different types of clinical decision support system. I will describe them 
individually. 
Alerts or reminders 
These are the commonly used computerised decision support tool. For example if a 
patient is allergic to a medication but the physician unintentionally prescribes the 
medication to the patient, then the computer will alert the physician of the potential 
hazard. Similarly where a patient is due for a routine check-up a reminder will be 
generated to the physician as an alert when he logs into the computer or in the form 
of an email. There are population level reminders that are often used to generate a 
list of patients whom for example are due for annual influenza vaccine or diabetes 
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review. Other common alerts include abnormal blood results and observations both 
in primary care and secondary care. 
Electronic triggers are a specific type of alert where they may identify potential harm 
that might have occurred to patients. For example naloxone medication can be a 
trigger of opioid overdose, similarly high INR can be a trigger of higher than needed 
dose of Warfarin prescription [73].  
Diagnostic system 
Here when patient symptoms and sign are recorded the system can generate a set 
of differential diagnosis that needs to be considered.  The first such attempt was in 
the diagnosis of acute abdominal pain presenting in accident and emergency 
department, to diagnose acute appendicitis [74,75]. Since then many complex tools 
have been developed such as the Isabel clinical decision support tool which 
generates differential diagnoses when presented with symptoms and signs [76].   
Electronic guidelines 
These are tools that encourage use of evidence based decisions in the management 
of patients. For example if a physician were to deter from the guideline then the 
CDSS will alert or warn him. The physician then can override the warning on clinical 
grounds or change practice and adhere to the guideline. 
 Computerised Physician Order Entry (CPOE) 
CPOE are systems which enable ordering of prescriptions, laboratory tests, referrals, 
imaging and even meals in hospitals through a computer based system. CPOE on its 
own are often not termed as part of CDSS but in recent history almost always have 
features that support decisions. For example they may highlight duplication of blood 
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test requests, give guidance on prescription by suggesting medication doses and 
automate referrals if the patient meets certain clinical criteria.   
Prognostic risk engines 
Many prognostic risk scores have been developed over the last two decades such as 
the Framingham [71] and Q-risk [77] for cardiovascular disease, UKPDS risk score 
[78] for cardiovascular risk in type 2 diabetes patients, Q-fracture [79] for detecting 
patients with high risk of fragility fracture, Patient At Risk for Readmission (PARR) 
algorithm [80] for identifying patients at high risk of hospitalisation and many more. 
These are gradually being implemented as part of electronic health records and are 
used at individual patient level to detect disease, discuss prognosis and provide 
treatment (lipid lowering medication for those with a cardiovascular risk of greater 
than 20% in the next ten years) [81] and at population level to invite a list of patients, 
assess their risk of developing disease and to drive prevention programmes in these 
patients [82].  
1.2.2.2 Benefits and challenges of computerised clinical decision support 
systems 
Many reviews have identified the benefits of CDSS, in particular CPOE systems [83-
88]. CDSS as part of CPOE have been found to reduce medication errors and 
adverse drug events [83,84,87,88]. They also have shown to improve physician 
performance, these include correct dosing, adherence to guidelines and to an extent 
efficient use of time [85,86,89]. CDSS have a role in prevention at outpatient clinics 
and primary care, for example by alerting physicians of the need for routine blood 
pressure checking, to offer influenza vaccination and to recommend cervical 
screening [86]. Other individual studies have also shown better communication 
between primary and secondary care [90] and improved documentation of problem 
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lists for patients [91]. For example if a patient is prescribed levothyroxine then the 
system could alert the physician to add hypothyroidism to the patient’s diagnosis list. 
This approach using medications to identify diagnoses is used in chapter three to 
study under reporting of diabetes diagnosis, where a prescription for diabetes exists 
but a diagnosis of diabetes is not entered in the discharge summary [92].  
 However there are challenges in using CDSS and many studies have questioned 
the above advantages. Ash et al [93] categorised the unintended consequences of 
information technology on health care as those that occur during entering and 
retrieving information, and those that occur in the communication and process co-
ordination the system is expected to support [93]. Most of the unintended errors the 
author described are relevant to CDSS.  
In the first category the errors she describes include: 1) the interface between the 
computer and the practitioner may not be suitable in an environment where one 
needs to multitask; 2) physicians often complain about the crowded nature of the 
options available on the screen which may result in choosing the wrong option 
unintentionally; 3) some systems ask for elaborate information which could be time 
consuming; 4) the need to switch between screens to assimilate information may 
fragment the overall view of the patient; and 5) at times too much information could 
be difficult to go through in busy clinics. In the second category of possible errors 
Ash et al [93] first discusses about the inability of the CDSS to have options that will 
fulfil every single patient’s needs. This can lead to what is known as automation bias 
[94,95]. The bias occurs when a practitioner makes an error by carrying out the 
recommendations of the CDSS without duly considering the individual patient need 
(by commission) or by not following the recommendations of the CDSS when it 
would have benefited the patient (by omission) [95]. Secondly the system may be 
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inflexible, for example in providing medication during an urgent need. Thirdly an 
order in the system (physician ordering the medication) does not mean it has been 
communicated to the individual carrying out the order (nurse who administers it). 
Such an assumption by the physician can result in miscommunication. Lastly 
decision support overload with too many alerts is a common problem encountered. 
This can lead to health professionals ignoring essential warnings that potentially 
could lead to harm.  A term often used to describe this is alert fatigue [96]. Most of 
these errors described by Ash et al were identified in subsequent published studies 
and reviews using both quantitative and qualitative methods [97-99]. One study 
queried a possible rise in mortality in a paediatric hospital after implementation of a 
CPOE system, though this observational before and after study had several 
limitations [100]. 
1.2.3 Planning and development of computerised clinical decision support 
systems 
In order to develop CDSS that are beneficial, at the same time have the ability to 
overcome the challenges described above, careful planning is essential. It is 
important to know what features lead to success so that effective evidence based 
solutions can be developed. 
A review addressing the question about what components make a good clinical 
decision support tool found that computerised clinical decision support systems were 
much superior to that of manual decision support tools [101]. They also found 
decision support tools that are available at the point of decision making, that provide 
recommendations rather than assessment (example instead of displaying the 
cardiovascular risk for a patient if it recommends what medication should be given 
based on the risk score) and integrated within clinician workflow were more likely to 
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succeed [101]. This systematic review also considered additional features such as 
local user involvement and justification of decision support, by provision of reasoning 
(example stating why a reminder for HbA1c testing is recommended). Though these 
were not found to be significant, the authors concluded that they have a role in 
enhancing the acceptance of the CDSS among health care professionals [101]. 
Initially the problem should be defined [102], such as the high incidence of 
hypoglycaemia in hospitalised patients with diabetes and associated poor clinical 
outcomes (chapter 4). The identified need should have effective solutions that could 
be enhanced by CDSS. For example, in the case of hypoglycaemia if the electronic 
observation were to show severe or recurrent hypoglycaemia, I will explore the 
possibility of alerting diabetes specialist team. Similarly at a population level I will 
explore if it is feasible to have quality assurance at hospital or ward levels on how 
well they are preventing or managing hypoglycaemia. In addition one should 
consider if such approaches are likely to be successful in terms of effectiveness 
when measuring clinical outcomes and efficiency when measuring institutional 
outcomes. If previous studies haven’t demonstrated effectiveness or efficiency then 
evaluation methods should be in place to assess them. 
Once the problem and the need for CDSS are determined, the type of CDSS should 
be determined. This may be an alert based on simple logical sequence, or could 
involve set of rule based system or algorithm as often used in electronic guidelines 
or complex regression prediction models to identify those with poor clinical outcomes 
(chapter 5).     
1.3 Main aims and objectives of the thesis 
The overarching aim of the study is to determine the role of health informatics, in 
particular CDSS in the care of hospitalised patients with diabetes. This will be 
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explored : 1) using existing literature; 2) through analysing data from a locally 
developed Prescribing Information and Communication System (PICS) to identify 
problems; 3) by emphasising need for health informatics (CDSS) as a potential 
solution; and 4) by examining or developing potential CDSS tools that could improve 
care for the patients with diabetes. 
Specific objectives are to: 
 Examine the current evidence on the role of computerised clinical decision 
support systems in the care of hospitalised patients with diabetes (Chapter 2) 
 Determine the frequency of underreporting of diabetes as a discharge diagnosis 
using electronic prescription data in University Hospital Birmingham (Chapter 3) 
 Study the association between hypoglycaemia and mortality / length of stay in 
admissions with diabetes in University Hospital Birmingham (Chapter 4) 
 Determine the frequency of non diabetic hypoglycaemia in University Hospital 
Birmingham (Chapter 4) 
 Describe indicators of inpatient “glucose control” using electronic observations of 
point of care blood glucose in admissions at University Hospital Birmingham 
(Chapter 4) 
 Study the association between foot disease in admissions with diabetes and 
length of stay / mortality (Chapter 5) 
 Develop a model to predict admissions with diabetes that result in excessive 
length of stay or death using data from patient administration system and 
electronic prescribing system (Chapter 5) 
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CHAPTER 2 
Computerised clinical decision support 
systems in the Care of Hospitalised Patients 
with Diabetes: Systematic Review 
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2 Computerised clinical decision support systems in the Care of 
Hospitalised Patients with Diabetes: Systematic Review 
2.1 Background 
In the introduction the rising number of hospital beds occupied by patients with 
diabetes [14,15,103] and their poor clinical outcomes were discussed [16-31]. 
Current guidelines published by the ADA [104] and NHS Diabetes [47]  have 
recognised the above issues and have put forward key actions that need to be 
incorporated into inpatient care for patients with diabetes. These actions are to 
ensure (1) better control of blood glucose without increasing the risk of 
hypoglycaemia, (2) safe and effective use of insulin and (3) improved quality 
indicators in caring for hospitalised patients with diabetes. The use of electronic 
health records and prescriptions has been cited as key strategies to provide an 
efficient inpatient diabetes management programme in these guidelines.  
As stated in the introduction for this review CDSS are described as information 
systems designed to assist and improve clinical decision making [72]. I also stated 
CDSS have been shown to reduce prescription errors, increase adherence to 
guidelines, improve physician performance and enhance surveillance and monitoring 
of patients across a wide variety of patient conditions [72,85,87,105,106]. However a 
review into these systems in improving care for hospitalised patients with diabetes 
has not been conducted to support implementing them efficiently. 
To assist diabetes teams and service commissioners putting into practice CDSS the 
available evidence was systematically reviewed to determine the role and 
effectiveness of CDSS in improving care of hospitalised patients with diabetes in the 
non critical care setting.  
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2.2 Methods 
A systematic review aims to adhere to an explicit and stated method to minimise bias 
by critically appraising and synthesising the evidence for a clearly defined question 
[107,108]. Once the research question is defined the key steps defined by Centre for 
Review and Dissemination (CRD) [109] which I have followed in conducting this 
systematic review are: 
- A clear search strategy 
- Inclusion and exclusion criteria 
- Data extraction 
- Quality assessment 
- Synthesis of the data 
2.2.1 Search strategy 
I searched for CDSS interventions in secondary care for patients with diabetes or 
hyperglycaemia in MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EBSCO) and the 
Cochrane Library (Wiley).  Keywords and free text search were conducted in all 
these databases. Search terms for CDSS are often poorly defined [110]. Further 
health informatics tools that are beneficial for inpatient care but that may not fulfil the 
exact definition of CDSS may be missed. Therefore multiple terms that may identify 
the interventions under interest were used. These included ‘informatics’, ‘computers’, 
‘decision support’ and ‘computerised physician order entry system’ (a detailed 
search strategy is given in appendix 2.1). I did not set search limits based on study 
design, study outcome, language or peer reviewed journals. The search was limited 
from 1970 to 2010 (EMBASE, CINAHL and Cochrane August 2010 and MEDLINE 
December 2010). My secondary search strategy included searching bibliographies of 
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all included studies and a search in selected journals in the fields of diabetes and 
health informatics using available search engines in their respective websites. 
2.2.2 Inclusion criteria 
Inclusion criteria were defined based on population, intervention, comparator and 
outcome. The population were hospital patients with diabetes or hyperglycaemia. 
This review did not exclude children with diabetes, pregnant women with gestational 
diabetes or patients diagnosed during admission. The setting was limited to in-
patient non critical care. The decision to exclude intensive care settings was taken 
on the basis they differ in their goals in treating hyperglycaemic patients and that 
almost all interventions are related to computerised / computer based protocol driven 
continuous insulin infusions. A review into these types of devices in this care setting 
already exists [111].  
Interventions were defined based on the description of CDSS [72] stated in the 
background. Even though the comparator was set to that of no CDSS I included 
surveys that were valuable for planning diabetic care where both reviewers agreed. 
Outcomes were either beneficial or harmful effect in relation to glucose control, use 
of insulin, patient satisfaction, length of stay and quality of diabetic care. 
Studies that reported preliminary data of another included study were excluded. 
Case reports or case series with fewer than 5 patients, studies specific for outpatient 
setting, and inpatient experiments used for the sole basis of a controlled environment 
were also excluded.  The inclusion criteria checklist is given in appendix 2.2. 
2.2.3 Data extraction and assessment of study quality 
Titles and abstracts of all studies identified were reviewed by two independent 
members of the research team (the author and JJC). Papers identified as relevant or 
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of uncertain relevance based on the abstracts were further independently evaluated 
by both the researchers. Any discrepancies between the two reviewers were 
resolved by discussion. Reasons for exclusion were documented. 
The data extraction and quality assessment of the studies were done by author and 
individually checked by JJC and YFC for accuracy and to identify any missing 
information. The data extraction form used was a modified version of the template 
from the CRD guidance for systematic reviews and included quality criteria according 
to its guidelines [109]. Many studies were based on before and after analyses, either 
as retrospective observational studies or as prospective interventional studies. The 
most useful classification system to grade such studies was the one produced by the 
Australian National Health and Medical Research Council (NHMRC) [112]. The data 
extraction form used is given in appendix 2.3. 
2.2.4 Data synthesis 
A meta-analysis was not carried out due to the variety of different outcome 
measures, poor quality of the studies and due to the heterogeneous nature of the 
interventions. Therefore I did a narrative synthesis by tabulation based on the 
interventions, textual description clustered on the basis of outcome and by 
developing the theory on how the interventions work. 
2.3 Results 
In the primary database search a total of 2,057 references were identified. After 
duplicates were excluded there were 1,110 articles for which titles and abstracts 
were screened by author and JJC. After discussion between author and JJC, 63 
articles were identified for possible inclusion. After review of all 63 full texts by author 
and JJC, 11 studies meeting the full inclusion criteria were identified [113-123]. 
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Another 3 articles meeting the inclusion criteria were identified through the 
secondary searches [124-126] (Figure 2.1). Eleven studies were from United States, 
two from Germany and another from Israel.  
2.3.1 Quality of studies 
Two of the studies were cluster Randomised Controlled Trials (RCT) [115,124]. 
Another 8 studies were before and after analysis [114,116,119,120,122,123,125,126] 
however only one of them was a planned interventional study [116] and another a 
prospective analysis of observational data [126] while all others were retrospective 
analysis of observational data. Of the remaining studies one was a case series [117] 
and the other 3 observational descriptive studies [113,118,121].  Both the RCT 
evaluated computerised provider order entry (CPOE) as an individual component 
where as all the before and after analytical studies had the CDSS as one component 
of a complex intervention and were also prone to change in secular trends and 
regression to the mean (table 2.1). One RCT looked at a computerised insulin 
ordering template alone [124] whereas the other had a CPOE with built-in 
components on prescription, investigations and diet orders, referral indication, and 
discharge orders [115]. 
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Figure 2.1: Study selection flow chart 
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
Wexler, 
2010 
[124] 
Cluster 
RCT 
 
 
 
 
II 
Electronic Insulin Order 
Template 
Inclusion criteria – Patients prescribed insulin by 7 
internal medicine team between a period of 30th 
Apr 2009 to 27th May 2009. Exclusion criteria - 
Patients with type 1 diabetes (n=11) and type 2 
diabetes with blood glucose between 60 and 
180mg/dL (because the order set was designed to 
apply to hyperglycaemia in patients with type 2 
diabetes without other risks for hypoglycaemia 
(i.e.liver or renal failure)). 
Random allocation of clusters – Using a 
computerized coin toss, 7 teams were assigned  
either to have the option to use the order 
template (Intervention) or to use the usual insulin 
ordering (control).  
Allocations of participants to cluster – Participant 
were not randomised to the clusters. Usual 
admission protocol to the teams. 
Blinding - The providers prone to know who were 
in the intervention arm. Not clear if the patients or 
the data analysts were aware of this. 
No 
Type of 
analysis 
(Intentio
n to treat 
analysis 
or 
protocol 
based 
analysis) 
– Not 
reported 
 
Power 
calculati
on - 
Done 
Period of Study- One 
month with each 
patient followed till 
discharge. 
 
Outcome 
measurement - 
Similar but depend on 
the number of glucose 
measurement taken in 
each patient. 
 
Drop out or 
withdrawals – Non 
reported 
Effect of differences at baseline 
- No differences 
 
Effect of co-intervention 
- Both arms  were given the 
same educational session 
 
Factors not included in the study 
- Given the short period of 
the study unlikely any 
other factors could have 
affected 
 
 
Patients selected 
are those who had a 
prescription of 
Insulin. There is 
possibility patients 
in need of insulin 
but not given would 
be left out. This 
would have 
introduced selection 
bias. Also likely 
those in the control 
group being aware 
of the intervention 
might have 
prescribed better 
than in usual 
circumstances 
reducing effect size 
of the outcome. 
Guerra 
2010, 
[123] 
 Observat
ional 
retrospec
tive 
study 
 
 
 
III-3 
Computerised Physician 
Order Entry Based 
Hyperglycaemic Inpatient 
Protocol (CPOE-HIP) - 3 
main elements: 
1. Modification of CPOE to 
comply with ADA 
guidelines  
2. In service training of all 
nursing personnel on the 
details of CPOE-HIP  
3. Hospital wide online 
availability of the HIP 
 
Inclusion criteria – Patients with a previous 
diagnosis of type 1 or 2 diabetes. Exclusion criteria 
- Patients transferred from ITU and those 
identified as hyperglycaemic without previous 
diagnosis of diabetes 
 
Only a sample of the population before and after 
the intervention analysed. Variability in the 
admission patterns in the months specified could 
lead to bias. (Before -15 March 2006 to 11 April 
2006 (1325 patient days) compared with: After -
patients admitted between 3 October 2007 and 
30th October 2007 (1490 patient days)). 
Age (1.6 
years) 
 
No 
information 
on co-
morbidities  
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Outcome 
measurement – 
Number of glucose 
samples per patient 
day similar. Also the 
metric used are the 
currently widely 
accepted measures for 
glucose control. 
Effect of differences at baseline 
- No adjustment made for 
age but agree that clinically 
the difference unlikely to 
be important. Also note no 
information on co-
morbidity 
Effect of co-intervention 
In service training of nursing staff  
could have affected the outcome. 
 
Factors not included in the study 
Given the data is more than year 
apart other changes especially 
national initiatives could have led 
to the improved changes. 
 
 
The analysis is 
before and after 
and therefore 
subject to 
regression to the 
mean and secular 
trend changes. 
 
 
 
 
Schnipp
er 2010, 
[115] 
Cluster 
RCT 
II 
Computerised order set 
with components on 
insulin prescriptions, POC 
testing, HbA1c testing, 
Inclusion criteria – Consecutive patients admitted 
to the general medical service (GMS) teams 1 
through 4 with either known diabetes mellitus or 
inpatient hyperglycaemia (1 lab glucose value  
No 
Intention 
to treat 
analysis. 
 
Period of Study- 79 
days with each patient 
followed till discharge  
 
Effect of differences at baseline 
Even though the co-morbidity 
index was not significant 
between the group there were a 
The study was 
conducted in one 
institute with only 
four teams being 
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
hypoglycaemic orders, 
discharge orders and 
indication for endocrine 
consultation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>180mg/dL) 
 Exclusion criteria - pregnant, presented with 
HONK, DKA, receiving parenteral nutrition, other 
indication for insulin, receiving palliative care or 
had zero POC glucose determinants 
Random allocation of clusters –Method of random 
allocation not reported 
Allocation of participants to cluster – Not 
randomised to the teams likely followed usual 
admission protocol.  
Blinding - The providers prone to know who were 
in the intervention arm. Not clear if the patients or 
the data analysts were aware of this. 
Power 
calculatio
n done. 
Outcome 
measurement –
Measurement of the 
glucose values could 
have been varied 
between patients and 
lead to bias in 
outcome 
measurement 
 
Drop out or 
withdrawals –  
None reported 
higher percentage in the control 
group with an index of 4 or above 
(54%) compared to that of the 
intervention group (36%). When 
adjusting for the primary 
outcome this was not included.  
 
Effect of co-intervention 
Additional training and protocol 
for management provided for 
both arms equally. 
 
Factors not included in the study 
None identified 
 
 
involved in the 
randomisation 
process. Method of 
randomisation not 
described.  Since it 
is impossible to 
blind and because 
all wards were 
situated in the same 
floor with likely 
interaction between 
the staff 
contamination is 
likely to have 
occured.  
Schnipp
er, 2009 
[116] 
Before 
and after 
study 
III-2 
The study intervention 
consisted of three 
components,  
initiated in January 2006: 
1.  Glycaemic management 
protocol 
2. Diabetes education 
3. Order Set: an order set, 
built into the proprietary 
computer provider order 
entry (CPOE) system 
Inclusion criteria –  Inclusion - Eligible subjects 
were patients scheduled for admission to the 
hospital Physician Assistant/Clinician Educator 
(PACE) service with either a known diagnosis of 
type 2 diabetes mellitus or inpatient 
hyperglycemia (at least 1 random laboratory 
glucose >180 mg/dL) Exclusion Criteria - Type 1 
DM, Hyperosmolar hyperglycaemic non ketotic 
coma, Diabetic ketoacidosis, Total parental 
nutrition and patients receiving palliative care. 
 
Prospective recruitment of patients meeting 
eligible criteria for the study. 
Case mix 
index was 
not 
different 
but 
difference 
in Charlson 
index was 
statistically 
significant 
Intention 
to treat 
analysis 
 
Power 
calculatio
n done. 
Study period and 
follow up- 5 month 
before and after with 
patients followed up 
till discharge 
Outcome 
measurement – A 
complex primary 
outcome rather than 
the preferred patient 
day weighted blood 
glucose. The reported 
outcome depends on 
the number of 
measurement carried 
out. 
Drop out or 
withdrawals – None 
reported  
Effect of differences at baseline 
Adjustment made for baseline 
characteristics that determine 
glucose control but not for the 
co-morbidity index (Charlson 
Score). 
 
Effect of co-intervention 
Impossible to separate the effect 
of the other two components. 
 
Factors not included in the study 
Considering this is before and 
after study cannot exclude 
initiatives that took place during 
the same time period would not 
have contributed to the findings. 
 
Regression to the 
mean and secular 
trend change is 
possible considering 
it is a before and 
after study.    
Maynar
d , 2009 
[126] 
Observati
onal 
retrospec
tive 
study 
III-3 
Interventions evaluated 
had three components: 
 
1. Structured 
subcutaneous Insulin 
Inclusion criteria  
Adult inpatients on non-critical care units with 
electronically reported point of care (POC) glucose 
testing from November 2002 through December 
2005.  
Difference 
noted in 
Case-mix 
index score 
and % with 
Type of 
analysis  
and 
Power 
Calculati
Baseline period – Nov 
2002 to Oct 2003 
 
After structured order 
set period – Nov 2003 
Effect of differences at baseline 
 
Not adjusted for case mix index 
however the statistical 
significance of the outcomes are 
Regression to the 
mean and secular 
trend change is 
possible considering 
it is a before and 
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
Order Set (Order set 
introduced as paper 
based in Oct 2003 
and then as 
computer based 
from Jan 2004 to Sep 
2004). 
2. Inpatient insulin  
management 
algorithm 
3.  Background 
educational 
programme 
 
 
Exclusion criteria 
 Patients who did not have either a discharge 
diagnosis of Diabetes (ICD 9 codes 250- 
251.XX) or demonstrated hyperglycemias 
(fasting POC glucose >130 mg/dL, or a 
random value of >180 mg/dL) 
 Women admitted to Obstetrics  
 
To assess insulin usage insulin orders were 
audited. Monthly 70-90 orders were audited 
any 
intensive 
care unit 
days.  
on - Not 
reported 
to Apr 2005 
 
After structured order 
set and protocol 
period – May 2005 to 
Dec 2005  
 
Outcome 
measurement – 
Primary analysis for 
hyperglycaemia and 
hypoglycaemia 
included most data 
available. A secondary 
analysis has also been 
conducted to validate 
the findings using data 
obtained from those 
with 8 or more POC 
BG. 
highly significant.  
 
Effect of co-intervention 
The inpatient management 
protocol could explain the 
difference seen after its 
implementation. Equally there 
was likely background 
educational programme going on 
throughout which may explain 
some of the improvement that 
took place with the introduction 
of the order set alone. Beside the 
order set initially was paper 
based and therefore it is not 
possible to attribute the effect to 
computer based order set on its 
own. 
after study 
Murphy 
2009 
[125] 
Observati
onal 
Retrospe
ctive 
study 
Not 
applicabl
e 
Multi-component 
interventions included: 
 
1. Education regarding 
basal bolus concept 
and release of Non-
Intensive Care Unit 
(ICU) hyperglycaemia 
management 
protocol  
2. Insulin order sets in 
electronic medical 
records 
3. Guideline for 
inpatients on 
continuous tube feed 
Inclusion criteria 
 
Analysis was carried out on patients with any code 
on their hospital bill for diabetes as coded by the 
medical record department.  
 
Exclusion criteria 
 
Patients with hyperglycaemia not coded as 
diabetes, glucose readings <40 and >400mg/dL, 
patients younger than 18 years and observation 
cases were not included in the analysis 
Differences 
were not 
reported. 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Period of data 
analysis 
Stepwise introduction 
of intervention 
component from 2004 
to 2005.  Data analysis 
period 2003-2007 
 
 
Outcome 
Measurement Bias 
Not clear why median 
was chosen as the 
outcome when there 
were large number of 
BG values available.  
Effect of differences at baseline 
 
Possibly multiple considering 
characteristics of patients before 
and after are not described.   
 
Effect of co-intervention 
Many interventions reported and 
therefore results can be 
interpreted with electronic 
insulin order as a component of 
multiple interventions.   
 
Factors not included in the study 
–awareness about the inpatient 
glycaemic management was 
increased nationally during the 
same period 
 
Regression to the 
mean and secular 
trend change is 
possible considering 
it is a before and 
after study 
Achtme
yer, 
2002 
Observati
onal 
retrospec
III-3 
Modification of CPOE to 
prescribe insulin sliding 
scale according to best 
Inclusion criteria – Insulin orders using 
computerised order entry. Excluded orders written 
by surgical providers, one  time orders to 
Differences 
were not 
reported. 
Type of 
analysis  
and 
Period of study- 
34 weeks before 
intervention and 16 
Effect of differences at baseline 
 
Possibly multiple considering 
The intervention 
was poorly designed 
with alteration done 
Table2.1 – Quality Assessment of Studies 
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
[119] tive 
study 
practice supplement regular insulin and any orders written 
on wards not using full-computerised order entry.  
 
Extracted data on all electronic prescriptions for 
hospitalised patients (1 st Dec 1998 - 16th 
November 1999).  Intervention 26th July 1999. 
 
 
 
 
 
Power 
Calculati
on - Not 
reported 
weeks 
after intervention. 
 
 Shorter follow-up 
data after the 
intervention.  
 
Outcome 
measurement - There 
is a chance for 
misclassification when 
classifying orders  
before the 
intervention into the 
two categories 
(Traditional sliding 
scale orders as 
opposed to minimal 
intervention orders).  
characteristics of patients before 
and after are not described.   
 
Effect of co-intervention 
No co-intervention reported 
 
Factors not included in the study 
- Other than the baseline 
characteristics it is possible any 
teaching, junior doctors training 
that might have taken place 
during the time could have led to 
the improvement reported. 
 
 
 
later on due to 
physician request. 
 
 
Cook, 
2009 
[113] 
Descripti
ve 
observati
onal 
study  
Not 
applicabl
e 
Connective software to 
automatically transfer and 
analyse POC BG 
Inclusion criteria – Adult inpatient data on POC BG 
from January to December 2007 were collected.   
Exclusion Criteria: Out-of-range values of ‘‘LO’’ 
(<10 mg/ dL) and ‘‘HI’’ (>600 mg/dL) were 
discarded. The number of HI/LO values totaled less 
than 0.4% of the measurements. Repeat measures, 
largely performed to verify hypoglycemia were 
found to be present for <3% of the measures and 
were retained in the analyses. 
Not 
reported 
Not 
applicabl
e 
Period of data 
described – 1 year 
Outcome 
measurement – 
Description is based 
on the acceptable 
glucometrics 
published. 
 
 
Not applicable since it is purely 
descriptive of data show how 
data capture can be useful in 
describing outcomes. 
 
 
The study only 
describes the ability 
to capture POC-BG 
data from multiple 
sites in a hospital 
and between 
hospitals. The 
outcomes are 
therefore process 
orientated (abilty to 
connect all portals 
and produce 
measures of glucose 
control) and not a 
measure of end 
point in achieving 
better glycaemic 
control in hospitals. 
However 
considering this is 
important this study 
has been incluced in 
this review.    
Table2.1 – Quality Assessment of Studies 
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
Boaz, 
2009 
[114] 
Observati
onal 
retrospec
tive 
study 
III-3 
Program for the Treatment 
of the Hospitalised 
Diabetic Patient (PTHDP) 
with the Institutional 
Blood Glucose Monitoring 
System (IGMS) as an 
integral component 
Inclusion criteria – Included in the study were data 
from all internal medicine and surgical 
departments and intensive  care units. Data from 
pediatric, obstetrics, and emergency care  
departments were not included. Data  reported 
are those from the 15th day of each month, 
starting from August 2007 to October 2008. 
Included were  the results of any blood glucose 
test measured using the time stamped from 12:01 
through 23:59 on the 15th day of a given month. 
Not 
reported 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Period of study data - 
14 months 
Outcome 
measurement -  
Bias could have been 
introduced depending 
on the frequency of 
measurement of BG 
values of each patient 
and difference in 
measurement 
frequency throughout 
the period. It also has 
to be noted only the 
15th day of the month 
values were used to 
assess trend over 
time.    
Effect of differences at baseline- 
Multiple considering 
characteristics of patients before 
and after are not described.. 
Effect of co-intervention and 
Factors not included in the study 
- The glucose monitoring system 
which is a connectivity tool to 
monitor blood glucose in 
institutions has been used for 
measurement of outcome and 
does not consist as part of the 
main intervention. Therefore the 
change cannot be attributed to 
the connectivity tool alone. Also 
due to the before and after 
analysis many reasons could 
explain the change other than 
the connectivity tool and the 
glucose control program. 
Subject to 
Regression to the 
mean as well. 
 
Thomps
on, 
2009 
[120] 
Observati
onal 
retrospec
tive 
study 
III-3 
Multiple components 
implemented in stages 
over a period of 3 years. 
Multidisciplinary 
committee (Early 2003) 
established to develop 
glucose control program. 
The program consisted of 
1) subcutaneous insulin 
order form (May 2004) 2) 
Out of range glucose 
report derived 
electronically (Feb 2006), 
and 3) Clinical Intervention 
team (Aug 2006) 
Inclusion criteria – All patients hospitalised in non-
critical care wards - (medical, surgical, and 
psychiatric). They were categorised as 
dysglycaemic if they 1) received subcutaneous 
insulin or oral diabetic medication and had any 
single glucose level outside the normal range of 
>125 mg/dL or <60 mg/dL.. All others categorised 
as euglycaemic.  
Described 
difference 
between 
dysglycaem
ic patients 
and 
euglycaemi
c patients. 
However 
most 
outcomes 
(except 
Length Of 
Stay) are 
based on 
the trend in 
dysglycaem
ic patients 
over four 
years. 
Difference 
between 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Period of data 
reported- Looked at 
trend in prescribing 
and glucose control 
over four years. 
 
Outcome 
measurement –. 
There could have been 
many measurement 
error in the outcomes 
reported. It is not 
clear if all patients had 
blood glucose 
measurements done 
systematically. There 
are likely to be 
variation in the 
number of blood 
glucose recorded per 
patient and therefore 
the reported values 
 
Effect of co-intervention and 
factors not included in the study 
 
As noted during the same time 
period there was a greater 
emphasis for tigher glycaemic 
control and appropriate insulin 
usage which could explain most 
of the changes occurred.   
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
patients in 
each year 
has not 
been 
described. 
will not reflect the 
true picture. As in any 
trend analysis there is 
a chance for 
Regression to the 
mean. The subset 
selected for analyses 
of short acting insulin 
is fewer in number 
and therefore lacks 
the power to detect 
important reductions 
in sliding scale 
insulins. The reporting 
for hypoglycaemic 
episode is 
inappropriate. Trend 
analysis has been 
performed to the data 
available after the 
intervention only. The 
author defends the 
increase in 2004-2005 
to that of the global 
drive for intensive 
blood glucose control 
in in-patients.    
O'Neill, 
2006 
[118] 
Observati
onal 
Descripti
ve study 
Not 
applicabl
e 
Real time data displayed in 
a Diabetic Dashboard, 
which alerts the clinician 
to abnormal blood glucose 
values for hospitalised 
patients 
Inclusion criteria – Not reported. The findings 
reported are part of a report and poorly 
presented. 
 
 
Not 
reported 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Period of follow up- 
11 months 
 
Outcome 
measurement -  
The findings are 
reported as part of an 
article in the use of 
clinical informatic 
tools. No information 
on methods were 
provided. 
 
Effect of co-intervention and 
factors not included in the study 
 
Trend could have been due to 
chance and many other 
interventions not described in 
this paper.   
 
The paper was 
included to give a 
breadth of CDSS 
interventions that 
are in place. The 
causal relationship 
between the 
outcome and the 
interventions 
cannot be assessed 
due to inadequate 
reporting of 
methods used in the 
study.  
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Study Design 
Grading 
of study 
design 
# 
Intervention 
 
Recruitment of study participants 
 
Differences 
at baseline 
Analytical 
method 
 
Follow up and 
measurement bias 
 
Assessment of confounders 
Additional notes 
Roman, 
1995 
[122] 
Observati
onal 
retrospec
tive 
study 
III-3 
Identification of patients 
with blood glucose <40 
mg/dL or >450 mg/dL on 
two occasions or positive 
serum acetone >1+ 
through laboratory 
information system and 
reviewing documentation 
and management of these 
patients based on 4 
continuous quality 
improvement indicators 
Inclusion criteria – All patients with a blood 
glucose less than 40 mg/dL or greater than 450 
mg/dL on two occasions or serum acetone >1+ 
 
 
Not 
applicable 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Period of follow up- 3 
years 
 
Outcome 
measurement - Since 
the identification of 
patient is reliant on 
the laboratory system 
some hypo's could be 
missed if they are 
being measured on 
POC glucometers.  
 
Effect of co-intervention and 
factors not included in the study 
 
Different population with no 
characteristics reported and 
muliple components in the 
intervention makes it difficult to 
decide which could have led to 
the improvement.   
Given it is an anlysis 
over time without 
control it is subject 
to many bias.The 
trend could have 
been due to natural 
variation. 
 
Piwerne
tz, 1990 
[121] 
Observati
onal 
descriptiv
e study 
Not 
applicabl
e 
Clinical information system 
to store, retrieve and 
evaluate long term blood 
glucose monitoring data 
and to help identify type of 
diabetes patients. Three 
components of the 
information systems: 
DIALIN - Data bank 
designed for the use in 
hospitals or out clinics  
CAMIT - Diabetes 
management system for 
advanced evaluation of 
long-term blood glucose 
monitoring data. 
DIACONS - Expert system 
Which determines 
diabetes type and 
adequate initial therapy 
Inclusion criteria –  Not reported (Likely diabetes 
patients selected by a non random method to test 
components of the information system) 
 
 
Not 
applicable 
(uncontroll
ed study) 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Outcome 
measurement - 
outcome measures 
were not clearly 
defined.    
Drop out or 
withdrawals – not 
applicable (not a 
longitudinal study)  
Not applicable (the study did not 
evaluate clinical outcomes). 
 
 
 
The methodology is 
hardly described 
 
Schulz, 
1985 
[117] 
Case 
series 
with pre 
and post 
test 
outcome 
IV 
Insulin dose adjustment 
program based on 
handheld computer 
Inclusion criteria – Not reported. Included 
diabetes patients (primarily insulin dependant with 
C-peptide below 0.3 ng/ml and patients failing 
secondarily after oral antidiabetic therapy) 
admitted to the hospital for metabolic stabilisation 
Not 
applicable 
(uncontroll
ed study) 
Type of 
analysis  
and 
Power 
Calculati
on - Not 
reported 
Methods of follow up 
and outcome 
measurement were 
not described.    
 
 
Given the lack of a control group, 
regression to the mean could not 
be ruled out. Any changes in 
patient care that occurred during 
the study period other than the 
computer program could be 
confounding factors.    
The methods of the 
study are poorly 
described. 
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Results are described mainly based on outcomes as noted in glucose control and 
efficient insulin prescribing. Efficient insulin prescribing in this context refers to 
reduced errors in insulin prescription, increased use of basal insulin regimen and 
avoiding unnecessary sliding scale insulin. Summary of the individual study findings 
are categorised on the basis of types of interventions in table 2.2. 
2.3.2 Glucose control 
In assessing glucose control among inpatients, Point of Care Blood Glucose (POC 
BG) has been cited as more practical and therefore superior to that of venous 
sampling [127]. The ability to capture such information effectively using connectivity 
technology within and across hospitals was demonstrated by Cook et al [113]. Using 
recommended blood glucose measurement metrics [127] they were able to 
demonstrate difference in glucose control between Intensive Care Unit (ICU) and 
non-ICU settings and in between different hospitals. Boaz et al [114] in their analysis 
showed such an institutional blood glucose monitoring system as part of a glucose 
control program involving a multidisciplinary team and insulin treatment protocols 
can contribute to reduction in mean blood glucose and reduced hyperglycaemic 
events. Further description and discussion on the value of connective technology in 
capturing POC BG information is given in chapter 4 (section 4.4). 
Both the cluster RCTs [115,124] and before and after analytic studies 
[116,123,125,126] commenting on the effect of CPOE involving either an insulin 
order template, or modification of CPOE by inserting alerts on efficient insulin 
prescription guidelines reported significant reduction in patient day weighted mean 
blood glucose concentration or similar alternative measures (mean/median blood 
glucose). Reported reduction in patient day weighted blood glucose ranged from 
10.8 to 15.6 mg/dl (0.6 to 0.8mmol/l) from an initial/control value ranging from 158.3 
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to 179 mg/dL (8.8 to 9.9mmol/l). Wexler et al [124] in their Cluster RCT reported 
mean blood glucose (SD) reduction from 224 (57) to 194 (66) mg/dl (12.4 (3.2) to 
10.8 (3.7)mmol/l).  All but one [124] of these studies reported a statistically significant 
reduction in proportion of patients with hyperglycaemia. A case series using an 
insulin dose adjustment programme [117] and an active case finding approach using 
an information system [118] also reported reduction in mean blood glucose 
concentration.  
One observational study reported an increase in proportion of patient days with 
hypoglycaemia after the intervention, however the frequency of severe 
hypoglycaemic episodes was not different between the before and after intervention 
groups in this study [123].Neither of the two cluster RCTs or any other studies 
reported increase in hypoglycaemic events. One study reported a significant 
reduction [126].        
2.3.3 Effective use of insulin 
Greater use of basal insulin regimens was noted in all of the four studies considering 
this outcome [115,116,120,124]  but among the three studies reporting statistical 
significance only one was significant. Significant reduction in use of sliding scale or 
unnecessary use of supplementary short acting insulin was noted in 5 
[115,116,119,123,126] out of 7 [115,116,119,120,123,124,126] studies reporting 
these outcomes. Sliding scale refers to stat bolus doses of subcutaneous insulin, 
given in response to the blood glucose level and not changes to the rate of an 
intravenous insulin infusion in relation to prevailing blood glucose [47]. Roman et al 
[122] used an active case finding approach to identify in-patients with extremes of 
blood glucose or with positive ketones and reviewed their management. He reported 
improvement in quality indicators with time in two domains; 1) documentation of 
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capillary blood glucose; and 2) implementation and documentation of intravenous 
insulin infusions in needful patients. 
2.3.4 Miscellaneous outcomes 
Two [115,123] out of three studies showed significant increased testing for HbA1c as 
per hospital guidelines after the introduction of the CPOE [115,116,123]. One study 
reported a significant reduction in length of stay [116] whereas the other studies that 
reported length of stay did not identify any significant changes [115,123,124,126]. 
One study reported positively the validity and acceptance of information system to 
store and analyse data of diabetes in-patients [121] . 
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Study 
Coun
ty 
Design Intervention and Description 
Number of 
Participants* 
Mean 
Age (Yrs) 
Duration of 
Study 
Key Outcomes # 
Computerised Physician Order Entry System (CPOE) based interventions 
Wexler, 
2010 
[124] 
USA 
Cluster 
RCT 
Electronic Insulin Order Template 
 
Control - 63 
 
Intervention - 65 
Control- 
70 
 
Intervent
ion -68  
 
1 month 
  Control Intervention P Value 
 
Glucose Control 
Mean BG (mg/dL) 
 
 
224 
 
 
194 
 
 
0.004 
Prolonged Hyperglycaemia%(3 consecutive 
BG>240mg/dL) 
38 26 0.2 
Hypoglycaemia at any time <60mg/dL% 14 12 0.7 
Severe Hypoglycaemia at any time <40mg/dL% 1 0 0.5 
 
Efficient Insulin Use 
Basal insulin prescribed day of admission% 
 
 
31 
 
 
30 
 
 
0.9 
Basal insulin prescribed any time% 65 61 0.7 
Basal Insulin dose (Median Units) 16 18 0.4 
% on sliding scale insulin alone 35 38 0.7 
 
Length of stay (Median) 
 
5 
 
6 
 
0.6 
 
Guerra, 
2010 
[123] 
 USA 
 Obser
vationa
l 
retrosp
ective 
study 
Computerised Physician Order Entry 
based Hyperglycaemic Inpatient Protocol 
(CPOE-HIP)  
 
3 main elements: 
1. Modification of CPOE to comply with 
ADA guidelines  
2. In service training of all nursing 
personnel on the details of CPOE-HIP  
3. Hospital wide online availability of the 
HIP 
 Before - 241  
 
After - 197 
 Before - 
60.7  
 
After - 
58.1 
 Before -1 
month cross 
sectional data  
 
After -1month 
cross sectional 
data 
 Before After P Value 
 
Glucose Control 
Patient day weighted mean POC BG (mg/dL) 
 
 
175.5 
 
 
164.7 
 
 
<0.001 
Hyperglycaemic patient days% 16.9 13.8 <0.001 
Patient days on target for hyperglycaemia% 41.1 46.1 <0.001 
Hypoglycaemic patient days% 9.1 11.7 <0.05 
Severe hypoglycaemic patient days% 0.95 1.27 NS 
Efficient Insulin Use 
% on Insulin 
 
46.9 
 
63.9 
 
<0.001 
% in compliance with guidelines on insulin 
initiation and modification of dose 
36.4 50.7 0.067 
% on sliding scale insulin 22.8 0.5 <0.001 
 
Compliance with HbA1c testing% 
 
37.3 
 
64.5 
 
<0.001 
 
Length of stay (Mean) 
 
5.1 
 
5.2 
 
NS 
    
 
Table 2.2: Summary of characteristics and findings of included studies (categorised according to type of intervention) 
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Schnipp
er, 2010 
[115] 
 USA 
Cluster 
RCT 
Computerised order set with components 
on: 
 
Ordering diet  
Insulin prescriptions 
 POC testing 
HbA1c testing 
Hypoglycaemic orders 
Discharge orders 
Indication for endocrine consultation 
Control -89 
 
Intervention – 90 
Control - 
65.4 
 
Intervent
ion -64.8 
2-3 months 
  Control Intervention Effect Size P Value 
Glucose Control   (Adjusted)  
Mean % glucose readings 60-180mg/dL 
per patient 
71.3 74.6 RR=1.36 <0.05 
Patient day weighted mean POC BG 
(mg/dL) 
158.3 148.2 AD=12.5 <0.05 
Percent patient days with any glucose 
<60mg/dL% 
<40mg/dL% 
>300mg/dL% 
 
3.5 
0.3 
14.8 
 
6.8 
0.5 
7.3 
 
OR=1.85 
OR=2.54 
OR=0.38 
 
NS 
NS 
<0.05 
 
Efficient Insulin Use 
Basal insulin if inpatient 
hyperglycaemia% 
 
 
63 
 
 
76 
 
(Unadjusted) 
OR=1.8 
 
 
NS 
Nutritional Insulin if inpatient 
hyperglycaemia and oral intake% 
 
22 
 
41 
 
OR=2.4 
 
NS 
Adequate initial dose of nutritional 
insulin% 
20 67 OR=8 <0.05 
Supplemental insulin alone % 58 25 OR=0.2 <0.05 
Insulin order change if 2 or more 
previous day’s glucose out of range% 
 
HbA1c testing during hospitalization if 
not available within last 30 days% 
 
26 
 
 
48 
 
37 
 
 
63 
 
OR=1.65 
 
 
OR=1.8 
 
NS 
 
 
<0.05 
Length of stay (days) 5.7 6.2  NS 
 
Schnipp
er, 2009 
[116] 
USA 
Before 
and 
after 
study 
The study intervention consisted of three 
components, 
initiated in January 2006: 
1.  Glycaemic management protocol 
2. Diabetes education 
3. Order Set: an order set, built into the 
proprietary computer provider order 
entry (CPOE) system 
Before – 63 
 
After- 106  
Before-      
63.0 
 
After- 
64.7        
Prior to 
Intervention:         
5 months            
Post 
Intervention:  
5 months 
 Before After Effect Size P Value 
Glucose Control   (Adjusted)  
Mean % glucose readings 60-180mg/dL 
per patient 
59.1 64.7 AD=9.7 <0.05 
Patient day weighted mean POC Blood 
Glucose (mg/dL) 
174.7 164.6 AD=15.6 <0.05 
Percent patient days with any glucose 
<60mg/dL% 
<40mg/dL% 
 
5.5 
1 
 
6.1 
1.2 
 
OR=1.1 
OR=1.1 
 
NS 
NS 
 
Efficient Insulin Use 
Basal insulin if inpatient 
hyperglycaemia% 
 
 
81 
 
 
91 
 
(Unadjusted) 
OR=2.2 
 
 
NS 
Nutritional Insulin if inpatient 
hyperglycaemia and oral intake% 
 
40 
 
75 
 
OR=4.5 
 
<0.05 
Adequate initial dose of nutritional 
insulin% 
 
22 
 
45 
 
OR=2.9 
 
NS 
Supplemental insulin alone % 29 8 OR=0.2 <0.05 
Insulin order change if 2 or more previous 
day’s glucose out of range% 
 
HbA1c testing during hospitalization if 
not available within last 30 days% 
 
56 
 
60 
 
56 
 
70 
 
OR=1 
 
OR=1.5 
 
NS 
 
NS 
 
Length of stay (Hours) 
 
112.2 
 
86 
(Adjusted) 
RI=-25% 
 
<0.05 
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Study 
Coun
ty 
Design Intervention and Description 
Number of Study 
Participants* 
Mean 
Age (Yrs) 
Duration of 
Study 
Key Outcomes 
Maynar
d, 2009 
[126] 
USA 
Observ
ational 
prospe
ctive 
study 
Interventions evaluated had three 
components: 
 
1. Structured Subcutaneous Insulin 
Order Set (Introduced as paper 
based in Nov 2003 and then as 
computer based from Jan 2004 to 
Sep 2004). 
 
2. Inpatient insulin management 
algorithm 
 
3. Background educational 
programme 
 Glucose Control 
Assessment 
Baseline(TP1) – 
2504 patients 
After structured 
order set  (TP2) -
4515 patients 
After structured 
order set plus 
protocol (TP3)– 
2295 patients 
 
Effective Insulin 
use assessment –  
70 to 90 orders 
sampled each 
month  
Baseline – 477 &  
TP1 -  499 patients 
Baseline 
period 
(TP1)– 56 
After 
Structure
d Order 
period 
(TP2)  – 
56 
After 
structure
d order 
set and 
protocol 
period 
(TP3)– 56 
Baseline period 
(TP1) – Nov 
2002 to Oct 
2003 
After 
Structured 
Order period 
(TP2)  – Nov 
2003 to Apr 
2005 
After 
structured 
order set and 
protocol period 
(TP3)– May 
2005 to Dec 
2005 
 TP1 TP1 TP2 RR (TP3 
Vs. TP1) 
P Value 
Glucose Control      
Patient day weighted mean  
(mg/dL) 
179 170 165 NA NR 
% Uncontrolled patient days 
(Patient day mean> 180mg/dL) 
37.8 33.9 30.1 0.79 <0.005 
% Uncontrolled patient stay 41.5 37.6 34.2 0.84 <0.005 
% Hypoglycaemic patient days 
(<60mg/dL) 
3.8 2.9 2.6 0.68 <0.05 
% Hypoglycaemic patient stay 11.8 9.7 9.2 0.77 <0.05 
% Severe hypoglycaemic patient 
days (<40mg/dL) 
0.74 0.52 0.57 0.77 NS 
%Severe hypoglycaemic patient 
stay 
2.9 2.1 2.4 0.82 NS 
Efficient Insulin Use      
Sliding scale insulin % 72 26 NR  <0.0001 
Length of stay (Days) 4.6 4.6 4.8  NS 
 
Murphy
, 2009 
[125] 
USA 
Observ
ational 
Retros
pective 
study 
Multi-component interventions included: 
1. Education regarding basal bolus 
concept and release of Non-ICU 
hyperglycaemia management protocol 
2. Insulin order sets in electronic medical 
records 
3. Guideline for inpatients on continuous 
tube feed 
Analysis done on 
blood glucose 
values. Number of 
values ranged 
from 29 
591(2003) to 48 
965 (2007) 
Not 
reported 
Stepwise 
introduction of 
intervention 
component from 
2004 to 2005.  
Data analysis 
period 2003-
2007 
Glucose Control 
 
Median Glucose Level – Before 159mg/dL (2003) to After 135mg/dL (2007) 
Hyperglycaemia – (% Patients with a measurement of >180mg/dL in a day)  Before 66% After 53% 
Hypoglycaemia - (% Patients with a measurement of <60 mg/dL in a day) Before 6% After 6% 
Achtme
yer, 
2002 
[119] 
 USA 
Observ
ational 
retrosp
ective 
study 
Modification of CPOE to prescribe insulin 
sliding scale according to best practice 
Prescriptions of 
insulin: Pre-/  
Post-intervention      
(n= 1007/n=398) 
Not 
reported 
34 weeks before 
(Dec 98 to Aug 
99 )and 16 
weeks after (Aug 
to Nov 99) 
Sliding scale insulin orders as a proportion of regular insulin prescription reduced from 97.1% to 63.8% 
(P<0.001). (Denominator are insulin prescriptions and do not include prescriptions for oral medications). 
Connectivity technology based interventions (POC blood glucose values transferred to a central information system to analyse) 
Cook, 
2009 
[113] 
USA 
Descrip
tive 
observ
ational 
study  
Connective software to automatically 
transfer and analyse POC BG 
12,559,305 POC-
BG values from 
1,010,705 
patients  
Not 
reported 
1 year (Jan to 
Dec 2007) 
Ability to describe glucose control for a given period: 
1. Patient-day-weighted mean POC-BG  Non-ICU 166 mg/dL and ICU - 165 mg/dL 
    2.Hyperglycaemia - Proportion of patient-days with a patient-day-weighted mean POC-BG >180 mg/dL -   
        31.3% in non-ICU and 26.3% in ICU. 
    3. Hypoglycaemia Proportion of patient days with a recorded BG <70 mg/dL -3.5% of patient-days in    
         the non-ICU and 10.1% of patient-days in the ICU setting.  
    4.Relationship between hospital patient-day-weighted mean POC-BG values and specific hospital   
        characteristics: ICU - Hospitals with <200 beds had significantly higher patient-day-weighted mean    
        POC-BG levels than those with 200 to 299 beds (P < 0.05), 300 to 399 beds (P < 0.01), and 400 beds (P <  
        0.001). Rural hospitals - higher patient day- weighted mean POC-BG values compared to urban  
        community and academic hospitals (both P < 0.001). Similar less pronounced differences in non-ICU. 
Boaz, 
2009 
[114] 
Israel 
Observ
ational 
retrosp
ective  
Program for the Treatment of the 
Hospitalised Patient having diabetes with the 
Institutional Blood Glucose Monitoring 
System (IGMS) as an integral component 
5951 POC-BG 
values 
Not 
reported 
14 months (Aug 
2007 to Oct 
2008) 
1)  Mean blood glucose prior Vs after program: 206 vs. 186 mg/dl, (p < 0.0001). 
2) Hyperglycaemic events (> 300 mg/dl) prior Vs after program: 16.2% Vs 10.2% (p < 0.0001)  
3) “In target” values (between 80 and 200 mg/dl) prior Vs after program: 55.4% Vs 61.6% (p < 0.0001)  
4) Hypoglycaemic events (<60 mg/dl) prior Vs after program:  1.48 Vs. 1.4%.  (p = 0.2).  
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Active case finding of in need patients using information systems 
Thomps
on, 
2009 
[120] 
 USA 
Observ
ational 
retrosp
ective 
study 
Multiple components implemented in 
stages over a period of 3 years. 
Multidisciplinary committee (Early 2003) 
established to develop glucose control 
program. The program consisted of 1) 
subcutaneous insulin order form (May 
2004) 2) Out of range glucose report 
derived electronically (Feb 2006), and 3) 
Clinical Intervention team (Aug 2006 ) 
18 088 
Dysglycaemic 
patients  
 48.4 
years for 
all four 
years 
4 years (Jan 
2003 to Dec 
2006) 
Glucose Control 
1) No significant decline in hyperglycaemia over 4 years 
2) % of hypoglycaemia increased from 2003 to 2004. From 2005 significant decline (P=0.003). 
3) % dysglycaemic patients receiving basal insulin increased (≈ 10% to 27%)  
 
Efficient Insulin Use 
4). % dysglycaemic patients receiving short acting insulin increased (≈ 35% to 52%).  
5) The ratio of short acting to basal insulin decreased from 3.36 (2003) to 1.97 (2006).  
6) Subset random analysis of 100 case notes - Reduction in sliding scale insulin from 16% to 4% and an 
increase in prandial correction dose from 8% to 32%.  
7) No significant change in length of stay 
O'Neill, 
2006 
[118] 
 USA 
observ
ational 
descrip
tive 
study  
Real time data displayed in a Diabetic 
Dashboard, which alerts the clinician to 
abnormal blood glucose values for 
hospitalised patients 
Not reported 
Not 
reported 
11 months 
Mean blood glucose level reduced from 171.6 to 158.2 mg/dl  with fewer “diabetes related health 
complications” 
Roman, 
1995 
[122] 
 USA 
Observ
ational 
retrosp
ective 
study 
Identification of patients <40 mg/dL or 
>450 mg/dL on two occasions or positive 
serum acetone >1+ through laboratory 
information system and reviewing 
documentation and management of these 
patients based on 4 continuous quality 
improvement indicators 
Eligible for: 
 Quality Indicator 
1 and 2 - (1989) -
101 , (1990) -90 
and (1991)- 135 
patients 
Quality Indicators 
3 and 4 - (1989) -
52 , (1990)- 48 
and (1991) -50 
patients 
Not 
reported 
3 years 
Quality Indicator 1 - Documentation of Capillary Blood Glucose Monitoring (1989) -83/101, (1990) 90/90 
and (1991) 135/135 p<0.001.  
Quality Indicator 2 - Appropriate response to hypo and hyperglycemias (1989) -94/101 , (1990) 78/90 and 
(1991) 132/135 p=0.1  
Quality Indicators 3 - Implementation and documentation of intravenous insulin infusions (1989) -23/52 , 
(1990) 26/48 and (1991) 46/50 p<0.001  
Quality Indicators 4 - Appropriate use and management of intravenous insulin infusion (1989) -42/52 , 
(1990) 42/48 and (1991) 46/50 p=0.1 
Miscellaneous clinical decision support system initiatives 
Piwernet
z, 1990 
[121] 
Ger
man
y 
Observati
onal 
descriptiv
e study 
Clinical information system to store, 
retrieve and evaluate long term blood 
glucose monitoring data and to help 
identify type of patients with diabetes. 
Three components of the information 
systems: 
DIALIN - Data bank designed for the use 
in hospitals or out-patient clinics  
CAMIT - Diabetes management system 
for advanced evaluation of long-term 
blood glucose monitoring data. 
DIACONS - Expert system which 
determines diabetes type and adequate 
initial therapy 
CAMIT - 10 type 1 
patients with 
diabetes.  
Acceptability of 
computers in 
hospitals - 37 
discharged 
patients with 
diabetes.  
DIACONS validity 
in identifying type 
of diabetes –83 
patients with 
diabetes.  
Not 
reported 
NA 
CAMIT - precision of data 96% tested with 10 type 1 patients with diabetes.  
Questionnaire on attitude towards information system for diabetes reported “positive attitude”  
Type of diabetes derived by DIACONS was 94% identical to that of the judgement of two experts. 
Schulz, 
1985[117
]] 
Ger
man
y 
Case 
series  
Insulin dose adjustment program based 
on handheld computer 
10 inpatients 
Not 
reported 
7 days  Mean blood glucose value dropped from 194 mg/dL to 136 mg/dL in 5 days among inpatients. 
*individuals unless specified otherwise (example: prescriptions, blood glucose values)  
# BG –Blood glucose, POC BG – Point of care blood glucose, RR-Relative risk, AR – Absolute difference, OR – Odds ratio, RI – Relative increase, NR – No results available, NA – 
Not applicable, NS – Not significant 
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2.4 Discussion 
There is consistent evidence that CDSS can improve glucose control in inpatients 
and reduce sliding scale insulin use and to a more limited extent promote basal-
bolus insulin regimen.  However the studies are sub-optimal in quality and often the 
intervention is part of a complex programme making it difficult to attribute the effect 
solely to the CDSS alone. Active case finding of patients with diabetes in need of 
specialist team review utilising information systems can be useful but there were no 
clear criteria or mechanisms on how this can be achieved.  
The findings can be explained by exploring the mechanisms by which CDSS could 
lead to improved care for patients with diabetes (Figure 2.2). Reviews 
[85,89,128,129] have shown change in prescription behaviour and better compliance 
with guidelines where CPOE systems have been utilised. This should lead to 
efficient prescription of insulin and oral hypoglycaemic agents which in turn will result 
in avoidance of inappropriate sliding scale insulin and increased basal insulin 
regimen prescriptions.  Reduction in adverse drug events have been shown to 
reduce with CDSS system used for prescription of other medications [83,87,130]. 
Considering insulin prescriptions are prone to error and often can lead to harm [36] 
an efficient CPOE will negate these adverse events. 
Connectivity technology where POC BG results can be automatically integrated into 
the laboratory system will enable monitoring of hospital performance and thereby 
enhance actions to improve care. It will also allow for an online quality control 
program to validate the performance of POC BG meters [131]. Soon systems can 
also be instrumental in actively identifying patients that need to be managed by the 
multidisciplinary diabetes team. At present diabetes teams depend on inpatient 
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referral from other teams to intervene in patients needing their expertise. Information 
systems [118,120,122] and electronic referrals can be utilised to provide efficient 
referral to specialist teams. Previous studies have demonstrated better patient 
outcomes and reduced length of stay where, for example, diabetes specialist nurses 
have been utilised in the care of patients with diabetes [132,133].  
On the other hand not all electronic alerts are adhered to [134] and provision of the 
CDSS does not guarantee staff engagement or uptake of the system [135]. Even 
more often social, organisational and contextual characteristics are overlooked when 
implementing such systems [136]. In designing CDSS it is important they are not 
only based on evidence but take consideration of these factors to increase health 
care provider’s adoption and to reduce prescription errors.  
The main strengths of this review are its clearly defined search strategy and its 
inclusive approach in the types of interventions studied. The search strategy had few 
limits, spanned across all languages and included a secondary search strategy to 
minimise the chance of missing a relevant study. However most of the studies were 
from USA with only a few from elsewhere. Considering many European countries 
have implemented CDSS as well it was surprising to note the lack of evaluation of 
these systems in diabetes care.  Therefore the existence of publication bias cannot 
be ruled out. The studies often contained a before and after analysis without a 
concurrent control group. The interventions were often part of a complex strategy 
such that it was not possible to identify specifically the impact the CDSS has had on 
diabetes care. A previous review on the quality of studies reported in CPOE 
suggested time series analysis and regression-discontinuity analysis as alternative to 
randomised controlled trials where they are not pragmatic to conduct [110]. We were 
also not able to carry out a meta-analysis on the impact such system have on control 
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of blood sugar since the interventions were heterogeneous and the outcomes were 
reported in different metrics. The challenges we faced are similar to other reviews in 
CDSS [110,137]. Nevertheless the review identifies pragmatic approaches that can 
be incorporated into an efficient information system to maximise the care for 
hospitalised patients with diabetes.    
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Figure 2.2: Mechanism through which CDSS improve diabetic care in hospitals 
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2.5 Conclusions 
In the UK, electronic health records and CDSS have been increasingly implemented 
in the last decade within hospital setting. The findings of the study should help 
diabetes care providers to decide on the elements that need to be incorporated into 
the CDSS. These include (1) implementing validated alerts and guidelines on 
prescriptions of antidiabetic medications especially insulin, (2) planning ahead to 
capture POC BG values into their information system to provide timely care and 
monitor hospital performance, and (3) identifying referral criteria that can be 
incorporated into the CPOE to target patients with diabetes in need of specialist 
team input. Guidance on safe insulin prescription and glucose parameters to include 
in the alerts for hypoglycaemia  are available from the Joint British Diabetes Society 
guidelines [47,48].    Future studies evaluating CDSS should consider improving their 
methodology to study them within a complex programme in a controlled 
environment.  
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CHAPTER 3 
Electronic prescription data can be useful in 
finding ‘lost’ discharge codes for diabetes 
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3 Electronic prescription data can be useful in finding ‘lost’ 
discharge codes for diabetes  
3.1 Background 
In the first chapter we noted hospital admissions of patients with diabetes have been 
increasing steeply in parallel with the increasing prevalence of known diabetes in the 
general population. Research has also highlighted the financial implication of 
diabetes related hospital admissions, currently estimated to be about 12% of total 
hospital expenditure [103,138]. An accurate assessment of inpatient prevalence of 
diabetes is critical for effective planning of hospital diabetes services. The National 
Diabetes Inpatient Audit (NaDIA) for 2010 and 2011 found that 15% of audited beds 
were occupied by people with diabetes [14,15] . However current systems for data 
capture do not provide this level of accuracy, and appear to under-estimate the 
actual prevalence of hospitalised patients with diabetes. Anwar et al [139] linked 
primary care data to hospital data in Scotland and Whitston et al [42] linked Hospital 
Episode Statistics (HES) to the National Diabetes Audit (NDA) data in England and 
they estimated that underreporting occurred in 41% and 33% respectively of 
admissions with a diabetes diagnosis.  
As a result national bodies (in England) have asked for systems to be designed and 
implemented to improve diabetes-related discharge diagnostic coding [140]. 
Although the data linkage methodologies used in the analyses described above are 
useful for estimating diabetes underreporting, they are inadequate for real-time 
correction of missed diagnostic codes. I aimed to estimate the frequency of missed 
discharge diagnostic codes for diabetes using inpatient electronic prescription data 
and also to look at the feasibility of this approach in real-time correction. Based on 
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the correction I also aimed to estimate the impact it would have on diabetes related 
payments to the hospital Trust.  
3.2 Methods 
3.2.1 Population and health information systems 
University Hospital Birmingham (UHB) is a large (approximately 1200 bed) teaching 
hospital based in the West Midlands, UK which delivers secondary care services to 
the adult population of South Birmingham. However given that it is a tertiary hospital, 
patients are admitted from across the West Midlands region and beyond. 
Furthermore UHB is the main hospital in UK that provides care for military personnel 
(Royal Centre for Defence Medicine). A separate hospital (Birmingham Women’s 
Hospital) situated close to UHB provides women’s health services and another 
hospital (Birmingham and Solihull Mental Health NHS Foundation Trust) provides 
mental health services. A children’s hospital is situated a mile away and provides 
health care for children below the age of sixteen (Birmingham Children’s Hospital). 
These are not part of the services provided by the UHB. 
Inpatient admissions, aged 16 years old and older were identified using the Patient 
Administration Database (PAS) in the period 2007 to 2010 inclusive (4 years). The 
PAS database record information on age, gender, ethnicity, address (post code), 
admission, discharge and transfers, number of consultant episodes, inpatient death, 
type of admission, and discharge destination. Admission is defined as the time spent 
by an individual from recorded time of entry to recorded time of exit from the hospital, 
irrespective of the number of ‘finished consultant episodes’ the patient had during the 
entire stay.   Elective and emergency care admissions were included; regular day 
attendees and day cases were excluded from the analysis.  
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The PAS database was linked using unique patient identifiers (hospital number) and 
admission date/ time to a locally-developed electronic prescription computer system 
(Prescribing, Information and Communication System or PICS) which records all 
inpatient prescriptions. It is a purpose-designed system which also records 
laboratory results and electronic observations and generates alerts to reduce 
prescription errors and notify abnormal blood results [141]. Considering most of the 
analyses carried out required information from the PICS database (for example 
prescriptions, electronic observations and blood results), only data that we were able 
to link has been used for analyses throughout this thesis.  
3.2.2 Categorising diagnosis of diabetes 
Initially an admission was defined as having diabetes mellitus if they had an 
International Classification of Diseases version 10 (ICD-10) diagnostic codes of E10-
E14 or any of their sub classifications in the PAS database. I then interrogated the 
PICS audit database looking for admissions that were prescribed diabetes related 
medication. Medications included were from chapter 6.1 of British National 
Formulary [142] including all types of insulins, suphonylureas, biguanides and other 
anti-diabetic medications. Patients were categorised as having diabetes based on 
this prescription data if they were on any of the medications used for diabetes and 
did not meet the following exclusion criteria: 1) patients on metformin alone with a 
discharge diagnostic code for polycystic ovarian syndrome, or 2) patients who 
received short or rapid acting insulin only (unless clearly specified it was for DKA or 
Hyper-Osmolar hyperglycaemic Non-Ketotic coma (HONK)). The latter exclusion 
criterion was chosen on the basis that some patients have been noted to receive 
insulin infusions for optimal blood glucose control in acute illness (intensive care 
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units) despite recent contrary evidence of benefit [143-145] or may have received 
these treatments for correction of hyperkalaemia.  
3.2.3 Comparison of admissions with diabetes who had and did not have a 
discharge diagnostic code for diabetes  
I compared the demographic characteristics, admission type, use of insulin, co-
morbidities (using the Charlson score[146]) and length of stay of patients who had 
discharge diagnostic code of diabetes and those who did not have but were 
identified through their prescribed medication. Demographic characteristics included 
were age, gender, ethnicity and deprivation quintile. Deprivation quintiles were 
defined using disaggregated income deprivation score rather than the entire Indices 
of Multiple Deprivation (IMD) score [147]. Income deprivation is often preferred in 
health care research considering the entirety of IMD includes health related domains, 
which can mask or exaggerate the effect size when studying health outcomes. 
Where analyses were limited to admissions with diabetes, as is the case in most 
parts of this thesis, I modified the Charlson co-morbidity score [146] to identify 
burden of co-morbidities other than diabetes by excluding the scores linked with 
diabetes [58]. Charlson co-morbidity score was categorised as those with a score of 
0, 1 and 2 or more. 
3.2.4 Cost of missed discharge diagnostic codes for diabetes 
In order to assess the financial impact of potentially missed diabetes codes on the 
inpatient tariff, I added the diabetes code to the Healthcare Resource Group (HRG) 
for those admissions identified from prescription data alone. HRG codes group the 
different ICD-10 discharge diagnostic codes for each admission along with the 
operative procedure codes (known as OPCS codes) to derive a tariff code. For 
consistency for the four year period under study (2007 – 2010) I used the HRG v4 
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software to derive the tariff code. Whilst prescription data can sometimes inform the 
diagnostic coding (for example classifying patients on any oral anti-diabetic 
medications as having non insulin dependent diabetes mellitus (E11)), this is not true 
for all patients. Therefore I took a pragmatic approach and gave an ICD-10 
diagnostic code of E10 (insulin dependent diabetes mellitus) if they were less than 
40 years old and on Insulin and E11 (non insulin dependent diabetes mellitus) for all 
other admissions.  
3.2.5 Statistical analysis 
3.2.5.1 Descriptive analysis of all admissions 
Initially a descriptive analysis was performed to identify any differences between the 
PAS data we were able to and not able to link with PICS. Continuous variables are 
described as means (standard deviation) if normally distributed and in medians 
(inter-quartile range) if skewed. Categorical variables are given as proportions.  
3.2.5.2 Capture-recapture technique to estimate missed discharge codes for 
diabetes 
Even by combining diagnostic codes and prescription data it is unlikely that all cases 
of diabetes will be captured in the linked dataset. The capture-recapture technique 
was therefore used to estimate the true frequency of missed diagnostic codes for 
diabetes [148,149]. This statistical technique was originally developed by ecologists 
to estimate animal populations. In an ecological setting the animal of interest are 
counted twice. In the first stage within a predefined area they are captured, counted 
then marked and released. In the second stage at a different time point in the same 
defined area they capture and count the total and within that they also make a note 
of the marked ones (subjects that were recaptured). Therefore there are three 
parameters: 1) captured only in the first phase (a); 2) only in the second phase (b); 
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3) in both phases (c). In a closed population if these two phases were to occur 
independent to each other then we could estimate the total (T) numbers by the 
following formula: 
T = (a+c) * (b+c) / c 
And the unknown (X) numbers by: 
X= (a) * (b) / c 
Since then the capture-recapture technique has been used extensively in 
epidemiological studies to determine incidence of disease (including diabetes) [150-
154] and in evaluating the completeness of registers [155-158].  A key assumption is 
the independence and equal “catch-ability” of the two sources. However, in health 
care data there is often dependence and at times for specific reasons only one 
source may be able to identify the subject. For example patients with diabetes on 
diet control alone may not be identified by using prescribed medication lists. To 
overcome these limitations, dependence and unequal “catch-ability” between the two 
sources, I used Chao’s formula [159,160]. This is given in the box below. 
Box 3.1: Chao’s formula 
 
 
 
 
 
X = f1
2
/ (2f2) 
N = Nobs + f1
2
/(2f2) 
Where:  
x = Estimate of Unknown 
N = Estimate of total 
Nobs = Number Observed  
f1 = Number of Subjects Captured once (a + b) 
f2 = Number of Subjects Captured twice (c) 
The calculation of variance is by: 
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I have reported the frequency of admissions with a missed diagnosis of diabetes as 
a percentage of admissions with diabetes estimated using the capture-recapture 
technique.  
3.2.5.3 Analyses of admissions with diabetes with and without a discharge 
diagnostic code for diabetes 
To investigate associations between admission characteristics and a missed 
discharge diagnostic code, a logistic regression model was fitted (outcome with that 
as missed diagnostic discharge codes), adjusting for admission characteristics. To 
account for multiple admissions of the same patient Generalised Estimated 
Equations (GEE) were used. The admission characteristics included in the model 
were age (years), gender, ethnicity, deprivation quintile (income deprivation score 
based on the patient’s postcode), modified Charlson co-morbidity score, type of 
admission (emergency or elective), insulin use and length of stay (LOS). I checked 
linearity of effect for both age and LOS. The effect of age was found to be 
reasonably approximated by a linear relationship; whereas the effect of LOS was 
non-linear, but linear on the log scale. Therefore log LOS was included as a 
covariate (rather than LOS itself). Data were analyzed using Stata 10 software, 
using the GEE class of models.   
3.3 Results 
There were 222,104 inpatient admissions recorded in the PAS database between 
2007 and 2010 of which we were able to link 171,067 admissions with the PICS 
audit database (77% linkage). Admissions that were not linked in comparison to 
those that were linked were younger (mean age 52.4 vs. 55.8); had a lower 
frequency of diabetes diagnostic code (8.9 vs. 13.1%); less likely to have Charlson 
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co-morbidity score of 1 or more (41.7 vs. 50.8%); and had a shorter median length of 
stay (0.88 vs. 2.83 days) (Table 3.1).  
Further description is limited to linked data. The majority (79.2%) of the admissions 
were from white ethnic background, with south Asians constituting 9% of the 
admissions. Most admissions came from the lowest two deprivation quintiles 
(60.7%); reflecting the higher deprivation levels in Birmingham. Two thirds of the 
overall admissions were emergency admissions. (Table 3.1)    
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Table 3.1: Characteristics of admissions identified in PAS database that were linked 
and not linked to PICS database  
 Linked to PICS 
(N=171 067) 
Not Linked to PICS 
(N=51 037) 
Age in years Mean 
(SD) 
55.8 (20.6) 52.4 (21.1) 
   
Gender N (%)*   
Male 91 018 (53.2) 27 992 (54.8) 
Female 80 038 (46.8) 23 045 (45.2) 
  
Ethnicity %   
White 135 550 (79.2) 39 570 (77.5) 
Asian 15 422 (9.0) 4 114 (8.1) 
Black 5 817 (3.4) 1 702 (3.3) 
Other 14 278 (8.3) 5 651 (11.1) 
   
#Deprivation 
quintile % 
  
Most deprived 5 63 753 (38.6) 18 219 (38.2) 
4 36 493 (22.1) 10 444 (21.9) 
3 31 485 (19.0) 8 742 (18.3) 
2 20 122 (12.2) 5 868 (12.3) 
Least deprived 1 13 455 (8.1) 4 420 (9.3) 
   
Diabetes code   
Yes 22 412 (13.1) 4 550 (8.9) 
No 148 655 (86.9) 46 487 (91.1) 
   
Charlson co-
morbidity score 
  
0 84 074 (49.1) 29 752 (58.3) 
1 36 480 (21.3) 7 324 (14.4) 
2 or more 50 513 (29.5) 13 961 (27.4) 
   
Type of Admission 
% 
  
Elective 56 601 (33.1) 16 458 (32.2) 
Emergency 114 466 (66.9) 34 579 (67.8) 
   
   
Length of stay    
Median (IQR) in 
days 
2.83 (1.12 – 7.58) 0.88 (0.25 -3.08) 
 
* Adds to 171 066 instead of 171 067 in the first column due to one missing value.  
#
Deprivation quintile is based on income deprivation score of the patient’s post code. Adds to 165 308 instead of 
171 067 and 47 693 instead of 51 037 respectively in the first and second column due to missing post code 
values.  
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3.3.1 Determining the missing discharge diagnostic codes for diabetes using 
electronic prescription data 
Among the 171,067 linked admissions, 22,412 (13.1%) were coded with diabetes at 
discharge (Table 3.2 and Figure 3.1). On the other hand in the prescription data 
there were 26,017 admissions that were on anti-diabetic medications, of which 
19,802 met our inclusion criteria for a prescription defined diabetes admission 
(Figure 3.1 and 3.2). 17,096 admissions were common to both databases (Figure 3.1 
and 3.2).  
An additional 2,706 admissions could therefore be classified as having diabetes 
based on prescription data, which would increase in-patient cumulative incidence of 
diabetes from 13.1% to 14.7% over this period of 2007 to 2010. The total number of 
admissions with diabetes estimated by the capture-recapture technique suggests 
that the number of admissions with diabetes not captured by both lists is likely to be 
1,882 (95%CI 1,765 – 1,999) which would further increase the estimated cumulative 
incidence to 15.8% (95% CI (15.7-15.9%) for the same period (Table 3.3).  
Therefore on the basis of using capture recapture technique in the linked data I was 
able to estimate that the overall admissions with a discharge diagnostic code of 
diabetes should total 27,000 and of the 4,588 (17% of total estimated admissions 
with diabetes and 2.7% of all admissions) that are missed by current coding, 2,706 
(60%) could be obtained from prescription data.  
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Figure 3.1: Patients admitted with diabetes identified through discharge diagnostic 
code and electronic prescription data for 2007-2010 
 
 
*flow chart of the medication defined patient with diabetes are shown in figure 3.2 
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Figure 3.2: Flow chart for medication based diagnosis of diabetes 
 
 
 
 
 
 
Total hospital inpatient 
admissions in PAS 
222 104 
Number of admissions 
linked to PICS 
171 067 (77%) 
Admissions on a diabetic 
medication 
26 017 
Admissions classified as 
diabetes based on 
medication 
19 802 
Classified as diabetes 
based on medication and 
no ICD 10 code 
2706 
ICD 10 code present 
 
17 096 
Excluded: 
PCOS on Metformin alone 
29 
Short acting insulin alone and 
not identified for DKA or 
HONK 
6 186 
Number of 
admissions not linked                       
51 037 (23%) 
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Table 3.2: Estimation of missed discharge diagnostic code and cumulative incidence using 
electronic prescription data 
 Discharge 
diagnostic 
code present 
Either discharge diagnostic 
code or electronic 
prescription present 
Estimated number of  
admissions with diabetes 
and 95% CI*  
Admissions with 
diabetes 
22 412 25 118 27 000 (26 882 – 27 117) 
Cumulative 
Incidence per 100 
linked admissions$ 
13.1% 14.7% 15.8% (15.7% – 15.9%) 
* Estimation based on two source capture recapture technique (see appendix 3) 
$ Denominator 171,067 linked admissions 
3.3.2 Characteristics associated with missing discharge diagnostic codes for 
diabetes 
After adjusting for covariates missed discharge codes for diabetes that were 
identified only through electronic prescribing data had lower levels of co-morbidity 
score (Odds Ratio (OR) for score of 1 = 0.65; 95%CI 0.58-0.72 and for score of 2 or 
more = 0.70; 95%CI 0.63-0.77) and shorter length of stay (Median days 2.25 vs. 3.92 
(P<0.001)). They were also more likely in females (OR 1.12; 95%CI 1.03-1.22) and 
less likely in black ethnic minority population (OR for black 0.77; 95%CI 0.62-0.96). 
No significant associations were found with age, deprivation quintiles, admission 
type and use of insulin (Table 3.3).  
3.3.3 Cost implication of missing discharge codes for diabetes 
Extrapolating these results we can calculate the financial impact of using prescription 
data to improve diagnostic coding of diabetes. By including missed diagnostic codes 
driven by the prescription data there would be a change to the HRG tariff code and 
payment in only 12.8% (347 out of 2,706) of admissions with a missing diabetes 
diagnostic code. If coded correctly, on average for each of these admissions, this 
change in tariff would have been associated with a financial gain of £550 (95%CI 
£500-600). 
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Table 3.3: Characteristics of admissions identified by a diagnostic code and those 
identified only through prescription data; adjusted odds ratios for missing diagnostic 
codes  
 ICD 10 Diagnostic 
code present 
(N=22 412) 
ICD 10 Diagnostic 
code absent 
(N=2 706) 
Adjusted
$
 Odds 
Ratio (OR) and 
95% CI 
P value 
Age in years Mean 
(SD) 
64.9 (15.1) 64.3 (15.0) 1.001 (0.998-1.003) 0.58 
     
Gender N (%)*     
Male 12 991 (58.0) 1 507 (55.7) 1  
Female 9 420 (42.0) 1 199 (44.3) 1.12 (1.03-1.22) 0.01 
     
Ethnicity %     
White 15 929 (71.1)  1889 (69.8) 1  
Asian 3 929 (17.5) 500 (18.5) 1.05 (0.93-1.18) 0.43 
Black 1 223 (5.5) 108 (4.0) 0.77 (0.62-0.96) 0.02 
Other 1 331 (5.9) 209 (7.7) 1.22 (1.04-1.43) 0.02 
     
#
Deprivation 
quintile % 
    
Most deprived 5 9 955 (45.5)  1 171 (44.7)  1  
4 4 905 (22.4) 549 (20.9) 0.97 (0.86-1.10) 0.52 
3 3 741 (17.1) 481 (18.3) 1.10 (0..97-1.24) 0.09 
2 2 093 (9.6) 263 (10.0) 1.08 (0.92-1.26) 0.26 
Least deprived 1 1 199 (5.5) 158 (6.0) 1.11 (0.92-1.34) 0.21 
     
Modified Charlson 
co-morbidity score
#
 
    
0 8 893 (39.7) 1 366 (50.5) 1  
1 4 904(21.9) 469 (17.3) 0.65 (0.58-0.72) <0.001 
2 or more 8 615 (38.4) 871 (32.2) 0.70 (0.63-0.77) <0.001 
     
Type of Admission 
% 
    
Elective  6 586 (29.4) 851 (31.4) 1  
Emergency 15 826 (70.6) 1 855 (68.6) 0.96 (0.88-1.05) 0.42 
     
Use of Insulin %     
Yes 12 023 (53.6) 1 378 (49.1) 1  
No 10 389 (46.4) 1 328 (50.9) 1.04 (0.95-1.13) 0.39 
     
Length of stay      
Median (IQR) in 
days
~
 
3.92 (1.42–10.08) 2. 25 (1.00–7.96) 0.88 (0.85-0.91)
~ 
<0.001 
 
* Adds to 22 421 instead of 22 422 in the first column due to one missing value.  
#
Deprivation quintile is based on income deprivation score of the patient’s post code. Adds to 21 893 instead of 22 422 and 
2 622 instead of 2 706 respectively in the first and second column due to missing post code values.  
$ 
Adjustment made for all covariates displayed in this table and none independence between patients with multiple 
admissions using mixed effects logistic regression.   
~
 Odds ratio is for log transformed data of the LOS. Log transformation was necessary to meet the assumption of linear 
association between the outcome and length of stay. 
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3.4 Discussion 
The study suggests that in UHB, about 17% of admissions with a likely case of 
diabetes are missed in the PAS data. Electronic prescription data can be useful in 
correcting up to 60% of the missed codes at discharge. Patients with fewer co-
morbidities and who had a shorter length of stay were more likely to have a missed 
code at discharge. However, adding a diabetes discharge code to the admissions 
with a missing code only made a difference to the tariff payment in 12.8% of these 
admissions. 
The estimate of missed discharge diagnostic code for diabetes (17%) using these 
novel techniques in one large hospital is lower than that of previous estimates in 
Scotland (41%) [139] and in England (33%) [42]. The differences could be due to a 
different time period, population characteristics or better coding practice by local 
clinical staff and coders. One advantage in UHB is the availability of electronic 
discharge summaries generated within the PICS system in addition to the 
traditionally available case notes and written discharge summaries (also known as 
Korner Medical Record or KMR) which may have impacted on better coding. 
Furthermore the England estimate also took patients who were admitted as day 
cases and regular day attendees, which I did not consider. The finding of the 
association between missed diagnosis and lower co-morbidity score and shorter 
length of stay is consistent with the Scottish study [139]. Adding the missed 
diagnostic code had only a minor impact on the tariff code (HRG) with only 1 in 8 
corrected admissions resulting in any potential financial gain. This latter finding may 
indicate a weakness of the tariff system in costing for diabetes patients, and is 
supported by a recent paper where Simmons et al [161] showed that the actual cost 
of treating diabetes patients is far higher than the tariff that they are paid for. This 
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clearly indicates that any future review of tariff codes should take into consideration 
diabetes and similar co-morbidities with adverse hospital outcomes.   
The method used to correct missed discharge diagnostic code can be undertaken in 
any hospital with electronic prescription data. However this will need data linkage 
with corrections taking place on a regular basis. Therefore I have proposed to 
incorporate an algorithm within the PICS system that can identify patients on a 
diabetic medication and clarify if these patients have diabetes or not to make a real-
time impact. A flow chart of the algorithm is given in figure 3.3. This will automatically 
ensure that a diagnosis of diabetes is part of the discharge summary and thereby 
reduce the proportion of missed discharge diagnostic codes for diabetes. 
This study has limitations and strengths. Not all of the inpatient admissions were 
linked, as many admissions with shorter periods of stay do not get entered into the 
electronic prescribing system. In addition the prescription source used to identify the 
missed discharge diagnostic codes itself may be incomplete. For example, there are 
difficulties in differentiating between the use of short acting insulin for diabetes and 
other clinical needs and in identifying patients with diabetes who are managed with 
diet control alone. The estimated correction of 60% may be lower if extrapolated to 
the whole inpatient admissions including those that were not linked. The strengths of 
this study include the use of capture-recapture methodology, rather than simply 
assuming both sources of data adequately capture all diabetes patients; obtaining 
estimates that tally with the prevalence noted in the national inpatient audit [14]. The 
cost estimates are crude and do not take into account of the admissions not 
identified by both sources or any complications associated with diabetes. However in 
my view findings of this study suggest HRG codes poorly estimate the cost incurred 
by patients with diabetes. 
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Figure 3.3: Proposed algorithm to incorporate into electronic prescription and health 
information system to reduce missed discharge diagnostic codes 
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3.5 Conclusions 
Electronic prescribing systems may be a simple solution to correct missed discharge 
diagnostic codes and could make a difference in real-time if incorporated with 
decision support reminders. Further in-depth analysis of the validity of HRG codes in 
reflecting the cost of caring for diabetes patients needs to be undertaken to inform 
any future revision of HRG codes. 
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CHAPTER 4 
Inpatient Hypoglycaemia and Glucose Metrics 
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4 Inpatient Hypoglycaemia and Glucose Metrics 
4.1 Overview 
 
In chapter two I identified the usefulness of having an institutional blood glucose 
monitoring system [162].  Firstly this can enable a hospital to keep track of the 
number of admissions with ‘poor glucose control’ [113,114]. Secondly a centralised 
system with recording of point of care blood glucose (POC BG) can alert diabetes 
specialist teams to proactively identify and guide treatment of patients with severe or 
recurrent hypoglycaemia as well as patients with persistent hyperglycaemia 
[118,122]. An additional benefit is the ability to have an online quality control 
program to validate the performance of the glucose meters [131]. Furthermore it may 
be possible for diabetes specialist nurses to support wards with unexplained poor 
glucose control. This will lead to improvement of staff skills in managing patients with 
diabetes. 
In UHB until early 2012 all POC BG values were encouraged to be entered into the 
PICS system. This meant POC BG values were available as electronic observation 
charts.  However this was dependant on health care professionals entering values 
manually into the computers rather than using an automated system. Often there 
were missing blood glucose values during the period of the data I have analysed 
(2007-2010). At present some units have started replacing previous glucose meters 
with newer ones that can automatically feedback the values into the central server 
from a docking station (Figure 4.1).   
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Figure 4.1: Institutional blood glucose monitoring system 
 
*RALS –Remote Automated Laboratory System; HIS - Health Information System;  POCC – Point of Care Co-ordinator; TGCM 
– Tight Glycaemic Control Module; IMS – Information Management Station; LIS – Laboratory Information System; RRC – RALS 
Remote Connect  
 
Source: Cook CB et al. Diabetes Technol.Ther. 2007; 9:493-500. [163] (reproduced with permission) 
 
Before implementing strategies to incorporate an institution wide glucose monitoring 
system we need to answer the question: “how do we define good quality glucose 
control in a non critical care setting?” This question arises because, even though 
there is evidence that hyperglycaemia is associated with poor clinical outcomes as 
noted in the introduction (chapter 1), there is no clear evidence of the benefit of good 
glycaemic control and the best target range for patients with diabetes in non critical 
care setting. Further findings in critical care suggest tight glycaemic control 
(<6.1mmol/l) may be harmful to patients [144,164] contrary to previous belief. It is in 
this context that based on available evidence the American Diabetes Association 
(ADA) and UK guidelines recommended to keep the pre-meal glucose to below 
7.8mmol/l and post-prandial glucose to less than 10mmol/l in non-critically ill patients 
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[47,104]. At the same time hypoglycaemia should be avoided as this could lead to 
poor clinical outcomes [58]. However data to support the latter among in-patients 
with diabetes in non critical care is lacking, especially here in UK. This is addressed 
in the first section below (4.2) where I look at the: “Association of hypoglycaemia with 
length of stay and inpatient mortality in hospitalised patients with diabetes”. 
Recent events in Stepping Hill Hospital, where malicious use of insulin is suspected 
to have caused hypoglycaemia and death in elderly patients [165], has highlighted 
patient safety issues with insulin use. Unexplained hypoglycaemia in a non-diabetic 
patient or a cluster of hypoglycaemic incidents might be the only initial clue to such 
untoward incidents. One of the benefits of an institution wide glucose monitoring 
system is its ability to function as a surveillance tool in monitoring frequency of 
hypoglycaemia both in patients with and without diabetes. The system may have the 
potential to identify unexplained non diabetic hypoglycaemia provided: 1) they can 
be identified as non diabetic, which could be achieved by incorporating the algorithm 
in chapter 2; and 2) the number of occurrences of hypoglycaemia is within a 
manageable number to monitor in real-time and where necessary to review case 
notes. At present there are no precise estimates of the frequency of non diabetic 
hypoglycaemia in a non critical care setting. Furthermore as discussed earlier, in 
UHB the electronic observation charts of POC BG are not sufficiently complete to 
establish such a surveillance system. In the second section (4.3) of this chapter titled 
“Frequency of hypoglycaemia in non-diabetic hospitalised patients and the feasibility 
of setting up a surveillance system”, I have aimed to estimate the frequency of non 
diabetic hypoglycaemia in non critical care setting. At the same time I have looked at 
the feasibility of using available blood glucose values, prescription data of treatments 
given for hypoglycaemia and discharge diagnostic codes for hypoglycaemia as 
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databases that may assist in establishing a surveillance system to detect 
unexplained non diabetic hypoglycaemia. 
Finally in the last section of this chapter (4.4) I examine the utility of the quality 
indicators that have been described in the literature to monitor inpatient glucose 
control. 
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4.2 Association of hypoglycaemia with length of stay and inpatient 
mortality in hospitalised patients with diabetes  
 
4.2.1 Background 
Hypoglycaemia is common in hospitalised patients with diabetes [58,144,164,166]. 
In critical care hypoglycaemia is associated with prolonged length of stay and 
mortality irrespective of the diabetes status [144,164]. Limited evidence exists on the 
effect of hypoglycaemia on length of stay and mortality in a non critical care setting. 
A study by Turchin et al [58] based on analysis of 4,368 admissions in one teaching 
hospital (Boston, USA), showed that among inpatients with diabetes an episode of 
hypoglycaemia (< 2.8mmol/l), in comparison to no hypoglycaemia, was associated 
with increased length of stay, an 85% increase in the odds of inpatient death and a 
65% increase in the odds of death at 1 year.  The study elicited the relationship by 
categorising the exposure (hypoglycaemia) based on lowest recorded blood glucose 
as those with and without a value less than or equal to <2.8mmol/l and comparing 
their outcome during inpatient stay (length of stay and mortality) and after discharge 
(1 year mortality). In addition to these findings he showed that there was an 
incremental higher risk of inpatient mortality and excess length of stay with an 
increase in the number of hypoglycaemic days they encountered during their hospital 
stay. Another recent study from New York, USA reporting on mortality in a mixed 
population of patients, with and without diabetes, suggested that hypoglycaemia is a 
marker of disease burden and the greater mortality observed can be explained by 
the association between the hypoglycaemia and co-morbidities [166]. 
UK data is sparse on the outcome of in-patients with diabetes who have had a 
hypoglycaemic episode. It is important we know these outcomes to monitor and 
improve care through implementation of interventions that will reduce hypoglycaemic 
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episodes and adverse outcomes associated with them. To address this I studied the 
difference in length of stay and inpatient mortality of patients with diabetes who had 
and did not have an episode of hypoglycaemia in a non critical care setting at 
University Hospital Birmingham (UHB). The hospital as described previously has a 
purpose-designed computer-based patient information system, the Patient 
Information and Communication System (PICS), which records laboratory results, 
electronic observations and medication orders, and a Patient Administration System 
(PAS) which records discharge diagnostic codes. Therefore I had the opportunity to 
analyse retrospective data available for the year 2007 to 2010 from blood glucose 
concentration measurements, both from the bedside (POC BG) and the laboratory 
results of patients identified as having diabetes based on discharge diagnostic codes 
and prescribed diabetic medication. 
4.2.2 Methods 
4.2.2.1 Data sources 
Data sources have been described in detail in chapter 3. In summary I identified all 
patients 16 years old and above who were registered in the PAS as having been 
admitted to UHB during the period of 2007 to 2010 as either an elective or 
emergency inpatient admission. PAS data were linked to the PICS data and patients 
with a recorded diagnosis of diabetes in the PAS, or who did not have a diabetes 
diagnostic code but were identified in PICS as having received treatment with anti-
diabetic medication, were classed as having diabetes if they did not meet the 
exclusion criteria. The exclusion criteria were 1) patients on Metformin but without a 
discharge diagnostic code of diabetes and with a discharge diagnostic code for 
polycystic ovarian syndrome 2) patients who received short or rapid acting insulin 
alone but without a discharge code of diabetes. The latter criteria was chosen to 
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avoid misclassifying patients as having diabetes when they might have received this 
treatment for hyperkalaemia or control of blood sugar in seriously ill patients with 
hyperglycaemia.  
Only admissions with at least one recorded blood glucose concentration were 
included for the study. All admissions with a stay in intensive care unit (ICU) were 
excluded from the analysis. Any inconsistent records, where a discharge diagnostic 
code for hypoglycaemia was present but blood glucose values did not indicate 
hypoglycaemia, were also excluded from the analysis.  
I identified episodes of hypoglycaemia at any point during the admission by 
interrogating blood glucose concentrations from the PICS database, recorded either 
from bedside (POC BG) or laboratory. I did not differentiate between laboratory 
blood glucose values and point-of-care blood glucose values, or consider the type of 
equipment used to measure glucose values.  
4.2.2.2 Cut-off value for hypoglycaemia 
I used the NHS Diabetes guideline treatment cut-off value (3.9mmol/l or less) to 
categorise hypoglycaemia [48]. Severe hypoglycaemia is best categorised by the 
need for third party assistance in treating the episode. Considering this information is 
not possible to obtain from the data, a cut-off value of 2.2mmol/l was used to 
describe severe hypoglycaemia [167]. Therefore blood glucose concentration of 
greater than 3.9 mmol/l were categorised as non hypoglycaemic; 2.3 to 3.9mmol/l as 
mild to moderate hypoglycaemia; and less than or equal to 2.2mmol/l as severe 
hypoglycaemia. Admissions were categorised based on the lowest value of blood 
glucose recorded during the spell.  
74 
 
I then compared the inpatient mortality and length of stay among these three groups 
to look for any association. Length of stay was calculated by deducting the 
admission time from the discharge time to the closest hour. 
4.2.2.3 Statistical analysis 
The demographic and morbidity characteristics of the patients with and without an 
episode of hypoglycaemia are summarised using means (standard deviation; SD) or 
medians (inter-quartile range; IQR) for continuous data and using proportions for 
categorical data. To allow for the clustering effect of some of the patients being 
admitted more than once Generalised Estimation Equations (GEE) were used.  
Logistic regression was used to study the inpatient mortality outcome; and linear 
regression model was used to study the effect on length of stay. Due to the skewed 
length of stay data, a log transformation was carried out to normalise the data before 
multivariate analysis. Covariates controlled for in the regression analyses were age 
(years), gender, ethnicity, deprivation quintiles (based on income deprivation score), 
admission type (emergency / elective), modified Charlson co-morbidity score, and 
use of insulin. Modified Charlson co-morbidity score is calculated by deducting the 
score given for diabetes [58]. Effect size from the multivariate analysis is reported as 
odds ratio for inpatient mortality and as relative ratio (exponential of the regression 
coefficient of the log transformed data) for the length of stay. Confidence interval is 
given at 95% and P-value of less than 0.05 was deemed significant. Data were 
analyzed using Stata 12 software, using the GEE class of models.   
4.2.3 Results 
There were 25,118 admissions with diabetes between 2007 and 2010. Of these, 
6,374 met the inclusion criteria (figure 4.1). There were 148 admissions (2.3%) with 
severe hypoglycaemia (≤2.2mmol/l), 500 admissions (7.8%) with mild to moderate 
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hypoglycaemia (2.2-3.9mmol/l) and 5,726 admissions with no hypoglycaemic 
episodes (>3.9mmol/l) (table 4.1).   
Patients with increased severity of hypoglycaemia tended to have an older mean age 
and were more likely to be admitted as an emergency and be on insulin. Fewer of 
those who did not have a hypoglycaemia episode had a co-morbidity score of 1 or 
higher (64%) compared to 73% of those with mild to moderate and 74% of those with 
severe hypoglycaemia (table 4.1). 
Median length of stay (days) in the >3.9mmol/l group was 5.9 (IQR 2.1-12.9), 11.0 
(IQR 4.7-21.1) in the 2.3-3.9mmol/l and 17.0 (IQR 8.0-37.2) in the ≤2.2mmol/l group 
(table 4.1). The adjusted length of stay was increased by 1.51 (95%CI: 1.35-1.68) 
times in the 2.3-3.9mmol/l group and 2.33 (95%CI: 1.91-2.84) times in the 
≤2.2mmol/l group when compared to those without a hypoglycaemic episode 
(>3.9mmol/l). The associations were highly significant (P<0.001) for both (table 4.2 & 
figure 4.3). 
Inpatient mortality was 15% in the ≤2.2mmol/l group, 10% in the 2.3-3.9mmol/l group 
and 5% in the >3.9mmol/l group (table 4.1). The adjusted odds ratio was 
1.62(95%CI: 1.16-2.27) in the 2.3-3.9mmol/l group and 2.05 (95%CI: 1.24-3.38) in 
the ≤2.2mmol/l group in comparison to the non hypoglycaemic group.  Both again 
were highly significant (P≤0.005) (table 4.2 & figure 4.3).  
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Figure 4.2: Flow diagram of admissions included for analysis 
Number of patients with diabetes identified 
25,118 
 
Median LOS-  3.79 (IQR  1.29-9.96) days 
Inpatient mortality - 5.1% 
Patients with diabetes not admitted to ICU 
23, 165 
 
Median LOS - 3.17 (IQR 1.21 - 8.67) days 
Inpatient mortality -  4.2% 
Patients with diabetes  who had atleast one 
electronically recorded blood glucose value 
6,535 
 
Median LOS - 6.29 (IQR 2.21 - 14.08) days 
Inpatient mortality -  5.9% 
Patients with diabetes included for final analysis 
6, 374 
 
Median LOS - 6.21 (IQR 2.21 - 14.00) days 
Inpatient mortality -  5.8% 
Admitted to ICU – 1,953 
Median LOS – 14 (IQR 8.38-26.02) days 
Inpatient mortality - 15.6% 
 
No electronic recording of blood glucose – 
16,630 
Median LOS – 2.5 (IQR 1.08 – 6.75) days 
Inpatient mortality - 3.6% 
 
Inconsistent data with hypoglycaemic 
discharge code but no electronic blood 
glucose value to support this  – 161 
Median LOS – 8.91 (IQR 2.64 – 24.5) days 
Inpatient mortality – 9.3% 
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Table 4.1: Characteristics and outcome of the admissions based on presence and severity of 
hypoglycaemia 
Patient 
Characteristics 
No hypoglycaemia 
> 3.9 mmol/l (N=5,726) 
Mild to moderate 
2.3 – 3.9 mmol/l (N=500) 
Severe hypoglycaemia 
<=2.2 mmol/l (N=148) 
Age mean (SD) years 63.8 (15.9) 65.1 (15.3) 67.8 (15.4) 
 
Gender N (%) 
   
Male  3,303 (57.7) 278 (55.6) 85 (57.4) 
Female 2,423 (42.3) 222 (44.4) 63 (42.6) 
 
Ethnicity N (%) 
   
White 3,904 (68.2) 338 (67.6) 108 (73.0) 
Asian 1,099 (19.2) 99 (19.8) 26 (17.6) 
Black 362 (6.3) 39 (7.8) 8 (5.4) 
Other 361(6.3) 24 (4.8) 6 (4.1) 
 
*
Social class N (%) 
   
Least deprived 1 295 (5.3) 25 (5.1) 6(4.2) 
2 484 (8.7) 45 (9.3) 13 (9.0) 
3 936 (16.8) 86 (17.7) 31 (21.5) 
4 1,201 (21.6) 95 (19.5) 36 (25.0) 
Most deprived 5 2,647 (47.6) 235 (48.4) 58 (40.3) 
 
Type of Admission N (%) 
   
Elective 934 (16.3) 56 (11.2) 7 (4.7) 
Emergency 4,792 (83.7) 444 (88.8) 141(95.3) 
    
Modified Charlson co-
morbidity score N (%) 
   
0 2,045 (35.7) 133 (26.6) 39 (26.4) 
1 1,188 (20.7) 86 (17.2) 29 (19.6) 
2 or more 2,493 (43.5) 281 (56.2) 80 (54.1) 
    
Insulin use N (%)    
Yes 3,442 (60.1) 357 (71.4) 119 (80.4) 
No 2,284 (39.9) 143 (28.6) 29 (19.6) 
    
Outcome    
In-patient death N (%)    
Yes 298 (5.2) 49 (9.8) 22 (14.9) 
No 5,428 (94.8) 451 (90.2) 126 (85.1) 
 
Length of stay median 
(IQR) days 
 
5.9 (2.1,12.9) 
 
11.0 (4.7,21.1) 
 
17.0 (8.0,37.2) 
 
*Social class based on income deprivation score. Adds up to 6,193 instead of 6, 374 due to missing post code values 
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Figure 4.3: Presence and severity of hypoglycaemia vs. inpatient mortality and length of stay* 
 
  
* Adjusted odds ratio for mortality and adjusted relative ratio for length of stay. Relative ratio here is the exponential of 
regression coefficient obtained from the analysis of log transformed length of stay data. Covariates adjusted for are age, 
gender, ethnicity, social class, admission type, insulin use and modified Charlson co-morbidity score. 
 
In multivariable (adjusted) analysis, increasing age, emergency admission, being on 
insulin and higher co-morbidity score were independently associated with both 
increasing length of stay and inpatient mortality (table 4.2).  
In assessing the bias of the excluded sample, admissions without a recording of 
blood glucose had a lower length of stay (median 2.5; IQR 1.08-6.75 days) and 
inpatient mortality rate (3.6%) (Figure 4.1). Interestingly those with a discharge code 
of hypoglycaemia but without any evidence of hypoglycaemia in the electronic blood 
glucose recording had similar inpatient mortality (9.3%) to that of mild to moderate 
hypoglycaemia group (9.8%). Admissions that resulted in Intensive Care Unit (ICU) 
had a similar mortality rate (15.6%) to that of the severe hypoglycaemia group 
(14.9%) (Figure 4.1). 
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Table4.2: Adjusted* odds ratio for inpatient mortality and adjusted* relative ratio# for length of stay in patients with diabetes 
Characteristics Unadjusted odds ratio 
for inpatient 
mortality 
Adjusted odds ratio 
For inpatient mortality 
P value 
(adjusted analysis) 
 Unadjusted relative 
ratio# for length of stay 
Adjusted relative 
ratio# for length of stay 
P value (adjusted 
analysis) 
Age 1.06 (1.06-1.08) 1.07 (1.05-1.08) <0.001  1.018 (1.016-1.020) 1.015 (1.013-1.018)  <0.001 
Gender 
Male 
 
1 
 
1 
  
 
1 
 
1 
  
Female 
Admission type 
1.13 (0.91-1.39) 1.02 (0.82-1.28) 0.83  1.07 (0.99-1.15) 1.06 (0.99-1.13)  0.10 
Elective 1 1   1 1   
Emergency 5.81 (3.26-10.35) 4.63 (2.57-8.35) <0.001  1.24 (1.13-1.36) 1.29 (1.18-1.40)  <0.001 
Ethnicity 
White 
 
1 
 
1 
 
 
 
 
1 
 
1 
  
Asian 0.70 (0.52-0.94) 0.75 (0.54-1.03) 0.07  0.86 (0.79-0.95) 0.89 (0.81-0.97)  0.01 
Black 0.85 (0.54-1.33) 0.70 (0.44-1.12) 0.14  1.00 (0.86-1.15) 0.91 (0.79-1.05)  0.21 
Other 0.80 (0.50-1.28) 0.94 (0.57-1.54) 0.79  0.58 (0.50-0.67) 0.68 (0.60-0.78)  <0.001 
Social Class         
 (Most Deprived) 5 1 1   1 1   
4 1.02 (0.78-1.34) 0.86 (0.65-1.15) 0.32  1.02 (0.93-1.12) 0.97 (0.89-1.06)  0.53 
3 0.89 (0.66-1.22) 0.81 (0.58-1.12) 0.21  1.10 (1.00-1.22) 1.06 (0.97-1.17)  0.21 
2 0.98 (0.66-1.44) 0.88 (0.58-1.33) 0.54  1.16 (1.02-1.32) 1.07 (0.95-1.21)  0.26 
(Least Deprived) 1 1.02 (0.63-1.65) 1.08 (0.65-1.78) 0.77  1.09 (0.93-1.29) 1.06 (0.90-1.23)  0.52 
Unavailable Post Code 0.09 (0.01-0.63) 0.11 (0.02-0.82) 0.03  1.23 (0.99-1.53) 1.30 (1.06-1.59)  0.01 
Modified Charlson 
co-morbidity score  
0 
 
 
1 
 
 
1 
  
 
 
1 
 
 
1 
  
1 3.21 (2.15-4.80) 2.56 (1.70-3.85) <0.001  1.64 (1.50-1.80) 1.49 (1.37-1.63)  <0.001 
2 5.85 (4.14-8.26) 5.16 (3.63-7.34) <0.001  2.46 (2.29-2.65) 2.14 (1.99-2.30)  <0.001 
Insulin use  
No 
 
1 
 
1 
  
 
1 
 
1 
  
Yes 1.52 (1.21-1.91) 1.69 (1.32-2.16) <0.001  1.60 (1.50-1.72) 1.57 (1.47-1.68)  <0.001 
Hypoglycaemia         
None 1 1   1 1   
Hypo 2.3-3.9mmol/l 1.98 (1.44-2.72) 1.62 (1.16-2.27) 0.004  1.76 (1.57-1.99) 1.51 (1.35-1.68)  <0.001 
Hypo <2.2mmol 3.18 (2.00-5.08) 2.05 (1.24-3.38) 0.005  2.97 (2.40-3.67) 2.33 (1.91-2.84)  <0.001 
 
* Covariates included in the multivariate analysis were age, gender, ethnicity, social class, admission type, modified Charlson co-morbidity score, insulin use and hypoglycaemia category. 
# Relative ratio is the exponential of regression coefficient obtained from the analysis of log transformed length of stay data
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4.2.4 Discussion 
Hypoglycaemia in people with diabetes admitted to hospital associates with 
increased length of stay and inpatient mortality. Length of stay was 51% greater in 
those having mild to moderate hypoglycaemia and 133% greater in those having 
severe hypoglycaemia. The odds of inpatient mortality increased by 62% in those 
with mild to moderate hypoglycaemia and by 105% in those with severe 
hypoglycaemia.   
My findings are consistent with that of Turchin et al who found an 85% increase in 
inpatient mortality with a hypoglycaemic episode [58]. This consistency persists 
despite the differing definitions of hypoglycaemia (2.8mmol/l) compared to my cut off 
value (3.9mmol/l). The findings indicate hypoglycaemia as either being a marker of 
poor prognosis or that the patients are being at risk of an adverse outcome as a 
consequence of hypoglycaemia. Increase in length of stay in patients with 
hypoglycaemia may result from the need to optimise glycaemic control prior to 
discharge, or may result from the increased chance of having and detecting an 
episode of hypoglycaemia with a longer inpatient stay.  
The limitations of the study were the inconsistent availability of electronic blood 
glucose values for admissions with diabetes and the retrospective nature of the 
study. The definition of severe hypoglycaemia was based on a biochemical cut-off 
value (<2.2mmol/l) rather than the accepted categorisation based on the need for 
third party assistance. By using the Charlson co-morbidity index I have adjusted for 
key confounding illnesses such as liver disease, renal impairment and congestive 
heart failure but this does not encompass all possible confounders such as 
excessive alcohol intake and septicaemia.  Inconsistent availability of blood glucose 
values might have led to the low (10.1%) number of hypoglycaemic admissions 
81 
 
noted in our analysis. The estimates reported in national audits using case note 
analysis are much higher (20-25%) [14, 15]. However the dataset is large with over 
6,000 admissions and findings are consistent with previous studies that used similar 
approaches [58,166]. Furthermore looking at the excluded data without blood 
glucose recordings which have much shorter length of stay and inpatient mortality, 
perhaps the effect sizes for inpatient mortality and length of stay derived in this study 
if at all are likely to be underestimates. 
4.2.5 Conclusions 
Hypoglycaemia is associated with increased length of stay and inpatient mortality. 
Whilst causative evidence is lacking, the data is consistent with the need to try and 
avoid hypoglycaemia in our current and continued approach for optimal glycaemic 
control in people with diabetes admitted to hospital. A computerised glucose 
monitoring system may have an important role to play in the management and 
monitoring of inpatient hypoglycaemia in patients with diabetes.  
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4.3 Frequency of hypoglycaemia in non-diabetic hospitalised patients 
and the feasibility of setting up a surveillance system 
4.3.1 Background 
Hypoglycaemia in hospitalized patients with diabetes is common and can lead to 
seizures, coma, death and increased length of stay [48,58,168]. Hypoglycaemia in 
patients without diabetes is much rarer. There is a wide range of potential causes for 
non-diabetic hypoglycaemia which includes excess alcohol intake, septicaemia, liver 
disease, renal impairment, haemodialysis, heart failure, cancer, dementia, 
pneumonia, self-harm with hypoglycaemic agents and autoimmune mediated 
hypoglycaemic disorders [169-181]. It has sometimes been the result of the 
malicious administration of insulin [46,165,182].    
Insulin related murder may be under-reported worldwide [46]. In reported cases, 
perpetrators are often carers or clinical staff, and victims their patients [46]. 
Prominent cases in the United Kingdom have involved multiple deaths of elderly 
hospital patients [183], and of children [184,185]. Similar cases have occurred in the 
United States [186-188] , at a Vienna medical centre [189] , and at old-age homes in 
Belgium and the Netherlands [46,186]. While confirmation of insulin poisoning 
requires serum insulin and C-peptide concentrations, the first suspicion may be 
raised by the occurrence of unexplained hypoglycaemia [165]. Better knowledge of 
the frequency of non diabetic hypoglycaemia in hospital patients is required to 
understand these complex forensic and clinical questions.    
 Hypoglycaemia is common in critical care settings [144,190], partly because of 
attempts to achieve tight blood glucose control, although this has now been shown to 
be harmful [144,164]. Few studies [169,172,179,191,192] have examined the 
incidence of non diabetic hypoglycaemia outside the critical care setting. Shilo et al 
[172] reported a frequency of 0.5% in elderly patients (>65 years) in a series of 
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nearly 12 000 admissions. Mannucci et al [179] described a remarkably high 
frequency of 8.6% in patients aged above 65 years but their relatively small study of 
678 patients was undertaken in a single geriatric unit, defined hypoglycaemia as a 
blood glucose concentration of 3.3 mmol/l or less even if patients were asymptomatic 
and did not specify if any of the patients received intensive care unit support.  Three 
other studies included both diabetic and non-diabetic patients but did not give the 
non-diabetic denominator population [169,179,191,192]. The differences between 
studies may result from differences in the population, the proportion of patients who 
have a blood glucose test performed, the cut-off value chosen to define 
hypoglycaemia, and the point in the course of their illness the test was done.  
Colleagues and I wished to establish the frequency of observed hypoglycaemia in 
patients outside the intensive care unit in UHB, a large university hospital with 
approximately 1200 beds.  As described previously the hospital has a purpose-
designed computer-based patient information system, the Patient Information and 
Communication System (PICS), which records laboratory results, electronic 
observations and medication orders, and a Patient Administration System (PAS) 
which records discharge diagnostic codes. Therefore I had the opportunity to 
analyse retrospective data available for the year 2010 from three distinct sources: 
blood glucose concentration measurements, both from the bedside and the 
laboratory; medication records for treatments (glucose, glucagon) commonly given to 
reverse hypoglycaemia; and diagnostic codes for individual patients. Each data 
source identifies a different sample of all hypoglycaemic episodes, but no single data 
source can be regarded as definitive. However the extent to which different data 
sources identify the same hypoglycaemic episodes allows the use of capture-
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recapture methods to establish the likely true rate of hypoglycaemia in non-diabetic 
in-patients outside intensive care units. 
Colleagues and I also considered whether it might be feasible to set up a hospital 
surveillance system to detect any unexpected increase in the frequency of 
hypoglycaemia, as might occur with the malicious administration of insulin.  
4.3.2 Methods 
 I identified all adult patients (≥16 years) who the Patient Administration System 
(PAS) identified as having been admitted to UHB during the calendar year 2010 and 
where the episode was noted as either an elective or non-elective (ie emergency) 
inpatient admission. PAS data were linked to the PICS data and patients with a 
recorded diagnosis of diabetes in the PAS or who were identified in PICS as having 
received treatment with anti-diabetic medication were excluded. This broad exclusion 
criterion was used because the main purpose was to determine the frequency of 
hypoglycaemia that could not be explained by the use of prescribed hypoglycaemic 
agents. The denominator also included patients admitted to the intensive care unit 
(ICU), as they invariably have a period of stay outside ICU (susceptible population). 
This identified a population of non-diabetic in-patients who could suffer a 
hypoglycaemic episode in a non-critical care setting.  
I identified episodes of hypoglycaemia in three ways. Firstly episodes were directly 
identified from low concentrations of blood glucose from the PICS database, 
recorded either from bedside or laboratory blood glucose estimations; secondly 
episodes were indirectly identified from prescribed treatments for hypoglycaemia 
from the PICS database; and lastly diagnostic codes for hypoglycaemia were 
identified from the PAS database. If the trigger occurred during a period of time the 
patient spent in ICU these were excluded from the numerator. 
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4.3.2.1 Cut-off value for hypoglycaemia 
Various blood glucose concentrations have been used to define hypoglycaemia in 
non-diabetic patients. Previous studies have used 2.7 [172,191], 3 [192] and 3.3 
mmol/l [169,179].  Meanwhile 2.2 mmol/l is used to define severe hypoglycaemia in 
Whipple’s triad [167] and 2.5 mmol/l has been used for forensic investigations [193]. 
Considering the uncertainty, I analysed the data at different values of blood glucose 
concentration, to establish the effect on perceived occurrence, and the optimum cut-
off value for surveillance. I did not differentiate between laboratory blood glucose 
values and point-of-care blood glucose values or apply any correction factors. The 
point of care blood glucose system in place at UHB during the study period was the 
ACCU-CHEK inform system marketed by ROCHE.  
4.3.2.2 Medication as an indirect trigger to indicate hypoglycaemia 
Electronic prescription records for medication used to treat severe hypoglycaemia 
were examined, to establish whether these may serve as triggers in detecting 
hypoglycaemia in non-diabetic patients. The triggers extracted from PICS were 
intramuscular glucagon injection; intravenous glucose 10%, 20%, and 50% solutions; 
and oral glucose 40% gel.  The case-notes of patients who received any of these but 
had neither a prescription for anti-diabetic medication in PICS nor a diagnostic code 
for diabetes in PAS were reviewed to establish whether they had in fact been 
hypoglycaemic. Reasons for false positives were documented. 
4.3.2.3 Discharge diagnostic codes for hypoglycaemia as an indirect trigger 
ICD10 discharge diagnostic codes for hypoglycaemia (E15, E16.0, E16.1, and 
E16.2) were identified from the PAS system for the year 2010.  The case-notes of all 
patients who had neither a prescription for anti-diabetic medication in PICS nor a 
diagnostic code for diabetes in PAS were reviewed to determine the validity of the 
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triggers in identifying non-diabetic hypoglycaemia. Again reasons for false positives 
were recorded. 
4.3.2.4 Electronic point-of-care and laboratory blood glucose concentrations 
as direct triggers 
From available electronic observations derived from PICS, point-of-care or laboratory 
blood glucose values were used to identify patients who had been hypoglycaemic 
during their in-patient spell. I reviewed the case-notes of patients categorised as 
non-diabetic by the criteria described above. 
4.3.2.5 Determining the causes of hypoglycaemia in non-diabetic patients 
Information on diagnosis that was noted in the discharge diagnostic codes from PAS 
was first verified as an accurate description by case-note review. Any missed 
diagnostic codes were documented. A check list of potential causes derived from 
previous literature was used to identify possible reasons for the hypoglycaemia [169-
181]. Considering the limitation of the ICD 10 codes in describing aetiology, for 
patients with a blood glucose value less than 2.7 mmol/l, based on the co-morbidity 
and patient condition, I made a judgement as to whether any of these patients may 
have had an unexplained hypoglycaemia. This was verified by a consultant 
diabetologist (PN). 
4.3.2.6 Statistical analysis 
4.3.2.6.1 Estimating the frequency of non-diabetic hypoglycaemia  
Data were analyzed using Stata 10 software.  Cases identified by any of the three 
triggers were used to estimate the incidence of hypoglycaemia in non-diabetic 
patients. As none of the three data sources is complete the capture-recapture 
technique for three sources was used [149].  As discussed in chapter 3 capture-
recapture methods have been used in health care to estimate population prevalence 
using multiple incomplete sources [194-199]. In summary, eight log-linear models, 
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each specifying different interactions between the three sources, are derived to 
estimate the size of the total population. The layout of the three-source models is 
given in the box below.  
Box 4.1: Three source model layout for estimating the numbers of non diabetic 
hypoglycaemia 
 
Three source model layout for estimating the numbers of non diabetic hypoglycaemia 
                                        Source 1: Anti-hypo treatment 
                                                                                                      Yes                                                                          No 
    
Source 2: Blood Glucose 
Values   
Source 2: Blood Glucose 
Values   
    Yes No   Yes No   
 Yes a b 
  
e f 
  
 Source 3: Discharge 
Diagnostic code 
  
    
No c d 
  
g X 
  
      
  
 
Nobs = a+b+c+d+e+f+g (total observed) 
N1=a+b+c+d (Source 1 total) 
N2=a+c+e+g (Source 2 total) 
N3=a+b+e+f (Source 3 total) 
X= Unknown value 
 Ntotal=Nobs + X 
 
Model depicting different 
interaction between sources 
DoF Formula to estimate X 
Independent 3 X = Ntotal - Nobs 
Where Ntotal is the solution of: 
(Ntotal-N1) (Ntotal-N2) (Ntotal-N3) = Ntotal
2
(Ntotal - Nobs ) 
1-2 2 X = (c + d + g)(f) / (a + b + e) 
1-3 2 X = (b + d + f)(g) / (a + c + e) 
2-3 2 X = (e + f + g)(d) / (a + b + c) 
1-2, 1-3 1 X = gf / e 
1-2, 2-3 1 X = df / b 
1-3, 2-3 1 X = gd / c 
1-2, 1-3, 2-3 0 X = (adfg) / (bce) 
Applying correction to the model: For model stability 1 is added to cells b, c and e when performing the analysis 
Adapted from: Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods and limitations. [Review] [140 refs][Erratum 
appears in Am J Epidemiol 1998 Dec 15;148(12):1219]. Epidemiologic Reviews 1995; 17: 243-264. 
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Calculations are based on the overlap between the three sources. The best estimate 
of the eight given is chosen using the Akaike Information Criteria (AIC) and the 
Bayesian Information Criteria (BIC). The 95% confidence intervals around the 
estimates were calculated using the goodness-of-fit based method [200]. An 
example of the working using the three source model is given in the box below [148]. 
Box 4.2: Example; three source model for estimating the numbers of non diabetic 
hypoglycaemia (<3.3mmol/l) 
                                        Source 1: Anti-hypo treatment 
                                                                           Yes                                                                     No 
    
Source 2: Blood Glucose 
Values   
Source 2: Blood 
Glucose Values   
    Yes No   Yes No   
 Yes 1 7 
  
1 9 
  
 Source 3: Discharge 
Diagnostic code 
  
    
No 5 19 
  
29 X 
  
      
  
 
 
DoF- Degree of Freedom 
AIC – Akaike Information Criterion 
BIC – Bayesian Information Criterion 
X – Missing or unknown numbers with blood glucose of <3.3mmo/l 
N – Total numbers and estimate lower and upper values 
The value in the highlighted line is the selected best estimate based on the AIC and BIC value 
Odel DoF G
2
 P value AIC BIC X N N 
(lower) 
N 
( Upper) 
Independent 3 7.42 0.06 1.42 1.58 67 141 106 209 
1-2 2 5.72 0.06 1.72 1.83 44 118 89 187 
1-3 2 0.77 0.68 -3.23 -3.12 115 189 124 352 
2-3 2 5.06 0.08 1.06 1.17 50 124 95 185 
1-2, 1-3 1 0.74 0.39 -1.26 -1.2 130 204 104 953 
1-2, 2-3 1 0.42 0.52 -1.58 -1.53 21 95 79 138 
1-3, 2-3 1 0.2 0.66 -1.8 -1.75 91 165 107 343 
1-2, 1-3, 2-3 0 0 1 0 0 51 125 75 851 
89 
 
I estimated the frequency at different cut-off values: 3.3, 3.0, 2.7, 2.5 and 2.2 mmol/l. 
Frequency is reported as a count for the observed number of admissions of patients 
who did not have diabetes or receive diabetic medication in a non critical care setting 
for the year 2010. I repeated the same analysis stratifying the population by age into 
those 65 years and above and those who were less than 65 years old. This was 
done as previous researches have limited the estimations to elderly population; this 
is therefore useful to make valid comparison. Furthermore often malicious use of 
insulin has been reported in elderly population within health care setting, making it 
useful to have an estimate for this age group for future reference in forensic cases. 
4.3.2.6.2 Estimating the validity of a surveillance system 
To look at the feasibility of monitoring the occurrence of non diabetic hypoglycaemia 
using the three sources I calculated the estimated sensitivities and positive predictive 
values if this was to be implemented as a surveillance tool.  These are presented for 
each of the cut-off values. Positive predictive values for the indirect triggers and for 
the whole system were calculated and confidence intervals derived using exact 
binomial methods. Estimated sensitivities of the surveillance system proposed were 
derived by dividing the observed episodes by those of the estimated total. All 
confidence intervals are reported at 95%. 
I did the same calculations to evaluate the impact of only using the two real time 
triggers as a live surveillance tool. The two live triggers are blood glucose 
observations and electronic prescriptions of anti hypoglycaemic agents. 
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4.3.3 Results 
There were 56 975 inpatient admissions to the hospital in 2010. The information 
analyst was able to match 81% of the PAS data to the PICS system (46 210 
admissions). Among them 37 898 were categorised as non-diabetic based on the 
absence of either discharge diagnostic code of diabetes or a record of the 
prescription of diabetic medication. There were 38 direct triggers from the blood 
glucose concentrations using 3.3 mmol/l as the cut-off value, 55 indirect triggers 
using treatment for hypoglycaemia and 25 indirect triggers using discharge 
diagnostic codes, yielding a total of 102 unique non-diabetic admissions with at least 
one episode of hypoglycaemia, excluding overlaps between the three sources 
(Figure 4.4). Case-notes were available for review for 95 (93%) admissions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
Figure 4.4: Flow diagram of the non diabetic hypoglycaemia triggers generated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded based on: 
Diabetes code alone 1251 
Diabetic medication alone 2067 
Both 4904 
 
1 
5 
41 
1 
31 
8 
15 
Total Inpatients 
56 975 
Inpatients matched 
to PICS 
46 120 (81%) 
Patients with no 
diabetes diagnostic 
code or antidiabetic 
prescription 
37 898 
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4.3.3.1 The frequency of hypoglycaemia among non-diabetic patients in non 
critical care setting 
In combination the triggers identified 71 hypoglycaemic episodes at a cut-off of 3.3 
mmol/l, 59 at 3 mmol/l, 37 at 2.7 mmol/l, 30 at 2.5 mmol/l and 23 at 2.2 mmol/l (see 
appendix 4.2). Each of these admissions was of a unique patient. Using capture-
recapture method at 3.3 mmol/l cut-off an estimate of 189 (95%CI 124 to 352) 
hypoglycaemic episodes is predicted in a non diabetic population of 37 898 giving a 
cumulative incidence of 50 per 10 000 admissions (95%CI 33 – 93). Estimated 
cumulative incidence at 3.0 mmol/l was 36 (95%CI 24 – 64), at 2.7 mmol/l, 13 
(95%CI 11 -19), at 2.5 mmol/l, 11 (95%CI 9-15) and at 2.2 mmol/l, 8 (95%CI 7-11) 
per 101000 admissions (Figure 4.5). 
Figure 4.5: Number of hypoglycaemic episodes -v- threshold blood glucose concentration (mmol/l) 
and upper and lower 95% confidence bounds per 10 000 admissions 
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Analysis showed admissions of patients aged over 65 years were more 
(approximately 50% more) likely to have an episode of hypoglycaemia compared to 
the younger age group at all cut-off points. Estimated frequency above the age of 65 
years at 3.3 mmol/l was 55 (95%CI 32 – 149), at 3.0 mmol/l, 39 (95%CI 24-158), at 
2.7 mmol/l, 18 (95%CI 15 -27), at 2.5 mmol/l, 15 (95%CI 13-23) and at 2.2 mmol/l, 
13 (95%CI 11-21) per 10 000 admissions (table 4.3).   
Table 4.3: Estimated number of hypoglycaemic episodes for different cut off values per 10,000 
elderly (≥65 years) and younger (<65years) admissions 
Cut-off value (mmol/l) 2.2 2.5 2.7 3 3.3 
Age > =65 years (per 13 494) 18 20 24 53 74 
Lower 95% Confidence Interval Limit 15 18 20 32 43 
Upper 95% Confidence Interval Limit 28 31 37 213 201 
Frequency (per 10 000) with 95% CI 13 (11-21) 15 (13-23) 18 (15-27) 39 (24-158) 55 (32-149) 
Age <65 years (per 24 404) 15 22 33 65 87 
Lower 95% Confidence Interval Limit 14 18 25 45 59 
Upper 95% Confidence Interval Limit 22 36 59 115 155 
Frequency (per 10 000) with 95%CI 6 (6-9) 9 (7-15) 14 (10-24) 27 (18-47) 36 (24-64) 
 
4.3.3.2 Possible surveillance system 
Assuming the observed results were used in a surveillance system, a cut-off value of 
2.7 mmol/l would have a sensitivity of 73% and a positive predictive value of 50% if 
all the datasets were used (table 4.4 and appendix 4.1 for detailed information).  
Table 4.4: Best estimates for the number of admissions of 37 898 patients without diabetes in 
which one or more episodes of hypoglycaemia occurred 
Cut of value Observed 
episodes 
Triggers 
generated 
Best estimate for 
total episodes 
(95% CI) 
*
PPV% (95% CI) 
#
Estimated 
sensitivity% 
(95% CI) 
2.2 mmol/l 23 65 31 (26-41) 35 (24-48) 74 (53-88) 
2.5 mmol/l 30 68 40 (34-56) 44 (32-57) 75 (54-88) 
2.7 mmol/l 37 70 51 (43-73) 53 (41-65) 73 (51-86) 
3.0 mmol/l 59 82 135 (91-244) 72 (61-81) 44 (24-65) 
3.3 mmol/l 71 91 189 (124-352) 78 (68-86) 38 (20-57) 
*PPV = Observed episodes / Triggers generated by proposed surveillance system 
#
Estimated sensitivity = Observed episodes / best estimate for total episodes 
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If only the two ‘real time’ data sources, namely blood glucose trigger and the 
treatment trigger were used the sensitivity and positive predictive value would be 
63% and 49% respectively at a cut off value of 2.7mmol/l (table 4.5).  
Table 4.5: Analysis for live triggers using blood glucose values and treatment triggers alone 
Cut of 
value 
Observed 
episodes 
Triggers 
generated 
Best estimate for 
total episodes 
(95% CI) 
PPV% (95% CI) Estimated 
sensitivity% (95% CI) 
2.2mmol/l 21 60 31 (26-41) 35 (23-48) 68 (49-81) 
2.5mmol/l 27 63 40 (34-56) 43 (30-56) 68 (48-79) 
2.7mmol/l 32 65 51 (43-73) 49 (37-62) 63 (44-74) 
3.0mmol/l 51 78 135 (91-244) 65 (54-76) 38 (21-56) 
3.3mmol/l 62 87 189 (124-352) 71 (61-80) 33 (18-50) 
4.3.3.3 Causes of non-diabetic hypoglycaemia 
Characteristics of the non-diabetic patients who had hypoglycaemia at a cut-off point 
of 3.3 and 2.7 mmol/l are given in Table 4.6. Most patients (>90%) were admitted as 
an emergency. The commonest co-morbidities linked to hypoglycaemia were sepsis, 
renal disease and alcohol dependence. Others included pneumonia, liver disease, 
cancer and self-harm with hypoglycaemic agents. Most patients had multiple 
possible reasons for their hypoglycaemia.  
Detailed case-note review of those with blood glucose concentrations less than 
2.7ammol/l revealed seven patients who did not have a plausible reason to explain 
the occurrence of hypoglycaemia. However all seven were either admitted for 
investigation of hypoglycaemia that occurred elsewhere or had an episode that was 
noted on admission; there was no unexplained hypoglycaemia that occurred after 
admission during inpatient stay (figure 4.6). A matrix showing the co-morbidities of 
these patients is shown in table 4.7. Over a third of patients whose blood glucose 
concentration was lower than the cut-off point of 3.3 mmol/l, and nearly 40% below 
2.7 mmol/l, died.  
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Table 4.6: Characteristics of the patients identified as non diabetic hypoglycaemic patients 
Patient Characteristics Glucose <3.3 mmol/l (N=71) Glucose <2.7 mmol/l (N=37) 
Age mean (SD) years 59.2 (22.5) 60.2 (23.6) 
Age Group   
<65 years 41 (57.7) 20 (54.1) 
>65 years 30 (42.3) 17 (45.9) 
Gender N (%)   
Male  37 (52.1) 20 (54.1) 
Female 34 (47.9) 17 (45.9) 
Ethnicity N (%)   
White 50 (70.4) 26 (70.3) 
Asian 8 (11.3) 4 (10.8) 
Black 5 (7.0) 3 (8.1) 
Other 8 (11.3) 4 (10.8) 
*
Social class N (%)   
Least deprived 1 4 (5.6) 0 (0.0) 
2 7 (9.9) 3 (8.1) 
3 17 (23.9) 10 (27.0) 
4 11 (15.5) 5 (13.5) 
Most deprived 5 31 (43.7) 18 (48.6) 
Type of Admission N (%)   
Elective 7 (9.9) 2 (5.4) 
Emergency 64 (90.1) 35 (94.6) 
In-patient death N (%)   
Yes 24 (33.8) 14 (37.8) 
No 47 (66.2) 23 (62.2) 
 
Length of stay median (IQR) 
days 
 
6.92 (11.54) 
 
7.42 (13.88) 
   
   
On  admission % 22 (31.0) 17 (45.9) 
   
#
Aetiology for hypoglycaemia   
Sepsis 20 (28.2) 11 (29.7) 
Renal Disease 20 (28.2) 12 (32.4) 
Alcohol  15 (21.1) 11 (29.7) 
Pneumonia 17 (23.9) 6 (16.2) 
Liver disease 9 (12.7) 6 (16.2) 
Congestive Heart Failure 9 (12.7) 6 (16.2) 
Cancer 10 (14.1) 2 (5.4) 
Self harm 4 (5.6) 4 (10.8) 
Under investigation for hypo 
occurring elsewhere 
5 (7.0) 3 (8.1) 
 
*Social class based on deprivation index score. Adds up to 70 & 36 instead of 71 & 37 respectively at 3.3 and 2.7mmol/l 
due to one missing post code 
# Will add up to more than 100% due to multiple co-morbidities in patients. All co-morbidities are based on ICD 10 code 
(verified by case-note review). Where ICD 10 code was not available a documentation of the diagnosis in case-note was 
accepted. 
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Figure 4.6: Plausible explanation for hypoglycaemia 
 
 
*One patient had leiomyosarcoma and hypoglycaemia. The association between these have been 
reported in association with insulin-like growth factor 1, which was not determined in this patient.  
One patient had SLE and admitted with sepsis but was very young (23 years) and had a blood glucose 
concentration less than 1.5 mmol/l. While hypoglycaemia may have been linked to sepsis, other 
clinical explanations were not excluded.  
Hypoglycaemia less 
than 2.7mmol/l 
37 
 
Plausible explanation 
available 
Yes 
30 
No need for further 
investigation unless 
recurring  
28 
Need for further 
investigation for 
clinical needs  
2* 
Plausible explanation 
available 
No 
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On admission or occured 
while admitted for 
investigation of 
hypoglycaemia that 
occured elsewhere 
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Occured after 
admission and 
unexplained 
0 
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Table 4.7: Matrix showing co-morbidity linked to hypoglycaemia in patients with glucose <2.7mmol/l 
 
 
 
 
 
  
Renal 
disease 
Sepsis Alcohol Cancer Liver 
disease 
Pneumonia Congestive 
heart 
failure 
Dementia Self harm Dialysis Occurred 
on 
Admission 
Admitted to 
investigate 
hypo 
1 1 0 1 0 1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 1 0 1 0 
3 0 0 0 0 0 0 0 0 0 0 0 1 
4 0 0 0 1 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 0 1 1 
6 1 1 0 0 0 1 0 0 0 0 1 0 
7 0 0 1 0 1 1 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 1 1 
9 0 0 0 0 0 0 0 0 1 0 1 0 
10 0 0 0 0 0 0 0 0 0 0 1 0 
11 1 1 0 0 0 0 1 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 0 0 1 1 
13 0 1 0 0 0 0 0 0 0 0 1 0 
14 1 1 0 0 0 0 0 0 0 1 0 0 
15 0 0 1 0 0 0 0 0 0 0 1 0 
16 0 0 0 0 0 0 0 1 0 0 0 0 
17 0 1 0 0 0 1 0 0 0 0 0 0 
18 1 0 0 0 0 0 1 0 0 0 1 0 
19 1 0 0 0 1 0 0 0 0 1 0 0 
20 1 1 0 0 0 1 1 0 0 0 0 0 
21 0 0 1 0 0 0 0 0 0 0 1 0 
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 Renal 
disease 
Sepsis Alcohol Cancer Liver 
disease 
Pneumonia Congestive 
heart 
failure 
Dementia Self harm Dialysis Occurred 
on 
Admission 
Admitted to 
investigate 
hypo 
22 0 1 0 0 0 1 0 0 0 0 0 0 
23* 0 0 1 0 1 0 0 0 0 0 0 0 
24 0 0 1 0 0 0 0 0 0 0 1 0 
25 0 1 0 0 0 1 1 0 0 0 0 0 
26 0 1 0 0 0 0 0 0 0 0 0 0 
27 1 0 0 0 0 0 1 0 0 0 1 0 
28 0 0 1 0 1 0 0 0 0 0 1 0 
29 1 1 0 0 0 0 0 0 0 0 0 0 
30 0 0 1 0 0 0 0 0 1 0 1 0 
31 0 0 0 0 0 0 0 0 1 0 1 0 
32 1 0 1 0 0 0 0 0 0 1 0 0 
33 0 0 0 0 0 0 0 0 0 0 1 0 
34 1 0 0 0 0 0 0 0 0 1 0 0 
35 0 1 1 0 1 0 1 0 0 0 0 0 
36 1 0 1 0 0 0 0 0 0 1 0 0 
37 0 0 0 1 0 0 0 0 0 0 0 0 
 12 11 11 2 6 6 6 1 4 5 17 4 
 
All diagnoses are based on the ICD 10 coding and mostly reflect the codes used in Charlson co-morbidity (Except self harm, dialysis, sepsis and pneumonia) 
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4.3.4 Discussion 
4.3.4.1 Summary of findings 
Non-diabetic hypoglycaemia is rare in hospital in-patients. Estimates show that at a 
cut-off value of 2.7 mmol/l, 13 (95% CI 11–19) episodes per 10 000 admissions 
occurred in one year; and with a cut-off value of 3.3 mmol/l 50 (95% CI 33–93) 
episodes per 10 000 admissions per year. Estimates are slightly higher in patients 
above the age of 65 years (39 and 55 per 10 000 admission respectively at cut-off 
values of 2.7 and 3.3 mmol/l). All the cases of hypoglycaemia that occurred after 
admission could be explained by co-morbid conditions, principally alcohol 
dependence, renal failure, and sepsis.  
4.3.4.2 Comparison with other studies 
The estimates are similar to previous studies [172,191,192] except that of Mannucci 
et al [179] who reported an incidence of 8.6% in an elderly population from a single 
medical unit. However the study was often based on routine blood glucose 
concentrations measured in fasting state, at a cut-off point of 3.3 mmol/l, in patients 
with a high mean age (81 years) and admitted with co-morbidities commonly 
associated with hypoglycaemia.  The study supports the previous observations that 
non-diabetic patients who develop hypoglycaemia are more likely to die than those 
who do not [169,179,191]. Similarly, hypoglycaemia in my study was often 
associated with renal disease, sepsis or pneumonia, and alcohol dependence, and 
other co-morbid diseases, in accord with previously suggested associations 
[176,179,181,191].  
4.3.4.3 Future surveillance 
Based on my analysis, a surveillance system could be established to detect an 
unexpected increase in the incidence of hypoglycaemia in non-diabetic patients. The 
optimal cut-off value of blood glucose concentration using the three sources was 2.7 
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mmol/l, which gave an estimated sensitivity of 73% and a positive predictive value of 
53% in the training set.  The value of 2.7mmol/l has also been used by others to 
define and establish the causes of hypoglycaemia in non-diabetic hospital patients 
[172,191]. The surveillance system would allow non-diabetic hypoglycaemia to be 
monitored, but for it to become routine, it would be necessary to integrate real-time 
blood glucose concentration estimates and the treatment trigger with the discharge 
data from the hypoglycaemic code trigger.  
There were false positives in the proposed surveillance system, for the treatment 
trigger this was often a higher blood glucose value than 3.3mmol/l being treated or 
rare metabolic diseases that needed carbohydrate replacement. Reasons identified 
for the false positives are summarised in the box below. 
Box 4.3: False Positives 
Hypoglycaemia in discharge diagnostic code but no blood glucose value below 3.3 mmol/l:  
1) Known to have hypoglycaemia intermittently linked to endocrinopathy following non Hodgkin’s 
lymphoma but no episode while in hospital 
 2) Lowest blood sugar value in hospital was 3.4 mmol/l even though had a much lower value before 
admission  
3) Likely coding error where hypoglycaemia was coded instead of hypokalaemia.   
Hypo treatment given but no blood glucose value less than 3.3mmol/ l: 
1) Treatment that was given for a higher blood glucose value than that of the cut-off stated 
(3.3mmol/l) –  5 admissions 
2) Treatment given for a rare metabolic conditions to increase carbohydrate levels as an alternative 
energy source(Glutaryl Coenzyme A Dehydrogenase deficiency and Citrullinaemia) – 5 
admissions (One patient admitted 4 times) 
3) Possibly to prevent hypoglycaemia in a liver disease patient and one during surgery – 2 
admissions  
4) Possibly for a malnourished patient as a nutritional source – 1 admission 
5) For collapse thinking it was due to hypoglycaemia but was not – 1 admission 
6) Unable to determine or prescribed and not given – 3 admissions 
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4.3.4.4  Limitations 
The study was retrospective and therefore has many limitations. All three sources of 
information were incomplete. I was able to overcome this by using capture-recapture 
technique and provide estimates of the true rates with relatively narrow confidence 
intervals. The estimates are derived using both, point of care blood glucose 
concentrations (capillary blood glucose) and laboratory blood glucose concentrations 
without applying any corrections. Therefore the estimates for each cut-off value 
could vary when comparing with estimates that are derived from either source alone. 
This may also alter the validity indicators (sensitivity and positive predictive values) 
of the proposed surveillance tool. However I would expect them to be within the 
confidence intervals calculated in my analysis. While I believe that PICS and the 
discharge diagnostic codes can be used together for surveillance of the incidence of 
non-diabetic hypoglycaemia, I have not formally tested this in a prospective data set. 
My study involves only one large hospital in UK but the reported frequency is unlikely 
to be an underestimate given the hospital has specialist renal and liver units where 
the incidence is likely to be higher.  
 
4.3.5 Conclusions 
Significant non-diabetic hypoglycaemia in hospital in–patients (at or below 
2.7mmol/l) outside critical care is rare. It is sufficiently rare for occurrences to merit 
case-note review and diagnostic blood tests, unless an obvious explanation is found. 
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4.4 Glucose Metrics 
4.4.1 Background 
In primary care and outpatient clinics, glycaemic control of patients with diabetes is 
assessed using HbA1c; however HbA1c may have limited prognostic value in acute 
admissions [201,202] and in assessing glycaemic control for the inpatient stay. 
Therefore during inpatient admission blood glucose values are the only parameter 
available to assess patients’ glucose control for the given period of stay. Even 
though evidence is lacking on what would constitute high quality targets for glucose 
control in non-critical care settings, there is consensus that both hyperglycaemia 
(>10mmol/l) and hypoglycaemia (<3.9mmol/l) should be avoided [47,104].  
There are many indicators proposed in the literature to assess glucose control. Most 
have been reported relating to patients treated in intensive care units. They include 
mean morning glucose, maximum glucose, mean blood glucose, time averaged 
glucose and hyperglycaemic index. Mean morning glucose is the arithmetic mean of 
all blood glucose values collected in the morning, often defined as between 6.00 and 
8.00AM [16,203]. Maximum glucose refers to just one glucose value, the highest 
observed during the inpatient stay [204]. However the mean morning glucose fails to 
take into account day time glucose and the maximum glucose indicator fails to give a 
comprehensive picture of all glucose values especially those indicating 
hypoglycaemia which have been shown to be harmful [58,59,144,164]. Mean blood 
glucose reflects the average of all blood glucose concentrations taken during a spell 
[205]. Time averaged glucose is described as the area under the curve after plotting 
all the blood glucose concentrations (y axis) in a specific time period and dividing it 
by the length of the observation period [203,206] . Hyperglycaemic index is again 
plotted in the same way but only the area above a predetermined cut off point (for 
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example above 7mmol/l) is taken into account and divided by the observation period 
[203,206]. The mean blood glucose and time averaged glucose don’t give a clear 
picture of high and low values, both of which are just as important in clinical practice 
as the average glucose. The hyperglycaemic index reflects only hyperglycaemia. 
Both the time averaged glucose and hyperglycaemic index are also complex to 
calculate in routine practice and therefore are difficult to translate into practice in non 
critical care settings. 
It is in this context that Goldberg et al [127] and colleagues proposed “Glucometrics”, 
a composite of indicators, as a measure of quality glucose control in critical and non 
critical care settings. The aim of this section is to use a sample of POC BG data from 
UHB to describe the indicators proposed by Goldberg et al in a non critical care 
setting [127] . 
4.4.2 Methods 
In this section (4.4) instead of using the blood glucose values that are in the 
database for the period of 2007-2010, we extracted POC BG value for September 
2012 to illustrate the different properties of Glucometrics and to look at the merits of 
using the different specified measures. This was done as current recordings of blood 
glucose values are much more complete than to previous years and will be 
pragmatically easier to demonstrate the indicators. September was chosen because 
it was the most recent month at the time of data extraction (October 2012). As the 
exercise is only to illustrate the value of indicators based on recorded POC BG 
values in measuring quality of blood glucose control in an institution, the data (POC 
BG values) derived from PICS were not linked to the PAS database or prescription 
data in PICS, therefore there is no differentiation between diabetes and non diabetic 
admissions. Blood glucose values are from non critical care setting. 
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Definitions of the indicators are derived from the publication by Goldberg [127] and 
the website [207] they have created to perform the Glucometric analysis for any 
institution. They describe three properties using three possible units (patient sample, 
patient day and patient stay). The first property, reflects the glucose exposure (mean 
glucose value); the second, reflects the efficacy of the glucose control (proportion 
within good control); and the third, a measure of adverse events (proportion with 
hypoglycaemia or hyperglycaemia). 
Calculations were done using the web tool maintained by Yale Centre for Medical 
Informatics & Yale School of Medicine [207]. The tool excludes patients with only 
one recording of blood glucose for a given spell. This is done as an admission with 
one glucose value cannot reflect the institutional performance [207]. Considering the 
data extraction was to reflect the blood glucose values available in September, 
admissions that started before September and continuing into the month of 
September and likewise admissions starting in September and continuing into the 
next few months have been trimmed to the days they contributed in September 
alone.  
Definitions of each indicator under the three properties are given below. 
Glycaemic exposure 
 Sample mean - This is calculated as the mean of all blood glucose values for the 
given period irrespective of whom and which date it originates from.  
 Patient stay mean - Each patient’s blood glucose throughout the stay is averaged 
and the mean of all average patient stays is calculated.  
 Patient day weighted mean - Here each day of every patient’s stay forms the unit 
of analysis. Therefore for a given patient on a given day the average of blood 
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glucose values are calculated. Thereafter the mean of all patient day averages is 
calculated. 
Efficacy 
 Samples within target range - The proportion of all available blood glucose 
concentrations that were within 4 – 10mmol/l (target range). 
 Patient stays within target range - The proportion of all patient stays that had all 
their blood glucose concentrations between 4 -10mmol/l. 
 Patient days within target range - Proportion of patient days that had all blood 
glucose concentrations within 4-10mmol/l (target range). 
Adverse events 
Hypoglycaemia 
 Proportion of blood samples with a blood glucose concentration ≤ 3.9mmol/l (mild 
to moderate hypoglycaemia) and ≤2.2mmol/l (severe hypoglycaemia). 
 Proportion of patient stays observed with a blood glucose concentration 
≤3.9mmol/l and ≤2.2mmol/l.  
 Proportion of patient days with a recorded blood glucose concentration 
≤3.9mmol/l and ≤2.2mmol/l. 
 Hyperglycaemia 
The definition used in the tool was blood glucose concentration ≥16.7mmol/l 
(300mg/dl). 
 Proportion of blood samples with a blood glucose concentration ≥ 16.7mmol/l. 
 Proportion of patient stays observed with at least one blood glucose 
concentration ≥16.7mmol/l.  
 Proportion of patient days with at least one recorded blood glucose concentration 
≥16.7mmol/l. 
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4.4.3 Results  
There were 2,181 spells with POC BG values during the month of September 2012. 
Just over 50% (1,111 spells out of 2,181 total spells) had more than one POC BG. 
The 1,111 spells (patient stays) included in the analysis contributed to 18,531 
samples and 6,231 patient days. Summary of the results are given in table 4.8 and 
described below. 
Table 4.8: Glucose control indicators in UHB for the month of September 2012 
  Patient-samples Patient-stays Patient-days 
Numbers contributing to analysis 18503 1111 6230 
       
Median (mmol/l) 8.0 7.8 7.9 
Mean (mmol/l) 9.3 8.6 8.8 
      
Adverse events N % N % N % 
At least one glucose ≤ 2.2mmol/l 76 0.4 36 3.2 52 0.8 
At least one glucose ≤ 3.9mmol/l 721 3.9 207 18.6 450 7.2 
At least one glucose ≥ 16.7mmol/l 1553 8.4 256 23.0 790 12.7 
             
Target range             
 3.9 mmol/l < glucose < 10 mmol/l 11,592 62.7 832 74.9 4,461 71.6 
             
Other ranges             
3.9mmol/l  ≤ glucose < 6.1mmol/l 3,830 20.7 201 18.1 1,249 20.1 
6.1 mmol/l ≤ glucose < 7.8mmol/l 4,069 22.0 347 31.2 1,679 27.0 
7.8 mmol/l ≤ glucose < 10mmol/l 3,693 20.0 284 25.6 1,533 24.6 
10 mmol/l ≤ glucose < 13.3mmol/l 3,117 16.9 200 18.0 1,085 17.4 
13.3mmol/l ≤ glucose < 16.7mmol/l 1520 8.2 57 5.1 386 6.2 
 
4.4.3.1 Glycaemic exposure in University Hospital Birmingham (September 
2012) 
The sample mean was 9.3mmol/l (median 8mmol/l) for the month of September in 
2012. Using the same data calculated patient stay mean was 8.6mmol/l (median 
7.8mmol/l) and patient day weighted mean was 8.8mmol/l (median 7.9mmol/l).  
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4.4.3.2 Efficacy in University Hospital Birmingham (September 2012) 
 
The proportion of samples within target range (4 – 10mmol/l) was 62.7%. With 
patient stay as the unit of analysis proportion of patient stays within target range was 
74.9%. A similar proportion (71.6%) was within target range when the unit of analysis 
was patient day.   
4.4.3.3 “Adverse events” in University Hospital Birmingham (September 2012) 
Hypoglycaemia 
A blood glucose value ≤3.9mmol/l was found in 3.9% of blood samples, 18.7% of 
patient stays and 7.2% of patient days. A blood glucose value ≤2.2mmol/l was found 
in 0.4% of blood samples, 3.2% of patient stays and 0.8% of patient days. 
Hyperglycaemia 
A blood glucose value ≥ 16.7mmol/l was found in 8.5% of blood samples, 23.4% of 
patient stays and 12.8% of patient days. 
4.4.4 Discussion 
Among the three units used to assess glucose control in an institution, samples 
derived from all patients as a unit have limited value. They reflect blood glucose 
control for a short period of time and are dependent on the number of samples taken 
and can exaggerate adverse events where multiple samples are taken in quick 
succession after a hypoglycaemic or hyperglycaemic event. Patient stay as a unit 
helps to identify a subset of population prone to adverse events. However the 
number of days a patient stays considerably varies resulting in inconsistent 
assessment of glucose control across different patients and therefore in or between 
institutions and hospital wards. In contrast the patient day unit has a fixed time 
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period (24 hours) and is not dependent on varying length of stay between patients 
and is therefore often recommended as the preferred unit [207,208]. 
Glycaemic exposure with patient day as a unit can help hospitals to look at seasonal 
fluctuation in glycaemic control and determine improved control over time.  
Describing the glucose control in a hospital based on all three properties has many 
advantages. As pointed out in the beginning of this chapter these metrics can act as 
a quality indicator for the care received by patients with diabetes. In particular 
monitoring of adverse blood glucose levels can instigate institution based initiatives 
that could help reduce these outcomes. Subset analysis of wards can identify 
educational needs of underperforming wards to improve their glucose control. 
Further any clustering of adverse outcomes such as severe hypoglycaemia in non 
diabetic patients may trigger the need to investigate for any unusual causes, such as 
malicious administration of insulin. 
These metrics as quality indicators are only valuable if the population it refers to can 
be identified as diabetic or not. The algorithm I have proposed in chapter 3 or an 
alternative one is a necessity to ensure identification of patients who are diabetic or 
not. In addition to this there will be wards that may have an atypical population such 
as the liver unit, where avoiding hypoglycaemia is one of the mainstays of treatment, 
which might result in blood glucose values often reaching the hyperglycaemic 
threshold. Similarly certain specialities may have high co-morbidities, such as the 
geriatric units, leading to higher fluctuation in blood glucose in the patients in these 
units. Therefore a league table of “good control” wards and “poor control” wards 
should not be displayed but the information used after careful assessment of the 
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circumstances to provide support to improve competencies of staff in any poorly 
performing units.  
4.4.5 Conclusions 
Electronic recording of point of care blood glucose can assist in assessment of the 
quality of blood glucose control in an institution. Glucose meters with an automated 
system that are due to be implemented in UHB should reduce the workload for 
nursing staff and capture most of the point of care blood glucose values.  
Glucometrics, a composite of indicators, can be a useful tool to measure quality of 
institutional blood glucose control. Identification of diabetes status is important to 
meaningfully interpret the results. 
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CHAPTER 5 
Identifying predictors and building a model to 
predict patients with diabetes who may have 
an adverse clinical outcome 
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5 Identifying predictors and building a model to predict patients 
with diabetes who may have an adverse clinical outcome 
 
5.1 Overview 
We noted in the introduction that people with diabetes are twice as likely to be 
admitted to hospital, have longer lengths of stay, higher frequency of complications 
and higher mortality rates compared to non-diabetics [14,20,23,28-30,33]. The 
Institute for Innovation and Improvement in UK (2008) has suggested that models of 
care based on specialist diabetes teams providing enhanced care, dietetic and foot 
care services for high risk inpatients, staff education and better care pathways can 
reduce these poor outcomes, a notion supported by clinical guidelines and other 
research findings [47,49,104,132,133]. However, as 15-20% of hospital beds are 
occupied by patients with diabetes, it has become increasingly difficult to identify 
which of these patients most need specialist team or nurse input. Recent national 
audits have shown that only a third of those in need of specialist input actually 
receive it [14,15] . I therefore hypothesized that an active case finding approach 
using clinical information systems to detect patients most in need of specialist input, 
without relying on referrals, may assist diabetes specialist teams to focus on the 
patients with the greatest need.   
Criteria need to be defined to identify patients most in need of specialist input. To be 
of practical use, these criteria preferably should be available on hospital information 
systems. The “Think Glucose” campaign in England identified criteria (table 5.1) for 
specialist input, some of which can be incorporated as part of an active case finding 
approach using clinical information systems with clinical decision support [209]. 
These criteria include patients on insulin infusions (including those admitted with 
diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome) who can be 
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identified through electronic prescriptions; and patients having severe or recurrent 
hypoglycaemia or persistent hyperglycaemia who can be identified through 
electronic observations. But these criteria may still only identify a small proportion of 
patients in need of specialist input. Meanwhile several patient characteristics, 
biochemical and haematological profiles and co-morbidities have been identified as 
useful markers of prognosis in secondary care for both patients with and without 
diabetes [146,210-215]. These could be useful to identify patients for specialist input. 
These markers are described in the methods of section 5.3.2. In this chapter: 
1) I will first examine one such prognostic marker, presence of foot disease, to 
determine if it is associated with increased length of stay and in-hospital 
mortality. I chose to look at this for the following reasons; a) to determine if 
these patients with foot disease have poor clinical outcome in University 
Hospital Birmingham; b) to advocate the documentation of presence of foot 
disease in the PICS information system on admission to automatically alert 
these patients to the foot care team; c) to add to the evidence base on excess 
mortality linked with diabetic foot disease, as there is sparse evidence on in-
hospital mortality as an outcome; and d) if found to have a link, to use this as 
part of the model (section 5.3) I will be building to identify patients with 
diabetes whom may have an adverse outcome during their inpatient stay. 
2) I aim to develop a prediction model that will help identify patients with 
diabetes who are most likely to have an adverse event during their stay. 
Adverse events are defined as either “excessive” length of stay or inpatient 
mortality. I chose to do this as there is no formal prognostic model that is 
available to identify, at or around the time of admission, patients with diabetes 
who may end up with poor clinical outcomes. I am particularly interested in 
113 
 
variables available at or around the time of admission, as a model built on this 
basis will be useful for anticipatory care (active case finding). If a useful model 
could be built then it could be incorporated into the PICS system and used to 
alert the diabetes specialist team just after admission or within the first few 
days of admission. This may have a positive impact on the patient related 
clinical outcomes and hospital related costs.  
Table 5.1: “Think Glucose” campaign referral criteria for specialist team input 
Referral Criteria Can it be identified by PICS 
Admission for urgent or major elective surgical 
procedure 
Possible if wards are specified, such as 
orthopaedic wards, and if identifiable codes are 
present stating if they are major surgical 
procedure 
Acute coronary syndrome Possible if either documented as reason for 
admission in PICS or using ward as an indicator 
(example: Coronary Care Unit)  
DKA/HONK Identifiable using prescribed insulin regime  
Hyperglycaemic state Possible as discussed in chapter 4 
Severe hypoglycaemia Possible as discussed in chapter 4 
Newly diagnosed type 1 diabetes Not identifiable. Reliant on referral 
Newly diagnosed type 2 diabetes Not identifiable. Reliant on referral 
IV Insulin infusion with glucose outside limits Possible using electronic prescription data and 
electronic observation together 
Previous problems with diabetes as inpatient Not identifiable 
IV insulin infusion for over 48 hours Possible using electronic prescription data 
Impaired consciousness Possible only in wards where Glasgow Coma 
Scale (GCS) is recorded as part of electronic 
observation chart 
Unable to self-manage Not possible. Reliant on referral 
Parenteral or enteral nutrition Possible using electronic prescription data 
Foot ulceration Only possible if foot examination is documented 
in PICS on admission 
Sepsis Not possible directly but blood results such as 
high CRP, Neutrophil count in combination with 
request for blood culture may give indications 
Vomiting Not identifiable. Reliant on referral 
Patient request Not identifiable. Reliant on referral 
 
 
 
114 
 
5.2 Inpatient outcomes in patients with foot disease who have diabetes 
5.2.1 Background 
 
In the introduction we noted national audits in the UK and USA suggest that 15-20% 
of hospitalised patients have a diagnosis of diabetes mellitus [15,103]. Around 10% 
of patients admitted with diabetes have active diabetic foot disease during their 
hospital stay [15]. Recent national reports have highlighted the economic cost of this 
problem [66] , the lack of a multidisciplinary team approach to foot care in hospitals 
[15] and the need for setting up such care to prevent adverse outcomes as per 
National Institute for health and Clinical Excellence (NICE) guidelines [216].  
Diabetic foot disease is often the precursor to severe sequelae such as amputation. 
Long term follow up studies have demonstrated poor quality of life and increased 
long term mortality among these patients [61,63-65,217,218].  Although evidence 
exists that diabetic foot disease is associated with increased length of stay during 
hospital admission [66], there is limited evidence on its association with inpatient 
mortality. Studies that investigated inpatient mortality included small cohorts of 
patients and had no control groups [219-221], or focused only on outcomes of those 
who had amputation [222]. Inpatient mortality and length of stay in patients with foot 
disease who do not undergo amputation are equally important to: 1) understand 
excess mortality observed in patients with diabetes in hospital settings; and 2) 
emphasise the need to establish multidisciplinary foot care teams providing the best 
quality of care.  
Therefore here I have aimed to determine whether in-patient mortality and length of 
stay in patients with diabetes is greater in those with foot disease than those without 
foot disease at University Hospital Birmingham (UHB).  
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5.2.2 Methods 
As previously described the setting is UHB and patients with diabetes were identified 
as having diabetes based on the diagnostic code for diabetes in PAS and based on 
prescribed diabetic medication in PICS [92]. 
Definition of foot disease 
Foot disease was defined based on NICE guideline definition by using ICD 10 codes 
and Office of Population, Censuses and Surveys Classification of surgical operations 
and procedures version 4 (OPCS 4) codes. NICE described foot disease as feet 
affected by neuropathy, peripheral arterial disease, foot deformity, infections, ulcers 
and gangrene [216]. I identified a list of codes (ICD 10 and OPCS 4) that may 
indicate foot disease. Then two colleagues, a consultant diabetologist with a special 
interest in foot disease (MS) and a clinical specialist podiatrist (IW), and myself, 
categorised them as either ‘highly’ or ‘less’ indicative of foot disease.  I predefined 
that those in the highly indicative category would be used as our case definition of 
foot disease in patients with diabetes. The final set of codes that were in the ‘highly’ 
indicative category were mostly similar to the ones used in the national report [223] 
produced by Diabetes Health Intelligence. There were two exceptions. One was the 
code for decubitus ulcer, which was used in the national economic study but we 
considered as less indicative. The common site for decubitus ulcer is the sacrum 
region, buttocks and the heel region [224,225]. However, due to these multiple 
common sites the predictive value of the code for foot disease is likely to be low. 
Further those with decubitus ulcers are known to have poor clinical outcomes [226] 
and therefore will bias any results obtained. We therefore categorised them as less 
likely to be indicative of foot disease.  The other exception was we accepted the ICD 
10 codes for atherosclerosis of arteries in extremities (I702), neuropathic arthropathy 
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(M146) and peripheral neuropathy (G632) as codes that independently describe foot 
disease. These codes indicate foot problem in diabetes patients and are in line with 
the NICE guideline definition [216], whereas these were not part of the Diabetes 
Health Intelligence definition [223]. Diabetes Health Intelligence primarily focussed 
on amputation and foot ulcers and therefore did not include these codes. Our 
approach meant we could also perform sensitivity analyses using; 1) only the highly 
specific category as predefined; and 2) the same codes as in the national report. 
Details of the codes included in each category are given in appendix 5.1. 
Outcomes 
I compared the inpatient mortality and length of stay recorded in PAS among 
patients with diabetes 1) who had amputation, 2) had foot disease but did not have 
an amputation, and 3) those without foot disease. I didn’t differentiate between major 
or minor amputation as the numbers in the amputation category was small. Length of 
stay was calculated by deducting the admission time from the discharge time to the 
closest hour.  
In the three groups I also looked at the available blood results taken in the first 48 
hours of admission that may indicate an underlying presence of inflammation (C-
Reactive Protein/CRP, platelet), infection (neutrophil, CRP), or tendency to develop 
foot disease (underlying poor nutritional status indicated by albumin and poor renal 
function indicated by creatinine & estimated Glomerular Filtration Rate (eGFR)).  
Statistical analysis 
The demographic characteristics, blood results and morbidity characteristics of the 
patients with and without foot disease are summarised using means (standard 
deviation; SD) or medians (inter-quartile range; IQR) for continuous data and using 
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proportions for categorical data. To allow for the clustering effect of patients being 
admitted more than once Generalised Estimated Equations (GEE) were used. A 
linear regression model was used to study the length of stay; and a logistic 
regression model was used to study the effect on inpatient mortality outcome. Due to 
the skewed length of stay data, a log transformation was carried out to normalise the 
data before multivariate analysis. Covariates controlled in the regression analyses 
were age (years), gender, ethnicity, deprivation quintile (based on income 
deprivation), admission types (emergency or elective), modified Charlson co-
morbidity score, admission to Intensive Care Unit (ICU) and use of insulin. The 
modified Charlson co-morbidity score was calculated by deducting the score given 
for diabetes [58]. The effect sizes from the multivariate analyses are reported as 
relative ratios (exponential of the regression coefficient of the log transformed data) 
for the length of stay and as odds ratios for inpatient mortality. Confidence intervals 
are given at 95% (95%CI) and P-values less than 0.05 were deemed significant. 
Data were analyzed using STATA 12 software, using the GEE class of models.  
The analyses was repeated (sensitivity analysis) using the combination of diagnostic 
codes used by Diabetes Health Intelligence as described earlier, to determine if this 
had any effect on the estimates obtained using highly indicative codes alone.  
 
5.2.3 Results 
 
As described in previous chapters 25,118 admissions with diabetes consisting of 
12,817 patients in the period of 2007 to 2010 were identified. In this period 1,149 
admissions (4.6%) had highly indicative codes for foot disease and another 195 
admissions (0.8%) had an amputation involving their lower limb carried out (table 
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5.2). In all three groups median ages were similar (varying between 66 to 68 years). 
Compared to those without foot disease, admissions with foot disease had a similar 
gender ratio (approximately 58% males) but in the amputation category three 
quarters (75%) were males. There was an incremental increase in the use of insulin 
observed from those without foot disease (52%), to those with foot disease (67%) 
and to those with amputation (91%). Similarly increasing co-morbidity burden was 
noted in these three categories (modified Charlson co-morbidity score of 1 or more 
59% in no foot disease; 63% in foot disease; and 77% in amputation related 
admissions) (table 5.2).   
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Table 5.2: Characteristics and outcome of the admissions based on presence of foot disease 
Patient 
Characteristics 
No Foot Disease 
 (N=23,774) 
Foot Disease excluding 
amputations 
(N=1,149) 
Amputations 
(N = 195) 
Age median (IQR) years 67 (55,76) 68 (56,77) 66 (56,74) 
 
*
Gender N (%) 
   
Male  13,675 (57.5) 676 (58.8) 147 (75.4) 
Female 10,098 (42.5) 473 (41.2) 48 (24.6) 
 
Ethnicity N (%) 
   
White 16,690 (70.2) 963 (83.8) 165(84.6) 
Asian 4,310 (18.1) 103 (9.0) 16 (8.2) 
Black 1,268 (5.3) 49 (4.3) 14 (7.2) 
Other 1,506 (6.3) 34 (3.0) 0 (0.0) 
 
*
Social class N (%) 
   
Least deprived 1 1,302 (5.6) 50 (4.4) 5 (2.6) 
2 2,219 (9.6) 110 (9.8) 27 (14.1) 
3 3,999 (17.2) 195 (17.3) 28 (14.6) 
4 5,098 (22.0) 310 (27.5) 46 (24.0) 
Most deprived 5 10,579 (45.6) 461 (40.9) 86 (44.8) 
 
Type of admission N (%) 
   
Elective 7,271 (30.6) 120 (10.4) 46 (23.6) 
Emergency 16,503 (69.4) 1,029 (89.6) 149 (76.4) 
    
ICU Use    
No 21,897 (92.1) 1,092 (95.0) 176 (90.3) 
Yes 1,877 (7.9) 57 (5.0) 19 (9.7) 
Modified Charlson co-
morbidity score N (%) 
   
0 9,793 (41.2) 421 (36.6) 45 (23.1) 
1 5,055 (21.3) 253 (22.0) 65 (33.3) 
≥2 8,926 (37.5) 475 (41.3) 85 (43.6) 
    
Insulin use N (%)    
Yes 12,452 (52.4) 772 (67.2) 177 (90.8) 
No 11,322 (47.6) 377 (32.8) 18 (9.2) 
    
Outcome    
In-patient death N (%)    
Yes 1,175 (4.9) 97 (8.4) 14 (7.2) 
No 22,599 (95.1) 1,052 (91.6) 181 (92.8) 
 
Length of stay in 
median (IQR) days 
 
3.4 (1.2,9.2) 
 
9.7 (3.97,20.9) 
 
17.5 (9.0,31.6) 
 
*Deprivation quintile based on income deprivation score. Adds up to 24,515 instead of 25,118 due to missing post code 
values. Gender adds up to 25,117 instead of 25,118 due to one missing value. 
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In-hospital mortality was 4.9% in the no foot disease group, 8.4% in the foot disease 
group and 7.2% in the amputation group. In comparison to those without foot 
disease the adjusted odds ratio was 1.31 (95%CI 1.04-1.65 P=0.02) in the foot 
disease group, and 1.02 (95%CI 0.56-1.85 P=0.95) in the amputation group (Table 
5.3). Association between in-hospital mortality and foot disease persisted when 
using the codes suggested by Diabetes Health Intelligence Unit but the odds ratio 
was much larger (1.87 vs. 1.31- Table 5.4). Other variables with key significant 
associations with in-hospital mortality noted were increasing age, emergency 
admission, ICU care, increasing modified Charlson co-morbidity score and use of 
insulin (Table 5.3). 
Median length of stay was 3.4 (IQR 1.2-9.2) days in the no foot disease group, 9.7 
(IQR 4.0-20.9) days in the foot disease group and 17.5 (IQR 9.0-31.6) days in the 
amputation group. Compared to those without foot disease the adjusted relative ratio 
was 2.01 (95%CI 1.86 – 2.16 P<0.001) in the foot disease group and 3.08 (95%CI 
2.60-3.65 P<0.001) in the amputation group (Table 5.3). In the sensitivity analysis 
this association persisted when the Diabetes Health Intelligence Unit codes 
(including decubitus ulcer) were used, although relative ratio was slightly larger (2.34 
vs. 2.01 and 3.16 vs. 3.08 respectively for foot disease and amputation-Table 5.4). 
Other highly significant (P<0.001) predictors noted were increasing age, female 
gender, emergency admission, ICU care, increased modified Charlson co-morbidity 
score and use of insulin (Table 5.3). Asian ethnicity interestingly was associated with 
shorter length of stay (OR 0.89, 95%CI 0.85-0.94, P<0.001).    
On admission, based on available blood results, there were gradient increases noted 
in markers of inflammation (CRP, platelet) and infection (neutrophil) when comparing 
no foot disease group, foot disease group and amputation group (Table 5.5). Median 
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CRP was 23mg/dL (IQR 8, 75 mg/dL) in the no foot disease group; 60mg/dL (IQR 
22, 135 mg/dL) for those with foot disease not resulting in amputation; and  84 mg/dL 
(IQR 40, 180 mg/dL) for those with amputation. Estimated GFR was lower in the foot 
disease and amputation groups (approximate median eGFR 50 ml/min/1.73m2) than 
the no foot disease group (median 60 ml/min/1.73m2). Lower levels of albumin were 
present on admission in the foot disease group (mean 36.0g/L) and amputation 
group (mean 34.2g/L) in comparison to the no foot disease group (mean 38.6g/L).  
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Characteristics Unadjusted odds ratio 
for inpatient mortality 
Adjusted odds ratio 
For inpatient mortality 
P value 
(adjusted analysis) 
 Unadjusted relative 
ratio# for length of stay 
Adjusted relative 
ratio# for length of stay 
P value  
(adjusted analysis) 
Age 1.06 (1.05-1.06) 1.06 (1.05-1.07) <0.001  1.016 (1.015-1.018) 1.015 (1.014-1.016)  <0.001 
Gender 
Male 
 
1 
 
1 
  
 
1 
 
1 
  
Female 1.11(1.00-1.25) 1.06(0.94-1.20) 0.32  1.05(1.01-1.09) 1.09 (1.05-1.13)  <0.001 
Admission type         
Elective 1 1   1 1   
Emergency 5.44 (4.42-6.69) 6.83 (5.48-8.50) <0.001  1.35 (1.30-1.40) 1.44 (1.39-1.49)  <0.001 
Ethnicity 
White 
 
1 
 
1 
 
 
 
 
1 
 
1 
  
Asian 0.76 (0.65-0.90) 0.87 (0.73-1.04) 0.13  0.81 (0.77-0.85) 0.89 (0.85-0.94)  <0.001 
Black 0.83 (0.64-1.08) 0.74 (0.56-0.99) 0.04  0.98 (0.89-1.07) 0.95 (0.87-1.03)  0.21 
Other 0.72 (0.55-0.93) 1.03 (0.78-1.37) 0.84  0.60 (0.55-0.65) 0.79 (0.73-0.84)  <0.001 
Social Class         
 (Most Deprived) 5 1 1   1 1   
4 1.21 (1.05-1.39) 1.03 (0.88-1.20) 0.75  1.08 (1.02-1.14) 0.99 (0.95-1.04)  0.75 
3 1.03 (0.87-1.21) 0.92 (0.77-1.09) 0.33  1.08 (1.02-1.14) 1.02 (0.97-1.08)  0.39 
2 0.96 (0.78-1.18) 0.83 (0.66-1.04) 0.11  1.17 (1.09-1.26) 1.05 (0.98-1.11)  0.16 
(Least Deprived) 1 0.87 (0.67-1.15) 0.84 (0.63-1.13) 0.26  1.20 (1.10-1.30) 1.13 (1.04-1.22)  0.002 
Unavailable Post Code 0.41 (0.24-0.73) 0.40 (0.23-0.72) 0.002  1.35 (1.19-1.53) 1.23 (1.10-1.38)  <0.001 
ICU care received         
No 1 1   1 1   
Yes 4.18 (3.64-4.80) 6.87 (5.80-8.13) <0.001  4.33 (4.07-4.59) 3.41 (3.22-3.62)  <0.001 
Modified Charlson 
co-morbidity score  
0 
 
 
1 
 
 
1 
  
 
 
1 
 
 
1 
  
1 3.22 (2.65-3.92) 2.47 (2.02-3.03) <0.001  1.59 (1.52-1.67) 1.40 (1.34-1.45)  <0.001 
2 6.10 (5.15-7.22) 5.46 (4.59-6.50) <0.001  2.21 (2.12-2.30) 1.85 (1.78-1.92)  <0.001 
Insulin use  
No 
 
1 
 
1 
  
 
1 
 
1 
  
Yes 1.67 (1.49-1.88) 1.34 (1.18-1.53) <0.001  2.22 (2.14-2.30) 1.78 (1.72-1.85)  <0.001 
Foot Disease         
No 1 1   1 1   
Yes 1.77 (1.43-2.20) 1.31 (1.04-1.65) 0.02  2.37 (2.18-2.57) 2.01 (1.86-2.16)  <0.001 
Yes with amputation 1.49 (0.86-2.57) 1.02 (0.56-1.85) 0.95  4.17 (3.44-5.04) 3.08 (2.60-3.65)  <0.001 
 
* Covariates included in the multivariate analysis were age, gender, ethnicity, social class, admission type, modified Charlson co-morbidity score, ICU care, insulin use and foot disease category. 
# Relative ratio is the exponential of regression coefficient obtained from the analysis of log transformed length of stay data 
Table 5.3: Adjusted* Odds Ratio for inpatient mortality and adjusted* relative ratio# for length of stay in patients with diabetes 
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Table 5.4: Sensitivity analysis using different set of codes to define foot disease 
Different set of ICD10 Codes Adjusted* odds ratio 
for inpatient 
mortality 
P 
value 
 
Adjusted* relative 
ratio
#
 for length of stay 
P 
value 
 
Foot disease based on highly indicative ICD10 
codes 
    
No 1  1  
Yes 1.31 (1.04-1.65) 0.02 2.01 (1.86-2.16) <0.001 
Yes with amputation 1.02 (0.56-1.85) 0.95 3.08 (2.60-3.65) <0.001 
Foot disease based on ICD10 codes used by 
Diabetes Health Intelligence 
    
No 1  1  
Yes 1.87 (1.52-2.29) <0.001 2.34 (2.17-2.51) <0.001 
Yes with amputation 1.06 (0.58-1.92) 0.85 3.16 (2.67-3.75) <0.001 
* Covariates included in the multivariate analysis were age, gender, ethnicity, social class, admission type, 
modified Charlson co-morbidity score, ITU care, insulin use and foot disease category. 
# Relative ratio is the exponential of regression coefficient obtained from the analysis of log transformed 
length of stay data 
 
Table 5.5: Difference in available admission blood results between the three foot disease categories 
Blood results (Based on 
available results in the first 
48 hours) 
No foot disease 
 
(N = 23,774) 
Foot disease excluding 
amputation 
(n=1,149) 
Amputation 
 
(N =195) 
Albumin (g/L)    
N (%) 16,344 (69) 863 (75) 156 (80) 
Mean (SD) 38.6 (6.2) 36.0 (5.8) 34.2 (6.4) 
    
Creatinine (µmol/L)    
N (%) 17,984 (76) 934 (81) 170 (87) 
Median (IQR) 106 (80,173) 118 (89,190) 122 (90,191) 
    
eGFR (ml/min/1.73m
2
)    
N (%) 17,984 (76) 934 (81) 170 (87) 
Median (IQR) 60 (38,81) 51 (31,73) 49 (33,73) 
    
CRP (mg/L)    
N (%) 10,344 (44) 746 (65) 148 (76) 
Median (IQR) 23 (8,75) 60 (22,135) 84 (40, 180) 
    
Neutrophil (10
9/
L)    
N (%) 17,335 (73) 923 (80) 169 (87) 
Median (IQR) 6.4 (4.4, 9.4) 7.6 (5.3,10.8) 9.0 (6.5,12.1) 
    
Platelet (10
9/
L)    
N (%) 17,194 (72) 919 (80) 168 (86) 
Mean (SD) 246.0 (104.5) 278.4 (112.9) 327.5 (121.9) 
 
N (%) indicate the number and the percentage of the total admissions contributing to the blood results 
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5.2.4 Discussion 
 
5.2.4.1 Summary of findings 
Foot disease in people with diabetes admitted to hospital is associated with higher 
inpatient mortality and increased length of stay. The odds of inpatient mortality and 
length of stay were respectively 31% and 101% greater in those with foot disease 
compared to those without foot disease. As expected, the length of stay for those 
with amputation was 3 times higher, although there was no difference in the odds 
ratio noted for inpatient mortality. The latter finding is likely due to the smaller 
numbers (N=195) in the amputation group and the fewer outcomes (14 deaths) 
noted during the period of study. In addition to these findings, admissions with foot 
disease (both with and without amputation) have higher CRP, neutrophil and platelet 
count. They also were found to have relatively poor renal function and nutritional 
status. 
5.2.4.2 Potential explanations and implications of findings 
Increased risk of inpatient mortality may be associated with complications arising 
from foot ulcers such as sepsis. Patients with foot ulcers identified early during their 
admission with raised markers of inflammation and infection such as CRP and 
neutrophils need to be managed aggressively to avoid such complications. The 
presence of foot disease may also be an indication of poor peripheral circulation; 
which has been shown to be associated with cardiovascular events and death 
[227,228]. Furthermore it may also be a marker of disease burden such as an 
indication of co-existing cardiovascular autonomic neuropathy, which is also 
associated with increased mortality [229]. The findings on length of stay is consistent 
with that of Kerr [66] who reported that people with diabetic foot ulcers even if 
admitted for reasons other than non ulcer related health conditions end up with 
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excess length of stay. Asian ethnicity interestingly was associated with reduced 
length of stay. One previous analysis in the same hospital over a much longer period 
of time (2000-2007) did observe this association [230]. As the association is limited 
to length of stay it may have been due to factors that were not accounted for in the 
analysis such as social circumstances and discharge care pathways. For example 
they may have extended family support that could facilitate early hospital discharge 
or they may have had premature discharge due to poor understanding of their care 
needs.  In addition to these findings I found that renal function was worse in those 
with diabetic foot disease and in those who underwent amputation. Chronic renal 
disease and being on dialysis have been shown to be predictors of long term 
mortality in diabetes patients with foot ulcers [218]. Such patients with diabetic foot 
ulcers who have renal impairment and /or poor nutritional status may need additional 
care and support during their inpatient stay.  
Altogether the findings highlight the presence of foot disease as an indicator for 
urgent action and the need for all hospital trusts to adhere to current NICE guidelines 
to assess the feet of patients with diabetes in the first 24 hours of admission and for 
each hospital to have a designated specialist foot care team. This on its own still 
could be inadequate without other interventions as only a third of clinically indicated 
patients are referred to these teams [15]. One option being discussed at UHB is to 
implement a proactive approach to use clinical decision support systems to make 
foot assessment mandatory and an automated alert of patients with foot problems to 
the multidisciplinary foot care team.  
5.2.4.3 Limitations 
The main limitation of the study is the likely bias created by the definition of foot 
disease using routinely available data.  In particular peripheral vascular disease and 
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peripheral neuropathy are poorly documented; in fact foot examinations are rarely 
actively carried out during hospital stays [15]. However, I hoped to minimise this bias 
by using pre-specified criteria for defining diabetic foot disease codes and by 
conducting sensitivity analysis using a different definition. It was reassuring to note 
the criteria were similar to that used in the national report [223]. Other limitations 
include, the retrospective nature of the study; not controlling for factors such as 
smoking, diabetes duration and glycaemic control; and only patients admitted to one 
hospital being included in the analysis. These limitations do not allow direct inference 
of causality or generalisability to other settings.  
5.2.5 Conclusions 
 
Foot disease in hospitalised patients with diabetes is associated with increased 
length of stay and inpatient mortality. Even though causative evidence is lacking, the 
data supports the current national priority to set up specialist inpatient diabetes foot 
care teams with the hope that it will reduce adverse outcomes and improve quality of 
care for patients with diabetes admitted to hospitals. Future studies should evaluate 
the impact of implementing the recommendations of NICE guidelines and possibly 
study the impact of a decision support to automatically refer patients with foot 
disease to foot care teams. 
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5.3 A prediction model to identify hospitalised patients with diabetes 
who may have an adverse outcome 
5.3.1 Background 
Prediction models are widely used in primary care for clinical decision making, such 
as the cardiovascular risk scores [71,77] to determine the requirement for lipid 
lowering treatment. There are prediction models in a hospital setting as well, for 
example the Rockall score [231] to aid the management of upper gastrointestinal 
bleeding. As justified in the overview of this chapter there is no formal prediction 
model to identify patients with diabetes whom might have an adverse outcome 
during their hospital stay.  Therefore in this section the aim is to develop one such 
prediction model that will help the diabetes specialist team to identify hospitalised 
patients with diabetes whom potentially may have an adverse event. 
5.3.2 Methods 
5.3.2.1 Setting and databases 
The setting, University Hospital Birmingham (UHB), and the databases (PICS and 
PAS) have been previously described. Patients were identified as having diabetes 
using both discharge diagnostic codes and prescription data as explained in chapter 
3. 
5.3.2.2 Outcome of interest 
The adverse outcome is a composite outcome and is defined as either “excessive” 
length of stay or death.   
5.3.2.2.1 Calculating “excessive” length of stay  
Initially all admissions (both with and without diabetes) were categorised into 260 
groups of clinical conditions based on the primary diagnosis in the discharge 
diagnostic code. The 260 groups are defined as per the clinical classification system 
(CCS) produced by the Agency for Health Care Research and Quality (AHRQ) and 
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recently adopted by the NHS information centre [232] (appendix 5.2). The median 
length of stay was derived for each clinical condition for non-diabetic patients. The 
excess length of stay for each admission with diabetes was defined as the difference 
between the actual length of stay and the median length of stay for non-diabetic 
patients with the same group of clinical conditions. An “excessive” length of stay is 
defined as an excess length of stay greater than 75th centile of all diabetic 
admissions. This cutoff was selected because 25% of admissions with diabetes 
accounted for 85% of excess length of stay in patients with diabetes. The cutoff point 
also corresponds to 6 days more than what would be expected for any given group 
of clinical conditions in a non-diabetic patient. 
The methodology avoids the need to know the condition with which the patient is 
admitted, this is important because the diagnosis (and hence group of clinical 
conditions) may not be clear at the time of admission.  
5.3.2.3 Prognostic models 
Three models are presented: a pragmatic model, a test model and an ideal model. 
The pragmatic model is intended to be used to predict adverse outcomes early in 
admission. It uses clinical pathological test results instead of a measure of co-
morbidity because diagnoses may not be available at or around the time of 
admission. The test model replaces the clinical pathological test results from the 
pragmatic model with a measure of co-morbidity (modified Charlson co-morbidity 
score); to determine whether these clinical pathological test results are a good 
alternative for measuring case-mix. The ideal model includes all variables available 
at discharge and so includes clinical pathological test results, modified Charlson co-
morbidity score and a measure of deprivation.  
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5.3.2.3.1 Prognostic factors included and not included in the pragmatic model 
As the purpose of the pragmatic model is to identify patients whom may benefit from 
being seen by specialist team, variables included should reflect those that are 
usually available within first 24-72 hours of admission. Variables such as age, 
gender, ethnicity and admission type (emergency or elective) are readily available. 
Deprivation levels (based on income deprivation level of the post code of a patient) 
are difficult to compute and are pragmatically not obtainable during the initial period 
of admission. Furthermore they do not seem to impact on the outcome of interest 
based on my previous work on foot disease. Considering that the presence of foot 
disease may be recorded in the future as part of PICS at UHB or any other electronic 
health record in other hospitals, in the first 24-48 hours as per NICE guidelines [49], 
this variable will be included in the model. Foot diseases were defined based on 
ICD-10 codes as described in the previous section. Here one of the assumptions is 
that foot disease was present at the time of admission and has not developed during 
the hospital stay. Similarly I have assumed patients who were prescribed insulin 
during their stay were initiated on the medication within 72 hours of admission. If the 
patient is in Intensive Care Unit (ICU) setting or not will also be included considering 
most are admitted to ICU within the first 24-72 hours (75% at 72 hours; 68% at 48 
hours; and 52% at 24 hours in our database). Information on co-morbidities may not 
be available to extract from hospital information system at time of admission and 
therefore a score such as modified Charlson co-morbidity score for patients with 
diabetes [58] may not be appropriate.    
In view of the non availability of co-morbidities, additional predictors that are 
available on admission, which can sufficiently replace modified Charlson co-
morbidity score, are needed. Albumin levels can reflect nutritional status or chronic 
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liver disease and similarly estimated Glomerular Filtration Rate (eGFR) can reflect 
renal disease: both liver and renal diseases are part of Charlson co-morbidity score. 
Low albumin levels and reduced eGFR have been cited in previous literature to be 
associated with poor clinical outcomes (mortality and increased length of stay) during 
hospital stay [233-235]. Low serum sodium levels have been also associated with 
increased length of stay and inpatient mortality [211,212,236]. In the same way high 
and low potassium levels have been cited as showing an association with inpatient 
mortality in acute myocardial infarction patients probably by precipitating arrhythmias 
[237]. Likewise inflammatory status, as indicated by C-reactive protein was found to 
be associated with higher length of stay, inpatient mortality, and subsequent 1-year 
hospital bed day occupancy [213]. Other clinical pathological results that have been 
reported to be associated with both the outcome include low haemoglobin [214], high 
white cell count [238] and high and low admission blood glucose concentrations 
[19,58,59,174,215]. I was not able to include admission glucose levels as they were 
sparsely available in the database (74% missing value for any glucose 
measurements). Instead of white cell count I have opted for neutrophil counts as 
markers derived from them have better predictability in terms of sepsis [239].  
The first value of the clinical pathology tests for each admission was included in the 
analysis. Most were available (94%) within the first 72 hours of admission.Cut off 
points to categorise the clinical pathological results were based on; 1) normal 
ranges; 2) definitions of severity for a given marker (example GFR reflecting stages 
of renal disease as per guidelines [240]); 3) adequate number of groups to illustrate 
any dose response relationship; and 4) sufficient numbers in each group to observe 
any meaningful results.  
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5.3.2.4 Dealing with missing biochemical values 
Missing values were mostly around 20% for most variables except for CRP where 
44% of the admissions had a missing value.  Multiple imputations (creating additional 
10 datasets) were carried out using the Multiple Imputations by Chained Equations 
(MICE) with Predicted Mean Matching (PMM). Stata 12 supports these imputation 
methods allowing imputing different type of variables (categorical as well as 
continuous) at the same time using the CHAINED command. PMM command helps 
to restrict the range (by matching the predicted value to the closest value in the 
dataset) from which an imputed value could be picked for each variable and at the 
same has the property to be used with the CHAINED command. More details are 
available in appendix 5.3 
5.3.2.5 Variable selection and model building 
Considering the outcome was binary (adverse event or not) a logistic regression 
model was constructed. All variables were selected based on their clinical 
significance as identified from the literature. Therefore they were preserved in the 
model irrespective of their statistical significance [241,242]. This meant I did not 
carry out any stepwise procedure in selecting the variables to be included. Neither 
did I use any interaction terms as these will often add complexity and are difficult to 
use in clinical practice.  
To account for the clustering effect created by the same patient being admitted more 
than once, Generalized Estimating Equations (GEE) were used [243,244].  
5.3.2.6 Internal validation 
This was carried out using bootstrapping techniques. For each of these 10 imputed 
datasets, I applied a bootstrap procedure (2000 re-samples) to obtain 10 sets of 
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shrunken regression coefficients and c-statistics which were then combined using 
Rubin’s rule [245]. 
5.3.2.7 Assessment of model performance 
I have assessed the model performance by its ability to discriminate those with and 
without the outcome of interest (discrimination) and by looking at the agreement 
between the observed and predicted outcome (calibration). In addition the sensitivity, 
specificity, positive predictive values, negative predictive values and likelihood ratios 
were determined. To assess discrimination, a Receiver Operating Characteristic 
(ROC) curve was constructed and area under the curve (Harrell’s C-statistics) was 
calculated. C statistics were compared between the three models using non 
parametric tests. Calibration was assessed by plotting predicted probabilities of 
outcome, by decile groups, against observed probabilities of outcome (in same 
decile group) and by overlaying a smoothed calibration curves (using lowess 
algorithm) to judge against a linear line [241].   
5.3.2.8 Presentation of findings and models 
The demographic characteristics, blood results and morbidity characteristics of the 
patients with and without the adverse outcome are summarised using means 
(standard deviation; SD) or medians (inter-quartile range; IQR) for continuous data 
and using proportions for categorical data. Odds ratios are presented from 
multivariate analysis with 95% confidence intervals. P values less than 0.05 were 
deemed significant. Data analyses were carried out using Stata 12 software [246]. 
Coefficients, model performance and sensitivity analysis are reported for the 
pragmatic model only. For the other two models (test model and ideal model) only 
the area under the curve are reported. 
133 
 
5.3.3 Results 
Out of the total 171,067 admissions to University Hospital Birmingham, during the 
period of 2007-2010, 25,118 (14.7%) had diabetes. Out of the 25,118 admissions 
6,281 (25%) were categorised as having an “excessive” length of stay and 1286 
(5.1%) died. Excluding overlaps this meant 6,928 (28%) had an adverse outcome. 
Among these 25,118 admissions, 10,596 (42%) admissions had an expected length 
of stay less than or equal to the median length of stay of the same presenting clinical 
condition of non diabetic patients. The remaining patients (N=14,522; 58%) 
contributed to 146,680 excess days with a median of 4.7 days and a mean of 10.1 
days. The 6,281 admissions identified as contributing markedly to excess length of 
stay accounted for 85% (124,803 days) of the excess days.  
Admission characteristics and clinical pathology tests of those with and without 
adverse events are given in table 5.6 and 5.7. Unadjusted and adjusted odds ratios 
of the predictors used in the final model are given in table 5.8. In the adjusted model 
with an increasing age group there was an incremental rise in the odds of adverse 
outcome. The oldest age group (≥85 years) had an OR of 5.64 (95%CI: 4.66-6.81) in 
comparison to the youngest (16-44 year). Females had a slightly higher odds of 
having an adverse event (OR=1.08, 95%CI: 1.00-1.16), while those of Asian ethnic 
minority had a significantly lower chance of having an adverse event (OR=0.86, 
95%CI: 0.78-0.94). Those admitted as an emergency (OR=2.94, 95%CI: 2.69-3.21), 
or on Insulin (OR=1.89, 95%CI: 1.76-2.03), or with foot disease (OR=2.46, 95%CI: 
2.16-2.80) were at high odds of having an adverse event. As expected being in an 
ICU setting had the highest odds ratio (OR=10.79, 95%CI: 9.52-12.22).  
Severe (<125 mmol/l) hyponatraemia had higher odds (OR=1.71, 95%CI: 1.26-2.32) 
of having an adverse outcome than mild to moderate (125-134 mmol/l) 
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hyponatraemia (OR=1.17, 95%CI: 1.06-1.28). Similarly the greater the severity of 
hypernatraemia the larger the effect size was (145-154 mmol/l OR=1.31, 95%CI: 
1.12-1.54 and >155 mmol/l OR=4.05, 95%CI: 1.84-8.91). Such a dose response 
relationship favouring an adverse outcome was also noted with; lowering 
haemoglobin level (anaemia) and hypoalbuminaemia; and rising CRP levels and 
neutrophil count. Hypokalaemia (OR=1.79, 95%CI: 1.34-2.39) but not hyperkalaemia 
(OR=1.00, 95%CI: 0.80-1.26) was associated with either having increased length of 
stay or death. An estimated GFR less than 30 ml/min/1.73m2 had an odds ratio of 
1.31 (95%CI: 1.15-1.48) in comparison to normal GFR (≥90 ml/min/1.73m2). 
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Table 5.6: Baseline characteristics of admissions with and without the adverse outcome 
 
* Adds up to 25,117 instead of 25,118 due to one missing value 
Patient Characteristics No adverse outcome 
(N=18,190) 
 
Adverse outcome present  
(N= 6,928) 
Age category N (%)   
16-44 2,051 (11.3) 373 (5.4) 
45-54 2,698 (14.8) 686 (9.9) 
55-64 4,039 (22.2) 1,245 (18.0) 
65-74 4,789 (26.3) 1,867 (27.0) 
75-84 3,755 (20.6) 2,031 (29.3) 
≥85 858 (4.7) 726 (10.5) 
 
*Gender N (%) 
  
Male  10,632 (58.5) 3,866 (55.8) 
Female 7,558 (41.5) 3,061 (44.2) 
 
Ethnicity N (%) 
  
White 12,668 (69.6) 5,150 (74.3) 
Asian 3,332 (18.3) 1,097 (15.8) 
Black 939 (5.2) 392 (5.7) 
Other 1,251 (6.9) 289 (4.2) 
 
Deprivation Quintile N (%) 
  
Least deprived 1 8,169 (44.9) 2,956 (42.7) 
2 3,875 (21.3) 1,579 (22.8) 
3 3,055 (16.8) 1,167 (16.8) 
4 1,673 (9.2) 683 (9.9) 
Most deprived 5 990 (5.4) 367 (5.3) 
Unknown 428 (2.4) 176 (2.5) 
 
Type of Admission N (%) 
  
Elective 6,240 (34.3) 1,197 (17.3) 
Emergency 11,950 (65.7) 5,731 (82.7) 
   
Modified Charlson co-
morbidity score N (%) 
  
0 8,360 (46.0) 1,899 (27.4) 
1 3,844 (21.1) 1,529 (22.1) 
2 or more 5,986 (32.9) 3,500 (50.5) 
   
Insulin use N (%)   
Yes  8,700 (47.8) 4,701 (67.9) 
No 9,490 (55.2) 2,227 (32.1) 
   
ICU Care N (%)   
Yes  524 (2.9) 1,429 (20.6) 
No 17,666 (97.1) 5,499 (79.4) 
   
Foot Disease N (%)   
Yes  604 (3.3) 740 (10.7) 
No 17,586 (96.7) 6,188 (89.3) 
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Table 5.7: Biochemical and haematological markers chosen for the model 
Variable* No adverse event –
N (%) 
Adverse event –  
N (%) 
Albumin (g/L)              
T=19,220 
  
≤24 170 (1.3) 388 (5.8) 
25-34 1,996 (15.9) 2,183 (32.7) 
≥35 10,387 (82.8) 4,096 (61.4) 
 
Haemoglobin (g/dL)     
T=20,035 
  
≤7.9 427 (3.2) 431 (6.5) 
8-9.9 1,769 (13.2) 1,435 (21.6) 
10-11.9 4,126 (30.9) 2,158 (32.4) 
≥12 7,054 (52.7) 2,635 (39.6) 
 
Neutrophil (109/L)             
T=20,221 
  
<8 10,259 (76.0) 4,178 (62.1) 
8-15.9 2,888 (21.4) 2,149 (31.9) 
≥16 345 (2.56) 402 (6.0) 
 
CRP (mg/L)                         
T=13,963 
  
0-9 2,670 (32.9) 1,039 (17.8) 
10-49 3,037 (37.4) 1,946 (33.3) 
50-99 1,127 (13.9) 1,121 (19.2) 
≥100 1,278 (15.8) 1,745 (29.8) 
 
Sodium (mEq/L)         
T=19,333 
  
≤124 105 (0.8) 122 (2.0) 
125-134 1,953 (14.9) 1,323 (21.1) 
135-144 10,506 (80.4) 4,418 (70.5) 
145-154 496 (3.8) 352 (5.6) 
≥155 8 (0.1) 50 (0.8) 
 
Potassium (mEq/L)            
T=19.282 
  
≤2.9 88 (0.7) 118 (1.9) 
3-5.9 12,660 (97.3) 5,932 (94.7) 
≥6 268 (2.1) 216 (3.5) 
 
eGFR (ml/min/1.73m2) 
T=20,699 
  
≤30 2,286 (16.4) 1,497 (22.2) 
30-59 4,295 (30.8) 2,381 (35.3) 
60-89 4,615 (33.1) 1,851 (27.4) 
≥90 2,756 (19.8) 1,018 (15.1) 
   
*T- total number of blood results
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Table 5.8: Regression co-efficients and odds ratios from the pragmatic and internally validated model 
 Pragmatic Model Validation Model (using bootstrap method) 
Characteristics Regression coefficients Odds ratio P value Regression coefficients Odds ratio P value 
Age (years)       
<45  0 1  0 1  
45-54 0.431 1.54 (1.29-1.84) <0.001 0.431 1.54 (1.31-1.81) <0.001 
55-64 0.606 1.83 (1.55-2.16) <0.001 0.606 1.83 (1.58-2.13) <0.001 
65-74 0.894 2.45 (2.09-2.87) <0.001 0.894 2.45 (2.12-2.83) <0.001 
75-84 1.249 3.49 (2.97-4.09) <0.001 1.249 3.49 (3.01-4.03) <0.001 
>85 1.729 5.64 (4.66-6.81) <0.001 1.729 5.64 (4.76-6.68) <0.001 
Gender       
Male 0 1  0 1  
Female 0.073 1.08(1.00-1.16) 0.050 0.073 1.08(1.01-1.14) 0.019 
Admission type       
Elective 0 1  0 1  
Emergency 1.080 2.95 (2.69-3.22) <0.001 1.080 2.95 (2.70-3.21) <0.001 
Ethnicity       
White 0 1  0 1  
Asian -0.155 0.86 (0.78-0.94) 0.002 -0.155 0.86 (0.79-0.93) <0.001 
Black 0.052 1.05 (0.90-1.23) 0.510 0.053 1.05 (0.93-1.20) 0.428 
Other -0.350 0.70 (0.60-0.83) <0.001 -0.351 0.70 (0.62-0.81) <0.001 
ICU care received       
No 0 1  0 1  
Yes 2.378 10.79 (9.52-12.22) <0.001 2.378 10.79 (9.57-12.16) <0.001 
Insulin use        
No 0 1  0 1  
Yes 0.636 1.89 (1.76-2.03) <0.001 0.636 1.89 (1.77-2.02) <0.001 
Foot Disease       
No 0 1  0 1  
Yes 0.898 2.46 (2.16-2.80) <0.001 0.898 2.46 (2.17-2.78) <0.001 
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Table 5.8: continued…. 
 Pragmatic Model Validation Model (using bootstrap method) 
Characteristics Regression coefficients Odds ratio P value Regression coefficients Odds ratio P value 
Albumin (g/L)       
≥35 0 1  0 1  
25-34 0.552 1.74 (1.59-1.90) <0.001 0.553 1.74 (1.60-1.88) <0.001 
<25 0.970 2.64 (2.15-3.23) <0.001 0.970 2.64 (2.16-3.22) <0.001 
GFR (ml/min/1.73m2)       
≥90 0 1  0 1  
60-89 -0.037 0.96 (0.86-1.07) 0.477 -0.037 0.95 (0.87-1.05) 0.444 
30-59 0.068 1.07 (0.96-1.19) 0.212 0.068 1.06 (0.97-1.17) 0.173 
<30 0.267 1.31 (1.15-1.48) <0.001 0.267 1.32 (1.18-1.48) <0.001 
HB (g/dl)       
≥12 0 1  0 1  
10-11.9 0.117 1.12(1.04-1.22) 0.004 0.117 1.12(1.04-1.21) 0.002 
8-9.9 0.287 1.33(1.20-1.48) <0.001 0.287 1.33(1.21-1.46) <0.001 
<8 0.492 1.64(1.38-1.94) <0.001 0.492 1.62(1.38-1.91) <0.001 
Neutrophil count (109/L)       
0-7.9 0 1  0 1  
8-15.9 0.180 1.19(1.10-1.29) <0.001 0.180 1.20(1.11-1.29) <0.001 
≥16 0.310 1.38(1.17-1.64) <0.001 0.310 1.36(1.16-1.60) <0.001 
Sodium (mmol/l)       
<125 0.537 1.71 (1.26-2.32) <0.001 0.537 1.71 (1.30-2.25) <0.001 
125-134 0.154 1.17 (1.06-1.28) <0.001 0.154 1.17 (1.08-1.26) <0.001 
135-144 0 1  0 1  
145-154 0.272 1.31 (1.12-1.54) <0.001 0.272 1.31 (1.13-1.52) <0.001 
≥155 1.400 4.05 (1.84-8.91) <0.001 1.400 4.06 (2.28-7.21) <0.001 
Potassium (mmol/l)       
0-2.9 0.581 1.79(1.34-2.39) <0.001 0.581 1.79 (1.37-2.34) <0.001 
3-5.9 0 1  0 1  
≥6 0.005 1.00 (0.80-1.26) 0.996 0.005 0.98 (0.82-1.23) 0.963 
CRP (mg/L)       
0-9 0 1  0 1  
10-49 0.320 1.38 (1.25-1.51) <0.001 0.320 1.38 (1.27-1.49) <0.001 
50-99 0.535 1.71 (1.49-1.96) <0.001 0.535 1.71 (1.54-1.89) <0.001 
≥100 0.690 1.99 (1.77-2.25) <0.001 0.690 1.99 (1.81-2.20) <0.001 
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The pragmatic model had an area under the curve (AUC) of 0.802 (95%CI: 0.795-
0.808), performing significantly (P<0.001) better than the test model (AUC 0.784; 
95%CI: 0.777-0.790); suggesting that the clinical pathology results replaced co-
morbidities as a measure of case-mix well. The ideal model performed better than 
the pragmatic model (AUC 0.810: 95%CI; 0.804-0.816, P<0.001) but the difference 
between the pragmatic model and ideal model was minimal (AUC 0.802 vs. 0.810) 
(Figure 5.1).  
At a cut off of >25% predicted chance of having an adverse event, the sensitivity and 
specificity total was maximum. At this point the sensitivity was 76%, specificity was 
70% and the positive predictive value was 49% (Table 5.9). However in reality, 
patients in ICU will not be part of the active case finding approach, and if one were to 
see only those in the non critical care setting, the approach will have a sensitivity of 
69%; specificity of 72%; and a positive predictive value of 43%. On the other hand 
the so called “false positive” patients in non critical care whom will be seen in an 
active case finding approach have characteristics such as high co-morbidity index 
(41% had modified Charlson co-morbidity score of 2 or more), insulin use (66%), foot 
disease (10%) and age above 75 years (51%). Therefore false positives are not 
necessarily admissions that will not benefit from a specialist team review.  
The lowess calibration plot was in close proximity to a line drawn at 450 suggesting 
the calibration of the model was good, that is the predicted probabilities were similar 
to that of the observed probabilities (Figure 5.2). 
The internal validation on the bootstrapped sample had an AUC of 0.798 (95%CI: 
0.792-0.805), only a marginal difference to that observed in the pragmatic model 
(AUC 0.802; 95%CI 0.795-0.808). The coefficients mostly varied only at third 
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decimal point and the odds ratios varied mostly at second decimal point (table 5.8). 
Therefore I did not make any adjustments to the coefficients obtained from the 
pragmatic model. 
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Figure 5.1: ROC curves for model comparison and assessment of discrimination 
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Table 5.9: Discriminating ability of the pragmatic model 
Cut off point for the 
probability of having 
an adverse outcome 
Sensitivity Specificity PPV NPV LR+ LR- Correct 
0.05 0.99 0.09 0.29 0.95 1.08 0.15 0.33 
0.1 0.95 0.29 0.34 0.94 1.34 0.18 0.47 
0.15 0.89 0.47 0.39 0.92 1.69 0.22 0.59 
0.2 0.83 0.60 0.44 0.90 2.06 0.29 0.66 
0.25 0.76 0.70 0.49 0.88 2.50 0.35 0.71 
0.3 0.68 0.77 0.53 0.86 2.98 0.42 0.75 
0.35 0.60 0.83 0.58 0.85 3.60 0.48 0.77 
0.4 0.54 0.88 0.62 0.83 4.34 0.53 0.78 
0.45 0.47 0.91 0.66 0.82 5.19 0.58 0.79 
0.5 0.40 0.93 0.69 0.80 5.98 0.64 0.79 
0.55 0.35 0.95 0.73 0.79 7.11 0.69 0.78 
0.6 0.30 0.96 0.76 0.78 8.45 0.73 0.78 
0.65 0.25 0.97 0.79 0.77 9.99 0.77 0.78 
0.7 0.21 0.98 0.81 0.76 11.35 0.81 0.77 
0.75 0.17 0.99 0.84 0.76 13.79 0.84 0.76 
0.8 0.13 0.99 0.87 0.75 17.34 0.88 0.75 
0.85 0.08 1.00 0.88 0.74 19.38 0.92 0.74 
0.9 0.04 1.00 0.90 0.73 24.02 0.96 0.74 
0.95 0.01 1.00 0.97 0.73 87.53 0.99 0.73 
1 0.00 1.00 - 0.72 - 1.00 0.72 
 
PPV – Positive predictive value 
NPV – Negative predictive value 
LR+ Positive likelihood ratio 
LR- Negative likelihood ratio 
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5.3.4 Discussion 
The study shows that if key predictor variables are available at the time or in the first 72 
hours of admission then it is possible to actively identify patients with diabetes likely to 
suffer either excessive length of stay (6 days or more for a given clinical presentation) or 
death. At a cut off of 25% probability of having an adverse outcome two thirds 
(sensitivity; 69%) of the admissions with adverse outcomes could potentially be 
identified in a non critical care setting. For every ten patients seen at this cut off point 
four will have an adverse outcome (PPV; 43%). The model performed well with an area 
under the curve of 0.802 with only a mild reduction being noted in the internal validation 
(AUC: 0.798; 95% CI 0.792-0,805). 
The association of the biochemical and haematological predictors with excess length of 
stay and death noted in my analysis corresponds with previous studies we identified in 
the literature but were often based on any type of patients; both with and without 
diabetes. These include hyponatraemia [211,212], anaemia [214], hypokalaemia [237] 
and raised CRP levels [213].  The data in the study validates these findings in people 
admitted to hospital with diabetes. Furthermore, some of these criteria may be more 
relevant in the context of diabetes; sodium and potassium imbalance can challenge the 
management of diabetic ketosis, anaemia and reduced renal function may indicate 
advanced diabetic nephropathy, and an elevated CRP and neutrophilia may indicate 
compromised sepsis/wound healing in diabetes.  
I believe the model will have important clinical utility. Timely identification of high-risk 
patients provides the opportunity for early intervention and improvement in clinical 
outcome.  In UHB, we plan to incorporate the model as part of decision support within 
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the electronic medical records. On identification of high risk patients, an automated 
consultation request would be generated to the ‘Inpatient diabetes team’. They can then 
be reviewed early in their admission. I believe this will be beneficial as there is clear and 
prior evidence that specialist nurse review can reduce length of stay [132,133]. Other 
potential uses include redesigning care models and pathways for patients with diabetes 
admitted to hospital.  
There are limitations to this approach. First it is assumed admissions with diabetes can 
be identified through information systems which may not be possible in all hospitals with 
electronic health information systems. However I have previously shown this is possible 
using either mandatory entry of the diabetes status on admission or in a compromised 
way using electronic prescription data alone [92]. Secondly I have assumed insulin 
treatment and ICU admissions took place early for all admissions even though this is 
not true for some patients. Thirdly many blood results may not be available and 
therefore these will be categorised as normal values when using the prediction model.  
Although this may compromise the validity of the model, my sensitivity analysis by 
replacing the missing categories with normal categories, and applying the coefficients 
obtained from the multiple imputation model to the dataset, suggested better 
performance than what I have shown (AUC: 0.816; sensitivity 73%; Specificity 75%; and 
positive predictive value 53%) (appendix 5.4). Other limitations include the inability to 
differentiate between type 1 diabetes and type 2 diabetes and not accounting for the 
admissions that were excluded due to non availability of information in PICs as 
discussed in chapter 3. Even though I have suggested a cut off value of 25% for the 
probability of having an adverse event, depending on hospital capacity this can be 
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varied to achieve better efficiency in terms of cost and staff time. The model might have 
performed better with additional important markers of poor outcome (especially 
mortality) such as smoking, duration of diabetes and glycaemic control. These variables 
were not available in the secondary care dataset and future studies should aim to 
improve on the model using linked primary and secondary care datasets. The strength 
of the study is that the model is developed in a hospital with a diverse population, from a 
large dataset with effect sizes that had narrow confidence intervals and rigorous 
methodological quality. Furthermore the definition of excessive length of stay is novel 
and mitigates the need to know the presenting condition. Similarly the model doesn’t 
rely on knowing the co-morbidities, replacing this instead with routinely performed blood 
tests. 
5.3.5 Conclusions 
An active case finding model can be a future tool to identify patients with diabetes whom 
may be at risk of poor outcomes such as increased length of stay and death. Further 
studies should aim to; 1) externally validate the model; 2) assess the practicality of 
using the model; and 3) demonstrate if the active case finding model either on its own or 
in combination with additional clinical indicators of poor outcomes (such as 
hypoglycaemia, hyperglycaemia and insulin infusions identified through electronic 
records), followed by a review by the specialist diabetes team, will positively impact on 
reducing adverse outcomes for patients with diabetes.         
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6 General discussion 
6.1 Findings in context of overall management strategy for hospitalised 
patients with diabetes 
The key components in successfully managing hospitalised patients with diabetes are 
delineated by the guidelines produced here in UK [47-51] and in USA [104]. Important 
components identified include: 1) obtaining the institutional support for the initiative to 
improve care for diabetes inpatients; 2) establishing a multidisciplinary diabetes team 
and steering committee; 3) educating health care providers on the management of 
diabetic inpatients; and 4) providing adequate information and support to diabetes 
inpatients. 
In a resource limited health care economy, institutions will naturally prefer to support 
initiatives that have a high impact on efficiency (value for money) and quality of care.  
The work on electronic prescription data in identifying missed discharge diagnostic 
codes for diabetes fulfils both the criteria where financial savings can be made and at 
the same time improved recording of patient information can be achieved. The studies 
establishing the association of hypoglycaemia and foot disease with in-hospital mortality 
and increased length of stay in diabetes inpatients have contributed to our 
understanding of poor inpatient outcomes for diabetes patients and can be valuable in 
persuading hospital managers to adapt national recommendations and guidelines in 
caring for in-patients with diabetes. In addition findings from the systematic review 
emphasises the need for implementation of CPOE system with CDSS functions to 
reduce prescription errors and promote appropriate insulin regimen. 
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A multidisciplinary diabetes team have a dual function: 1) to optimise individual patient 
care; 2) strategic role to drive policies behind good practice, to establish institution goals 
on management of glucose control and to develop or implement local and national 
guidelines.  Depending on the size and capacity of the institution the second role could 
be fulfilled by the same individuals in a multidisciplinary team or by establishing a 
separate steering committee. The team should drive the agenda on setting up guideline 
based CPOE as identified in the systematic review; ideally persuade hospitals to 
accommodate institution wide glucose monitoring system as identified in the systematic 
review and discussed in chapter 4; and set out appropriate institutional glucose control 
goals as discussed in chapter 4. They should explore mechanisms to safeguard 
patients from insulin prescription errors including possible surveillance systems such as 
discussed for non diabetic patients in chapter 4. Wherever electronic health records 
exist, as proposed in chapter 3, identification of every possible diabetes patients in real 
time should be encouraged. This in turn will help with proactive identification of diabetes 
patients whom are in need of specialist diabetes team input. Tools to identify high risk 
patients such as using the model developed in chapter 5 or electronic observations with 
decision support functions which can alert patients that could benefit from specialist 
diabetes team review, for example those with severe or recurrent hypoglycaemia as 
discussed in chapter 4, should be incorporated into electronic health records.    
The team also has a role in educating the wider health care providers in all wards and 
outpatient settings. Though not part of this thesis, computer and web based modules to 
train doctors and nurses on inpatient management of diabetes are being increasingly 
used [247-249]. These can have potential benefits that need to be further studied. This 
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is important as current evidence suggests there is clinical inertia in antidiabetic 
medication prescription (not intensifying treatment when there is persistent 
hyperglycaemia) and use of improper prescription such as sliding scale insulin where it 
is inappropriate [250,251] . Similarly innovative ways to educate patients are needed to 
achieve better patient satisfaction and empower them to self manage their illness during 
their inpatient stay. 
6.2 Implementing the findings of this thesis and evaluation framework 
In the introduction I briefly discussed planning and development of CDSS. Once the 
framework and health informatics tools have been developed or identified, as was the 
case in this thesis for diabetes inpatients, it is important to have partnership working 
between clinicians, IT professionals and if available clinical informaticians. A clinical 
informatician is a professional with clinical background whom use their knowledge on 
patient care with their understanding of informatics concepts to transform health care 
[252]  . They achieve this by establishing the clinical need for a health informatics 
solution and contributing to the improvement in patient care and population health 
through analysing, designing, implementing and evaluating health information systems 
with decision support [252] . Partnership working will ensure the right specification for a 
tool is provided to the IT professionals whom in turn will develop the programme and 
validate its functions, i.e. clarify the programme is working according to specifications. 
The next steps will involve evaluating the impact on users of the tool, patients and the 
institution. Evaluation can be quantitative, qualitative or both. In the example of reducing 
missed discharge diagnostic codes by implementing the algorithm specified in chapter 3 
into health information system, impact assessment will focus mainly on the user and the 
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institution. If the algorithm were to interrupt the workflow of the user or add to the 
increasing number of alerts generated to them for action (alert fatigue) then they may 
not comply with the tool to reduce missed discharge diagnosis of diabetes. Often 
questionnaire surveys to junior doctors to study their understanding (qualitative) and 
potential usage (quantitative) of the tool and / or focus groups (qualitative) to identify 
any barriers for potential poor usage can be valuable to improve the programme 
specification to increase utilisation of the tool. Once implemented, usage by the junior 
doctors in the field setting can be further assessed by analysing routinely available 
secondary data. The impact to the institution, with reduction in missed discharge 
diagnostic code for diabetes as an outcome, can be studied by a before and after 
interventional study. A diagrammatic representation of how the evaluation framework 
can be applied for studying the implementation of active case finding approach for 
diabetes patients having hypoglycaemic episode and in need of specialist input is given 
in figure 6.1. A similar approach can be taken for implementing and evaluating the case 
finding model developed in chapter 5. 
6.3 Evidence based health informatics 
The evidence based medicine movement became prominent in the 1990s when for the 
first time it was defined by Sackett et al [253]. He articulated it as “the conscientious, 
explicit, and judicious use of current best evidence in making decisions about the care 
of individual patients” [253] . It is an expression clarified further as giving recognition to 
not only the evidence but to that of the experience acquired by the clinician over the 
years and to that of patient held values. Following this evidence based health care was 
defined based on the available evidence, population health needs and available 
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resources [254] . In the field of health informatics, tools were introduced with limited 
evaluation therefore lacking adequate evidence on effectiveness and efficiency leading 
to many failures [255,256]. 
This has lead to the emergence of similar principles to that of evidence based medicine 
in health informatics termed Evidence Based Health Informatics (EBHI). Ammenwerth et 
al adapting from Sackett et al’s definition defined EBHI as “the conscientious, explicit 
and judicious use of current best evidence in making decisions about the introduction 
and operation of IT in a given health care setting” [110].  However practicing EBHI is 
challenging due to the scarcity of studies examining implementation of health 
information systems and CDSS [257].  Further quality of studies tend to be poor and 
rarely randomised controlled trials (RCT) that are considered to be of gold standard in 
EBM is performed [110,257,258]. 
To maximise the impact of the research findings in this thesis it is essential when 
implementing the recommendations in each chapter they are evaluated to improve their 
performance and at the same time to maximise the chance of the findings to be 
considered as generalisable. Recently guidelines have been published on good 
evaluation practice and on structured reporting of evaluation studies in health 
informatics [259,260]. 
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Establishing a need 
Identifying the role of health informatics as part of a 
complex intervention 
Assessment of structure 
Development of decision support tool 
Evaluate among users of tool 
Evaluate to see if there is improvement in patient / 
institutional outcomes 
High prevalence of hypoglycaemia in diabetes inpatients 
Inpatient hypoglycaemia is associated with poor clinical 
outcomes in diabetes patients 
Individual patient- Active case finding of severe or 
recurrent hypoglycaemia 
Institutional performance- Surveillance for 
hypoglycaemia 
Does the hospital have the necessary structure such 
as an institutional glucose monitoring system? 
If not can indirect triggers such as prescription for 
hypoglycaemia (glucogan or 50 / 20 % dextrose 
solution) used?  
Tool development team established - consisting 
memebers of diabetes team, IT professionals and 
preferably clinical informatician 
Consensus reached - IT professionals are provided 
with specifications (such as severe hypoglycaemia 
definition and how to define recurrent 
hypoglycaemia) 
IT professionals develop programme and validate 
the programme (does it do what it was intended to 
do) 
Are they happy with the screen specification when 
details of the patient are displayed on screen? 
Are the diabetes specialist nurses happy on how 
and when  the message is delivered to them?  
Has the product made positive changes to the 
behaviour and work efficiency of the user? 
 
An interventional study such as step wedged cluster 
RCT to look at for example reduction in length of 
stay and incidence of hypoglycaemia 
Figure 6.1: Evaluation framework to study the impact of clinical decision support tools 
Framework      Example 
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6.4  Future directions for research and action 
This collection of work has addressed some gaps in the role of health informatics in 
hospitalised patients with diabetes. There are implications for practice and future 
research. Firstly tools used elsewhere that were identified through the systematic review 
such as the CPOE to reduce prescription errors and improve glycaemic control in 
diabetes patients need to be adapted locally and implemented. Tools that have been 
proposed after establishing need such as the algorithm to reduce missed discharge 
diagnostic codes and model to identify diabetes patients with poor clinical outcomes 
need to be implemented and evaluated as discussed in the evaluation framework. In 
addition the model needs to be externally validated. The key feature of the thesis is the 
process of establishing where health informatics can make a difference for a focussed 
group of patients (hospitalised diabetes patients) which may be transferable to other 
groups of hospitalised patients.    
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8 Appendices 
 
Appendix 2.1: Search Strategy 
MEDLINE 
  Searches Results 
1 exp diabetes mellitus/ or exp diabetes mellitus, experimental/ or exp diabetes mellitus, type 
1/ or exp diabetes mellitus, type 2/ or exp diabetes, gestational/ or exp diabetic ketoacidosis/ 
or exp prediabetic state/ or exp glycosuria/ or exp hyperglycemia/ or exp hypoglycemia/ or 
exp metabolic syndrome x/ 
286990  
2 diabet$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier] 
348048  
3 exp Blood Glucose/ or exp Glucose Intolerance/ or glucose.mp. or exp Glucose/ or exp Blood 
Glucose Self-Monitoring/ or exp Glucose Tolerance Test/ 
343453  
4 1 or 2 or 3 612045  
5 exp informatics/ or exp dental informatics/ or exp medical informatics/ or exp nursing 
informatics/ or exp public health informatics/ 
240114  
6 clinical informatics.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
98  
7 exp medical informatics/ or exp medical informatics applications/ or exp decision making, 
computer-assisted/ or exp decision support techniques/ or exp "information storage and 
retrieval"/ or exp information systems/ or exp clinical laboratory information systems/ or exp 
databases as topic/ or exp decision support systems, clinical/ or exp geographic information 
systems/ or exp hospital information systems/ or exp integrated advanced information 
management systems/ or exp knowledge bases/ or exp management information systems/ or 
exp medical records systems, computerized/ or exp medlars/ or exp online systems/ or exp 
radiology information systems/ or exp reminder systems/ or exp medical informatics 
computing/ or exp pattern recognition, automated/ 
259147  
8 clinical decision support$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
870  
9 exp Computers/ or exp Clinical Pharmacy Information Systems/ or exp Medical Order Entry 
Systems/ or physician order entry system.mp. or exp Medication Errors/ or exp Medication 
Systems, Hospital/ 
76245  
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10 (physician order entry system$ or computerized physician order entry system$ or 
computerised physician order entry system$).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
131  
11 5 or 6 or 7 or 8 or 9 or 10 321329  
12 exp hospitals/ or exp hospitals, community/ or exp hospitals, general/ or exp hospitals, group 
practice/ or exp hospitals, packaged/ or exp hospitals, private/ or exp hospitals, public/ or exp 
hospitals, rural/ or exp hospitals, satellite/ or exp hospitals, special/ or exp hospitals, 
teaching/ or exp hospitals, urban/ 
171739  
13 hospital$.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
866237  
14 inpatient$.mp. or Inpatients/ 50961  
15 secondary care.mp. 2148  
16 13 or 14 or 15 886663  
17 4 and 11 6211  
18 16 and 17 903  
 
 
 
 
 
 
 
 
 
 
 
 
 
198 
 
EMBASE 
  Searches Results 
20 exp non insulin dependent diabetes mellitus/ or exp diabetes mellitus/ or diabet$.mp. 349026  
21 exp GLUCOSE TOLERANCE/ or exp GLUCOSE/ or glucose.mp. or BLOOD GLUCOSE 
MONITORING/ or exp ORAL GLUCOSE TOLERANCE TEST/ or exp GLUCOSE INTOLERANCE/ 
or exp GLUCOSE TOLERANCE TEST/ or exp INTRAVENOUS GLUCOSE TOLERANCE TEST/ or 
exp IMPAIRED GLUCOSE TOLERANCE/ 
343453  
22 20 or 21 598319  
23 exp information system/ or exp clinical data repository/ or exp computerized provider 
order entry/ or exp decision support system/ or exp electronic bulletin board/ or exp 
electronic medical record/ or exp expert system/ or exp hospital information system/ or 
exp medical information system/ or exp nursing information system/ or exp online 
system/ or exp performance measurement system/ or exp reminder system/ 
131501  
24 exp decision support system/ or exp medical informatics/ or exp computer program/ or 
clinical informatics.mp. 
288397  
25 exp medication error/ or physician order entry system.mp. or exp hospital information 
system/ 
28952  
26 computerized physician order entry system.mp. or exp computerized provider order 
entry/ 
59  
27 23 or 24 or 25 or 26 300107  
28 exp UNIVERSITY HOSPITAL/ or exp HOSPITAL ADMISSION/ or exp DAY HOSPITAL/ or exp 
PEDIATRIC HOSPITAL/ or exp COMMUNITY HOSPITAL/ or exp MENTAL HOSPITAL/ or exp 
PUBLIC HOSPITAL/ or exp HOSPITAL READMISSION/ or exp GENERAL HOSPITAL/ or exp 
NON PROFIT HOSPITAL/ or exp TEACHING HOSPITAL/ or exp GERIATRIC HOSPITAL/ or exp 
PRIVATE HOSPITAL/ or exp HOSPITAL PATIENT/ or exp HOSPITAL/ or hospital$.mp. 
873081  
29 inpatient$.mp. or exp hospital patient/ 50961  
30 secondary care.mp. 2148  
31 28 or 29 or 30 893320  
32 22 and 27 and 31 880  
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CINAHL 
 Query  Results  
S18  S5 and S12 and S17  156 
S17  S13 or S14 or S15 or S16  378272 
S16  TX secondary care*  1328  
S15  TX inpatient* or SU inpatient  53881  
S14  TX hospital*  350164  
S13  SU hospitals or hospitals, community or hospitals general or hospitals, group practice or 
hospitals, packaged or hospitals, private or hospitals, public or hospitals, rural or hospitals, 
satellite or hospitals, special or hospitals, teaching or hospitals, urban  
42339  
S12  S6 or S7 or S8 or S9 or S10 or S11  34709 
S11  TX physician order entry system* or computerised physician order entry system*  113  
S10  SU computers or clinical pharmacy information systems or medical order entry systems or 
medication errors or medication systems, hospital  
14948  
S9  TX clinical decision support*  400  
S8  SU medical informatics or medical informatics applications or decision making, computer-
assisted or decision support techniques or information storage and retrieval or 
information systems or clinical laboratory information systems or databases as topic or 
decision support systems, clinical or geographic information systems or hospital 
information systems or integrated advanced information management systems or 
knowledge bases or management information systems or medical records systems, 
computerized or medlars or online systems or radiology information systems or reminder 
systems or medical informatics computing or pattern recognition, automated  
18630  
S7  TX clinical informatics  234  
S6  SU informatics or dental informatics or medical informatics or nursing informatics or public 
health informatics  
4569  
S5  (S1 or S2 or S3 or S4)  74130 
S4  TX glucose*  19887  
S3  SU blood glucose or glucose intolerance or glucose or blood glucose self monitoring or 
glucose tolerance test  
19317  
S2  TX DIABET*  66238  
S1  SU diabetes or diabetes mellitus or diabetes mellitus, experimental or diabetes, mellitus, 
type 1 or diabetes mellitus, type 2 or exp diabetes, gestational or diabetic ketoacidosis or 
prediabetic state or glycosuria or hyperglycemia or hypoglycemia or metalbolic syndrome 
x  
48849  
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COCHRANE 
ID Search Hits 
#1 MeSH descriptor Diabetes Mellitus explode all trees 12389 
#2 (diabet*):ti,ab,kw 21675 
#3 MeSH descriptor Glucose explode all trees 10442 
#4 (glucose*):ti,ab,kw 18367 
#5 (#1 OR #2 OR #3 OR #4) 32401 
#6 MeSH descriptor Informatics explode all trees 52 
#7 (informatics):ti,ab,kw 166 
#8 MeSH descriptor Decision Support Systems, Clinical explode all trees 195 
#9 (clinical decision support*):ti,ab,kw 649 
#10 MeSH descriptor Medical Order Entry Systems explode all trees 31 
#11 (physician order entry system* or computerised physician order entry system* or 
computer* or information system* or medical records system* or reminder system* or 
medical informatics computing):ti,ab,kw 
16925 
#12 (#6 OR #7 OR #8 OR #9 OR #10 OR #11) 17389 
#13 MeSH descriptor Hospitals explode all trees 3148 
#14 (hospital*):ti,ab,kw 48251 
#15 MeSH descriptor Inpatients explode all trees 570 
#16 (inpatient*):ti,ab,kw 5388 
#17 (secondary care):ti,ab,kw 3128 
#18 (#13 OR #14 OR #15 OR #16 OR #17) 53183 
#19 (#5 AND #12 AND #18) 118 
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Appendix 2.2: Inclusion Checklist  
 Question Yes No 
Q1 Population 
Did the study include in-patients with diabetes/hyperglycaemia 
or inpatients whom were screened for diabetes? 
Go to Q2 Excluded based 
on population 
Q2 Interventions 
Did the interventions include one of the following terms or 
equivalent: 
 
o Clinical decision support system (information systems 
designed to assist and improve clinical decision 
making) 
o Computerised physician order entry system with CDSS 
component 
 
Comparator 
Usual practice or no clinical decision support system where 
controls used 
Go to Q3 Excluded based 
on intervention 
 
Q3 Outcomes 
Did the study report any clinical outcomes (reduced acute 
diabetes related complication during inpatient stay (hypo’s),  
better blood glucose control, fewer patients on insulin sliding 
scales etc), service related outcomes (reduced length of stay, 
readmission rates etc), patient satisfaction or improved 
efficiency of care provider (less time consuming for doctors, 
nurses etc) 
Go to Q4 Excluded based 
on outcome 
Q4 Study design 
Include study design other than case reports and case series 
with less than 5 patients 
Meets 
inclusion 
criteria to 
obtain full 
manuscripts 
Excluded based 
on study design 
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Appendix 2.3: Data Extraction Form 
 
General 
information 
Study Reference Number 
 
 Researcher performing 
data extraction    
 Date of data extraction   
 
Included 
 
 Citation   
 
 Type of publication  
 
 Study 
characteristics 
Aims/Objectives/hypothesis 
of the study  
Setting 
 
 Study design   
 
 Study inclusion and 
exclusion criteria    
 Recruitment procedures 
used (e.g. details of 
randomisation, blinding)    
 Unit of allocation (e.g. 
participant, GP practice, 
etc.)   
 
 
 
 
 
  
 Participant 
characteristics  
Age 
 
Gender 
 
 Ethnicity Socio-economic 
status    
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- Characteristics 
of participants 
at the 
beginning of 
the study e.g. 
Age Gender   
 Disease characteristics   
 
 Co-morbidities   
 
 Number of participants 
 
Measurements of 
Interventions and 
Outcomes 
 Intervention 
 
 Description of the 
intervention(s) and 
control(s)  
 Description of co-
interventions    
 Outcome 
 
Description of outcome 
 
 Length of follow-up, 
number and/or times of 
follow-up measurements    
Analysis Methods 
and Statistics 
 Statistical techniques used   
 
 For all intervention 
group(s) and control 
group(s): Number of 
participants and Summary 
outcome data 
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 Type of analysis used in 
study (e.g. intention to 
treat, per protocol)    
Results 
 Results of study analysis  
 
Outcome 2 
 
Outcome 3 
 
Outcome 4 
 
Outcome 5 
 
Other Key Details 
 Costs   
 
 Resource use   
 
 Adverse events   
 
Notes  Notes 
 
Quality 
Possible Bias 
 
Confounders 
 
Evidence Rating 
 
Actions to take 
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Appendix 4.1: Validity of triggers in detecting hypoglycaemia 
Positive predictive values for each individual indirect trigger and for the system as a whole are shown below.  
At a cut-off value of 3.3mmol/l, 18 out of the 21 discharge diagnostic code triggers for hypoglycaemia were 
positive, giving a positive predictive value of 86%; and for the indirect trigger of hypoglycaemic treatment, the 
positive predictive value was 65% (32/49). Overall positive predictive value at 3.3mmol/l was 78%, at 
3.0mmol/l, 72% at 2.7mmol/l, 50%, at 2.5mmol/l, 44%, and at 2.2mmol/l, 35%. 
Predictive value of the triggers for non diabetic hypoglycaemia 
 
Electronic blood 
glucose values 
(Direct Trigger) 
Electronic 
triggers by anti-
hypo treatment 
(Indirect Trigger) 
Discharge diagnostic 
codes for 
hypoglycaemia 
(Indirect Trigger) 
Total triggers 
generated (taking 
into account of 
overlaps) 
Case-notes needed 
reviewing to confirm 
hypoglycaemia for 
indirect triggers and 
confirm accuracy of 
diagnostic codes 
38 55 25 102 
Case-notes available 
for review  
36 (95%) 51 (93%) 23 (92%) 95 (93%) 
After exclusion of 
triggers that were 
found to be diabetic 
from case-notes 
36 49 21 91 
Positive triggers 
indicating 
hypoglycaemia 
at 3.3 mmol/l 
36 
 
PPV= NA 
32 
 
PPV = 65% 
18 
 
PPV=86% 
71 
 
OPPV=78% 
Positive triggers 
indicating 
hypoglycaemia 
at 3.0 mmol/l 
27 
 
PPV= NA 
30 
 
PPV= 61% 
17 
 
PPV=81% 
59 
 
OPPV=72% 
Positive triggers 
indicating 
hypoglycaemia 
at 2.7 mmol/l 
14 
 
PPV= NA 
24 
 
PPV= 49% 
12 
 
PPV=57% 
37 
 
OPPV=53% 
Positive triggers 
indicating 
hypoglycaemia 
at 2.5 mmol/l 
12 
 
PPV= NA 
21 
 
PPV= 43% 
9 
 
PPV=43% 
30 
 
OPPV=44% 
Positive triggers 
indicating 
hypoglycaemia 
at 2.2 mmol/l 
9 
 
PPV= NA 
18 
 
PPV=37% 
7 
 
PPV=33% 
23 
 
OPPV=35% 
 
PPV = Positive predictive value 
OPPV = Overall positive predictive value of the surveillance system (calculation of this is explained below) 
 
Overall PPV for cut-off value 2.7mmol/l = 59/70(total triggers (91) – Direct triggers that were 
between 2.7 and 3.3mmol/l (36-14=22) + but add any that overlap with the other 2 triggers (1))  
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Appendix 5.1: ICD-10 codes and OPCS4 codes used to identify foot disease in patients with diabetes 
We have defined diabetic foot disease based on the general description given by NICE guideline for inpatient management of diabetic foot disease. It describes it as feet 
affected by neuropathy, peripheral arterial disease, foot deformity, infections, ulcers and gangrene. Any difference between the codes we used and that of diabetes health 
intelligence unit is highlighted. 
ICD10 Codes DESCRIPTION 
Highly 
indicative codes 
for foot disease 
Codes used by 
Diabetes Health 
Intelligence 
Explanation for difference 
I702 Atherosclerosis of arteries of extremities 
x 
 
This will indicate peripheral circulation being 
compromised 
L030 Cellulitis of finger and toe X X  
L031 Cellulitis of other parts of limb X X  
L89X Decubitus ulcer and pressure area 
 
X 
As described earlier these can occur in many 
other areas (sacrum, buttock) other than the 
heel. They are likely to bias results. 
L97 Ulcer of lower limb, not elsewhere classified X X  
R02 Gangrene, not elsewhere classified X X  
E105 
Insulin-dependent diabetes mellitus with peripheral circulatory 
complications 
X X 
 
E115 
Non-insulin-dependent diabetes mellitus with peripheral circulatory 
complications 
X X 
 
E125 
Malnutrition-related diabetes mellitus with peripheral circulatory 
complications 
X X 
 
E135 Other specified diabetes mellitus with peripheral circulatory complications X X  
E145 Unspecified diabetes mellitus with peripheral circulatory complications X X  
M146 Neuropathic arthropathy X  
Commonly present in feet 
G632 Diabetic polyneuropathy  
X 
 
Mostly this reflects peripheral neuropathy as per 
the ICD 10 definition 
OPCS codes used were similar to both categories 
These were: 1) Wound debridement (S571) of a foot/leg (Z504, Z505, Z506) 2) Amputations - X091, X092, X093, X094, X095, X098, X099, X101, X102, X103, X104, X108, 
X109, X111, X112, X118, X119, X121, X122, X123, X124, X125, X128, X129
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Appendix 5.2: Clinical Classification System (CCS)  
Category label category Label 
1 Tuberculosis 51 Other endocrine disorders 
2 Septicaemia (except in labour) 52 Nutritional deficiencies 
3 Bacterial infection; unspecified site 53 Disorders of lipid metabolism 
4 Mycoses 54 Gout and other crystal arthropathies 
5 HIV infection 55 Fluid and electrolyte disorders 
6 Hepatitis 56 Cystic fibrosis 
7 Viral infection 57 Immunity disorders 
8 Other infections; including parasitic 58 Other nutritional; endocrine; and metabolic disorder 
9 Sexually transmitted infections (not HIV or hepatitis) 59 Deficiency and other anaemia 
10 Immunizations and screening for infectious disease 60 Acute post hemorrhagic anaemia 
11 Cancer of head and neck 61 Sickle cell anaemia 
12 Cancer of oesophagus 62 Coagulation and hemorrhagic disorders 
13 Cancer of stomach 63 Diseases of white blood cells 
14 Cancer of colon 64 Other hematologic conditions 
15 Cancer of rectum and anus 65 Mental retardation 
16 Cancer of liver and intra-hepatic bile duct 66 Alcohol-related mental disorders 
17 Cancer of pancreas 67 Substance-related mental disorders 
18 Cancer of other GI organs; peritoneum 68 Senility and organic mental disorders 
19 Cancer of bronchus; lung 69 Affective disorders 
20 Cancer; other respiratory and intra-thoracic 70 Schizophrenia and related disorders 
21 Cancer of bone and connective tissue 71 Other psychoses 
22 Melanomas of skin 72 Anxiety; somatoform; dissociative; and personality 
23 Other non-epithelial cancer of skin 73 Pre-adult disorders 
24 Cancer of breast 74 Other mental conditions 
25 Cancer of uterus 75 Personal history of mental disorder; mental and be 
26 Cancer of cervix 76 Meningitis (except that caused by tuberculosis or  
27 Cancer of ovary 77 Encephalitis (except that caused by tuberculosis o 
28 Cancer of other female genital organs 78 Other CNS infection and poliomyelitis 
29 Cancer of prostate 79 Parkinson`s disease 
30 Cancer of testis 80 Multiple sclerosis 
31 Cancer of other male genital organs 81 Other hereditary and degenerative nervous system c 
32 Cancer of bladder 82 Paralysis 
33 Cancer of kidney and renal pelvis 83 Epilepsy; convulsions 
34 Cancer of other urinary organs 84 Headache; including migraine 
35 Cancer of brain and nervous system 85 Coma; stupor; and brain damage 
36 Cancer of thyroid 86 Cataract 
37 Hodgkin`s disease 87 Retinal detachments; defects; vascular occlusion;  
38 Non-Hodgkin`s lymphoma 88 Glaucoma 
39 Leukaemia 89 Blindness and vision defects 
40 Multiple myeloma 90 Inflammation; infection of eye (except that caused 
41 Cancer; other and unspecified primary 91 Other eye disorders 
42 Secondary malignancies 92 Otitis media and related conditions 
43 Malignant neoplasm without specification of site 93 Conditions associated with dizziness or vertigo 
44 Neoplasms of unspecified nature or uncertain behaviour 94 Other ear and sense organ disorders 
45 Maintenance chemotherapy; radiotherapy 95 Other nervous system disorders 
46 Benign neoplasm of uterus 96 Heart valve disorders 
47 Other and unspecified benign neoplasm 97 Peri-; endo-; and myocarditis; cardiomyopathy 
48 Thyroid disorders 98 Essential hypertension 
49 Diabetes mellitus without complication 99 Hypertension with complications and secondary hype 
50 Diabetes mellitus with complications 100 Acute myocardial infarction 
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Category label category Label 
101 Coronary atherosclerosis and other heart disease 151 Other liver diseases 
102 Nonspecific chest pain 152 Pancreatic disorders (not diabetes) 
103 Pulmonary heart disease 153 Gastrointestinal haemorrhage 
104 Other and ill-defined heart disease 154 Non-infectious gastroenteritis 
105 Conduction disorders 155 Other gastrointestinal disorders 
106 Cardiac dysrhythmias 156 Nephritis; nephrosis; renal sclerosis 
107 Cardiac arrest and ventricular fibrillation 157 Acute and unspecified renal failure 
108 Congestive heart failure; nonhypertensive 158 Chronic renal failure 
109 Acute cerebrovascular disease 159 Urinary tract infections 
110 Occlusion or stenosis of precerebral arteries 160 Calculus of urinary tract 
111 Other and ill-defined cerebrovascular disease 161 Other diseases of kidney and ureters 
112 Transient cerebral ischemia 162 Other diseases of bladder and urethra 
113 Late effects of cerebrovascular disease 163 Genitourinary symptoms and ill-defined conditions 
114 Peripheral and visceral atherosclerosis 164 Hyperplasia of prostate 
115 Aortic; peripheral; and visceral artery aneurysms 165 Inflammatory conditions of male genital organs 
116 Aortic and peripheral arterial embolism or thrombosis 166 Other male genital disorders 
117 Other circulatory disease 167 Non-malignant breast conditions 
118 Phlebitis; thrombophlebitis and thromboembolism 168 Inflammatory diseases of female pelvic organs 
119 Varicose veins of lower extremity 169 Endometriosis 
120 Haemorrhoids 170 Prolapse of female genital organs 
121 the diseases of veins and lymphatics 171 Menstrual disorders 
122 Pneumonia (except that caused by tuberculosis or s 172 Ovarian cyst 
123 Influenza 173 Menopausal disorders 
124 Acute and chronic tonsillitis 174 Female infertility 
125 Acute bronchitis 175 Other female genital disorders 
126 Other upper respiratory infections 176 Contraceptive and procreative management 
127 Chronic obstructive pulmonary disease and bronchiectasis 177 Spontaneous abortion 
128 Asthma 178 Induced abortion 
129 Aspiration pneumonitis; food/vomitus 179 Post-abortion complications 
130 Pleurisy; pneumothorax; pulmonary collapse 180 Ectopic pregnancy 
131 Respiratory failure; insufficiency; arrest (adult) 181 Other complications of pregnancy 
132 Lung disease due to external agents 182 Haemorrhage during pregnancy; abruptio placenta; pl 
133 Other lower respiratory disease 183 Hypertension complicating pregnancy; childbirth an 
134 Other upper respiratory disease 184 Early or threatened labour 
135 Intestinal infection 185 Prolonged pregnancy 
136 Disorders of teeth and jaw 186 Diabetes or abnormal glucose tolerance complication 
137 Diseases of mouth; excluding dental 187 Malposition; malpresentation 
138 Oesophageal disorders 188 Feto-pelvic disproportion; obstruction 
139 Gastro duodenal ulcer (except haemorrhage) 189 Previous C-section 
140 Gastritis and duodenitis 190 Fetal distress and abnormal forces of labour 
141 Other disorders of stomach and duodenum 191 Polyhydramnios and other problems of amniotic cavity 
142 Appendicitis and other appendiceal conditions 192 Umbilical cord complication 
143 Abdominal hernia 193 OB-related trauma to perineum and vulva 
144 Regional enteritis and ulcerative colitis 194 Forceps delivery 
145 Intestinal obstruction without hernia 195 Other complications of birth; puerperium affecting 
146 Diverticulosis and diverticulitis 196 Normal pregnancy and/or delivery 
147 Anal and rectal conditions 197 Skin and subcutaneous tissue infections 
148 Peritonitis and intestinal abscess 198 Other inflammatory condition of skin 
149 Biliary tract disease 199 Chronic ulcer of skin 
150 Liver disease; alcohol-related 200 Other skin disorders 
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Category label category Label 
201 Infective arthritis and osteomyelitis (except that 231 Other fractures 
202 Rheumatoid arthritis and related disease 232 Sprains and strains 
203 Osteoarthritis 233 Intracranial injury 
204 Other non-traumatic joint disorders 234 Crushing injury or internal injury 
205 Spondylosis; inter-vertebral disc disorders; other  235 Open wounds of head; neck; and trunk 
206 Osteoporosis 236 Open wounds of extremities 
207 Pathological fracture 237 Complication of device; implant or graft 
208 Acquired foot deformities 238 Complications of surgical procedures or medical ca 
209 Other acquired deformities 239 Superficial injury; contusion 
210 Systemic lupus erythematosus and connective tissue 240 Burns 
211 Other connective tissue disease 241 Poisoning by psychotropic agents 
212 Other bone disease and musculoskeletal deformities 242 Poisoning by other medications and drugs 
213 Cardiac and circulatory congenital anomalies 243 Poisoning by non-medicinal substances 
214 Digestive congenital anomalies 244 Other injuries and conditions due to external cause 
215 Genitourinary congenital anomalies 245 Syncope 
216 Nervous system congenital anomalies 246 Fever of unknown origin 
217 Other congenital anomalies 247 Lymphadenitis 
218 Live born 248 Gangrene 
219 Short gestation; low birth weight; and fetal growth 249 Shock 
220 Intrauterine hypoxia and birth asphyxia 250 Nausea and vomiting 
221 Respiratory distress syndrome 251 Abdominal pain 
222 Haemolytic jaundice and perinatal jaundice 252 Malaise and fatigue 
223 Birth trauma 253 Allergic reactions 
224 Other perinatal conditions 254 Rehabilitation care; fitting of prostheses; and ad 
225 Joint disorders and dislocations; trauma-related 255 Administrative/social admission 
226 Fracture of neck of femur (hip) 256 Medical examination/evaluation 
227 Spinal cord injury 257 Other aftercare 
228 Skull and face fractures 258 Other screening for suspected conditions 
229 Fracture of upper limb 259 Residual codes; unclassified 
230 Fracture of lower limb 260 E Codes: All (external causes of injury and poison 
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Appendix 5.3: Dealing with missing values (table showing missing 
percentages and figure with pattern of missing) 
 
Three options were available to deal with the missing values; 1) complete case analysis; 2) single imputation 
method; 3) multiple imputation method. Complete case analysis is only possible if the variables are Missing 
Completely At Random (MCAR). MCAR assumes the data are missing independent of any other variables (both 
observed and unobserved), which if often not true for health care data. I have assumed the missing pattern is 
missing at random (MAR) where the missing values are dependent on other observed variables. Simple single 
imputation (allocating to the group with normal range) assumes if a blood test was not done or the result was 
not available they will be in the normal range category. The last option is to use multiple imputation 
techniques. I selected the latter considering the single imputation method will likely result in severe bias and 
overestimation of the effect size.  
 
 
 
 
 
 
 
 
 
 
 
Multiple imputations were carried out using the Multiple Imputations by Chained Equations (MICE) with 
Predicted Mean Matching (PMM). Stata 12 supports these imputation methods allowing to impute different 
type of variables (categorical as well as continuous) at the same time using the CHAINED command. Predicted 
mean matching (PMM) command helps to restrict the range (by matching the predicted value to the closest 
value in the dataset) from which an imputed value could be picked for each variable and at the same has the 
property to be used with the CHAINED command.  
Variable Complete Incomplete Percent missing 
Albumin 19220 5898 23% 
CRP 13963 11155 44% 
Sodium (Na) 19333 5785 23% 
Neutrophil 20221 4897 19% 
Potassium (K) 19282 5836 23% 
Haemoglobin 20035 5083 20% 
eGFR 20699 4419 18% 
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Appendix 5.4: Performance on assuming missing values are in normal 
categories 
Performance assessed by: 
1) In the original dataset replace missing values with normal values 
2)  Apply the co-efficients obtained in the multiple imputation model to the dataset to predict the 
probability of having an event 
3)  Look at the performance using the ROC curve and by calculating the sensitivity, specificity, positive 
predictive value, negative predictive value and likelihood ratios 
 
 Sensitivity Specificity PPV NPV LR+ LR- Correct 
0.05 0.99 0.13 0.30 0.96 1.14 0.10 0.37 
0.1 0.94 0.37 0.36 0.94 1.50 0.16 0.53 
0.15 0.88 0.54 0.42 0.92 1.91 0.22 0.63 
0.2 0.80 0.67 0.48 0.90 2.40 0.29 0.70 
0.25 0.73 0.75 0.53 0.88 2.95 0.35 0.75 
0.3 0.65 0.82 0.57 0.86 3.55 0.42 0.77 
0.35 0.59 0.86 0.62 0.85 4.20 0.48 0.78 
0.4 0.52 0.90 0.65 0.83 4.96 0.54 0.79 
0.45 0.46 0.92 0.68 0.82 5.65 0.59 0.79 
0.5 0.39 0.94 0.71 0.80 6.38 0.65 0.79 
0.55 0.34 0.96 0.74 0.79 7.56 0.69 0.79 
0.6 0.29 0.97 0.77 0.78 8.97 0.73 0.78 
0.65 0.25 0.98 0.80 0.77 10.67 0.77 0.78 
0.7 0.20 0.98 0.82 0.76 12.18 0.81 0.77 
0.75 0.16 0.99 0.85 0.76 14.91 0.84 0.76 
0.8 0.12 0.99 0.87 0.75 18.06 0.88 0.75 
0.85 0.08 1.00 0.88 0.74 20.03 0.92 0.74 
0.9 0.04 1.00 0.91 0.73 25.19 0.96 0.74 
0.95 0.01 1.00 0.96 0.73 64.99 0.99 0.73 
1 0.00 1.00  0.72  1.00 0.72 
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Appendix on Outputs  
The work around this thesis has yielded five papers that have been published in peer 
reviewed journals. Four of them have directly contributed to this thesis (identified as 1-4 of 
the articles listed below). Another two contributing to the thesis are currently under peer 
review (6 & 7). 
Presentations were also made in regional, national and international conferences and 
meetings. These are also listed below. 
 Peer reviewed articles published 
1. Nirantharakumar K, Chen YF, Marshall T, Webber J, Coleman JJ. Clinical decision support 
systems in the care of inpatients with diabetes in non-critical care setting: systematic review. 
Diabet Med 2012; 29(6): 698-708. 
 
2. Nirantharakumar K, Marshall T, Hemming K, Narendran P, Coleman JJ. Inpatient electronic 
prescribing data can be used to identify 'lost' discharge codes for diabetes. Diabet Med 2012; 
29(12): e430-e435. 
 
3. Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, Coleman JJ. 
Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes 
who are hospitalized. Diabet Med 2012; Dec; 29(12):e445-8. 
 
4.   Nirantharakumar K, Marshall T, Hodson J, Narendran P, Deeks J, Coleman JJ Ferner RE. 
Hypoglycaemia in non-diabetic in-patients: clinical or criminal? PLoS One 2012; 7(7): e40384. 
 
5. Nirantharakumar K, Toulis KA, Wijesinghe H, Mastan MS, Srikantharajah M, Bhatta S, Marshall T, 
Coleman JJ. Impact of diabetes on inpatient mortality and length of stay for elderly patients 
presenting with fracture of the proximal femur. J Diabetes Complications. J Diabetes 
Complications. 2013 Jan 8. doi:pii: S1056-8727(12)00337-6. 10.1016/j.jdiacomp.2012.11.010. 
[Epub ahead of print] 
 
6. Nirantharakumar K, Marshall T, Saeed M, Wilson I, Coleman JJ. In-hospital mortality and length 
of stay in patients with diabetes having foot disease. J Diabetes Complications. 2013. (In press). 
 
7. Nirantharakumar K, Hemming K, Narendran P, Marshall T, Coleman JJ. A prediction model to 
identify hospitalised patients with diabetes who may have an adverse outcome. Diabetes Care 
2013.(In press). 
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Diabetes UK conference. March 2013. (Poster) 
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prescription data in validating discharge diagnostic codes for patients with diabetes. 
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